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ABSTRACT 
Mitotically active cells at the sites of neurogenesis and primitive cells of the 
sympathetic nervous system are speculated to act as a source of stem-like tumor initiating 
cells (TICs) in neural cancers like glioma and neuroblastoma. Understanding how normal 
neural stem and progenitor cells regulate their growth and differentiation decisions 
throughout life is of high priority. Spy1 (Speedy, Spdya, RINGO) is a unique cyclin-like 
protein that enhances proliferation by activating the cyclin dependent kinase 2 (CDK2) 
and promoting the degradation of the CDK inhibitor p27
Kip1
. Spy1 levels are tightly 
regulated during developmental processes and Spy1 upregulation has been reported in 
several types of cancer including human glioma. Spy1 effectors, CDK2 and p27
Kip1
, play 
a regulatory role in many developmental events including neurogenesis and these 
effectors are aberrantly regulated in several aggressive forms of cancer. My study sought 
to investigate the role of Spy1 in regulating proliferation, self-renewal and differentiation 
processes of neural progenitors and to determine the implications of this protein in neural 
cancers. My work demonstrates that Spy1 is an important driver of the CD133+ brain 
tumour initiating cell (BTIC) population. Spy1 controls the ability of BTICs to 
symmetrically divide and the amplification of the SPDYA gene loci correlates with poor 
patient prognosis. We show that Spy1 is expressed at high levels in neurogenic regions of 
the adult brain and the overexpression of Spy1 significantly increases cell proliferation 
parameters including the number and longevity of neurospheres. These data demonstrate 
for the first time that the Spy1/RINGO family plays an important role in neural fate 
decisions and that overexpression of Spy1 is a driving factor in specific forms of neural 
cancer.  
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CHAPTER 1 
GENERAL INTRODUCTION 
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Cell Cycle regulation over cell fate decisions 
The cell cycle is the master network behind cell division that includes four distinct 
phases. Gap phase 1 (G1), DNA replication phase S and Gap phase 2 (G2) constitute the 
interphase that leads into mitotic division (M). During unfavourable growth conditions 
cells reside in G0 phase, a quiescent state, in which cells  halt progression through S 
phase, remaining metabolically active and capable of cell cycle re-entry. Each individual 
stage is regulated by an ordered set of events driving movement from one phase to 
another. G1 phase  represents an important stage capable of processing information from 
diverse environmental and developmental cues and external and internal stressors.  These 
regulatory signals play a key role in the regulation of both proliferation and 
differentiation of mammalian progenitors (Orford and Scadden 2008; Salomoni and 
Calegari 2010; Zhang, Ran et al. 2011). Understanding the subtleties of this phase will 
reveal essential mechanisms  responsible for the balance between stem and progenitor 
expansion and lineage commitment during development. The interplay between  
expansion and commitment in neural cells is indispensible for proper maturation of the 
nervous system. Furthermore, the inability to retain this balance is linked to many 
different clinical problems including neurodegenerative disease, brain injury and 
oncogenesis. To achieve a homeostatic environment, and ensure the appropriate neural 
cell maturation through development, G1 phase is equipped with several crucial proteins 
whose expression and function is set to occur at highly specified times (Fig. 1). 
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Figure 1. The eukaryotic cell cycle and regulatory components of G1 phase. Cell cycle 
consists of 4 distinct phases. Gap1 phase G1, DNA replication phase S, Gap2 phase G2 
and mitotic division phase M. G0 phase is a quiescent state in which cells don’t withdraw 
from the cell cycle permanently but do not divide either. The most important components 
of G1 phase machinery are D- and E-type Cyclins that drive the activity of CDK2 and 
CDK4/6 respectively. They all participate in the RB protein phosphorylation that is 
required for progression from G1 to S phase. Modified with permission: Nature 
Publishing Group© (license# 3126701221034) and Coleman, Marshall et al. 2004, Nature 
Reviews. Molecular Cell Biology, 2004 May; 5(5):355-66. doi:10.1038/nrm1365, 2004.  
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Cyclins serve as regulatory subunits of holoenzymes and control the activity of a 
family of serine/threonine kinases known as cyclin dependent kinases (CDKs) to regulate 
the phosphorylation processes on downstream proteins. CDKs are expressed at constant 
levels. Their enzymatically inactive state is terminated when bound to the cyclin subunit 
that not only facilitates the structural conformation of a more accessible catalytic cleft 
(Pacey, Stead et al. 2006) but also provides the CDK with a targeting domain essential for 
specific substrate selection (Schulman, Lindstrom et al. 1998). Besides the protein-protein 
interaction, activation of CDKs is regulated through posttranslational modification. CDK 
activating kinase (CAK) phosphorylates a conserved Thr residue of the CDK T-loop for 
full activation of the complex (Booher and Beach 1986; Gould, Moreno et al. 1991; Gu, 
Rosenblatt et al. 1992; Solomon, Lee et al. 1992). In turn, the inhibitory phosphorylation 
on the tyrosine residue, equivalent to CDK1 Tyr-15, is removed by Cdc25 phosphatases 
(Morgan 1996; Solomon and Kaldis 1998; Welburn, Tucker et al. 2007). G1 phase 
cyclins include D-type and E-type Cyclins that carry out their function by binding to 
CDK4/6 and CDK2 respectively. Although cyclins D1, D2 and D3 have been shown to 
have distinct roles in different cellular systems (Ciemerych, Kenney et al. 2002; Kong, 
Chua et al. 2002; Cooper, Sawai et al. 2006; Cole, Myant et al. 2010; Jirawatnotai, Hu et 
al. 2011), they share significant homology and are critical for G1 phase progression 
(Sherr 1994; Lukas, Bartkova et al. 1995). The expression inducing mechanism as well as 
the timing of the activation is distinct for D-type and E-type Cyclins. D-type cyclins are 
expressed in the early to mid portion of G1 phase and serve as functional linking elements 
between the cell cycle machinery and external mitogenic signals that regulate their 
expression. Several growth factors have been shown to stimulate Cyclin D1 levels 
including epithelial growth factor, insulin growth factor I and II and multiple hormones 
5 
 
(Albanese, D'Amico et al. 1999; Fu, Wang et al. 2002; Holnthoner, Pillinger et al. 2002). 
Once activated, Cyclin D binds to CDK4/6 and triggers phosphorylation of Rb, the 
product of the Retinoblastoma tumour suppressor gene, which subsequently leads to 
release of E2F transcription factors. Activation of E2F factors is an essential event for 
promoting the progression through G1 to S phase due to their ability to transcribe a 
battery of genes including Cyclin E (Ohtani, DeGregori et al. 1995; Botz, Zerfass-Thome 
et al. 1996; Geng, Eaton et al. 1996). The expression of Cyclins E1 and E2 starts in late 
period of G1 phase. Activation of CDK2 by Cyclin E (Koff, Cross et al. 1991; Koff, 
Giordano et al. 1992; Richardson, O'Keefe et al. 1993; Knoblich, Sauer et al. 1994) 
maintains the hyperphosphorylated state of Rb, abrogating its transcriptional repression. 
Multiple additional functions of Cyclin E-CDK2, including roles in centrosome 
duplication, histone biosynthesis and loading of the prereplication complex onto the DNA 
replication origins (Gladden and Diehl 2003), participate in the progression to S phase. 
Importantly, the activity of the Cyclin E-CDK2 complex and S phase entry can be 
inhibited by a Cip/Kip family of cyclin dependent kinase inhibitors (CKIs). p21
Cip1
, 
p27
Kip1
 and p57
Kip1
 can inhibit a broad range of cyclin-CDK complexes (Nakayama, 
Ishida et al. 1996; Di Stefano, Giacca et al. 2011). p27
Kip1
 has been shown to bind not 
only Cyclin E-CDK2 but also Cyclin A-CDK2 and Cyclin D-CDK4/6. The latter is 
known to sequester p27
Kip1
 in a trimeric complex (Koh, Enders et al. 1995; Montagnoli, 
Fiore et al. 1999). Upon mitogen withdrawal the sequestrated pool of p27
Kip1
 is released 
and free to bind and inhibit Cyclin E-CDK2 activity (LaBaer, Garrett et al. 1997; Cheng, 
Olivier et al. 1999; Sherr and Roberts 2004). In turn, the Cyclin E-CDK2 complex can 
phosphorylate p27
Kip1
 on Thr-187, a residue shown to target p27
Kip1
 for degradation 
mediated by SCF
Skp2 
ubiquitin ligase pathway (Pagano, Tam et al. 1995; Sheaff, Groudine 
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et al. 1997; Vlach, Hennecke et al. 1997). Another family of CKIs, Ink4 (p16
Ink4a 
or its 
alternate reading frame (ARF) p14
ARF
 , p15
Ink4b
, p18
Ink4c
, p19
 Ink4d 
or p19
ARF
), specifically 
inhibits CDK4 and CDK6.  
 
Putative function of G1 phase cyclins as fate determinants during neural development 
Embryonic stem cells (ESCs) and G1 phase regulators 
ESCs demonstrate unique cell cycle dynamics. The rapid division rate observed in 
ESCs is attributed to an extremely short cell cycle caused by a significant reduction in G1 
phase. This unique regulation of the cell cycle is speculated to conserve the pluripotency 
of ESCs and prevent differentiation (White and Dalton 2005; Orford and Scadden 2008; 
Singh and Dalton 2009; Lange and Calegari 2010). Murine ESCs demonstrate very low 
levels of D-type Cyclin expression and CDK4 kinase activity (Orford and Scadden 2008).  
In human ESCs there is a constitutive high expression of D-type and E-type Cyclins, and 
elevated activity of G1 phase CDKs (Orford and Scadden 2008). While there are subtle 
mechanistic differences in murine and human ESCs both have a significant reduction in 
the mitogen dependent portion of G1 phase, thereby significantly shortening the cell cycle 
(Becker, Ghule et al. 2006) (Fig.2).  
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Figure 2. The cell cycle changes in ESCs during differentiation.  
The cell cycle of ESCs is characterized by negligible levels and activity of the Cyclin D/ 
CDK4 or Cyclin D/ CDK6 (D/4,6) complexes and continuous overexpression of Cyclin E 
resulting in constitutively active CDK2. Cyclin E/ CDK2 (E/2) overrides the early, 
mitogen-induced portion of G1 phase and shortens the overall length of G1 phase leading 
to decreased total cell cycle time. As ESCs commit to differentiation D/4,6 and 
hyperphosphorylated Rb gains control over Cyclin E, early G1 phase reconstitutes and 
cell cycle undergoes lengthening. + refers to cyclin–CDK activity: +/-, negligible; +, low; 
++, intermediate; +++, high. Modified with permission: Nature Publishing Group© 
(license# 3126690068348) and Orford and Scadden 2008, Nature Reviews. Genetics. 
2008. Feb;9(2):115-28. 2008  
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G1 phase and the adult neural stem cell (NSC) regulation 
In the adult mammalian brain, self-renewal and neurogenesis are dependent on 
populations of rarely dividing adult stem cells residing in quiescence (G0) within a 
discrete anatomical niche. The quiescent state remains under the control of an 
orchestrated network of CKIs, thus preserving the genomic integrity of the adult NSCs 
and preventing them from proliferative exhaustion. 
 
Interestingly, while in quiescence, 
NSCs infrequently re-enter the cell cycle to self-renew.  Despite limitations in data on the 
G0 – G1 phase re-entry, the cell cycle components regulating G1 phase progression, as 
well as several oncogenes, are speculated to play a crucial role in the activation of 
quiescent cells (Geng, Yu et al. 2003; Wang, Plane et al. 2011). Powerful ultrastructural 
studies using transmission electron microscopy, contributed to the detailed data 
describing the quiescent cell population residing within neurogenic regions of the adult 
brain (Morshead, Reynolds et al. 1994; Doetsch, Garcia-Verdugo et al. 1997; Mirzadeh, 
Merkle et al. 2008). The forebrain subventricular zone (SVZ) of the lateral ventricles  and 
the dentate gyrus of the hippocampus constitute the primary discrete regions of adult 
neurogenesis (Doetsch, Caille et al. 1999). In addition, the rostral migratory stream 
between the SVZ and olfactory bulb was also found to contain a minor population of 
adult NSCs (Gritti, Bonfanti et al. 2002). 
In contrast to the abundant literature describing role of the cell cycle in ESCs, the 
critical cell cycle components responsible for maintaining self-renewing pools of neural 
progenitors during adulthood has yet to be determined. Nonetheless, the available data on 
cell cycle regulators essential for fate determination in neural systems through 
development is discussed in detail in this section.  
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G1 cyclin  regulatory network in neural fate decisions 
During central nervous system (CNS) development coordination between the core 
cell cycle mechanisms regulating G1 phase progression and intrinsic and extrinsic signals 
delivering cues from the external environment lie at the heart of fate decisions. The 
embryonic neuroepithelium of the neural tube constitutes the original source of 
multipotent NSCs (Gotz and Huttner 2005; Takashima, Era et al. 2007; Ohtsuka, Shimojo 
et al. 2011). NSCs give rise to the gradually more committed progenitor cells including 
radial glia and basal progenitors and all neuronal and macroglial (astrocytes and 
oligodendrocytes) cells composing the mature mammalian brain (Doetsch, Caille et al. 
1999; Gritti, Bonfanti et al. 2002; Bonaguidi, Wheeler et al. 2011; Guo, Patzlaff et al. 
2012). The number of progenitor cells produced at embryonic stages of development, 
significantly exceeds the amount of neural precursors generated at the later stages, due to 
their short cell cycle and predominant expansive division (Gotz and Huttner 2005). It has 
been established that as embryogenesis progresses, the cell cycle of the neural progenitors 
undergoes lengthening mainly due to the stretching of G1 phase (Takahashi, Nowakowski 
et al. 1995) (Fig 3). Also, at postnatal stages the length of the G1 phase is speculated to 
affect fate determination by regulating the time when a neural progenitor leaves the cell 
cycle (Das, Choi et al. 2009). The different points in time when a progenitor is arrested 
are reflected by fate influencing changes that include altered progenitor potential and 
extrinsic stimuli/cues available at a certain stage of development, reviewed in (Livesey 
and Cepko 2001). Therefore, several studies attempt to investigate the key cell cycle 
regulators that participate in G1 phase progression and the S phase transit and how they 
regulate cell fate choices along the course of development. 
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Figure 3. Cell cycle length and G1 changes during development. 
Stem cells from each germ layer are presented. Cell cycle length (top) is marked in colour 
gradient and a timeline aligned to the cell cycle length indicated specific stages including 
embryonic (E), postnatal (P) in months (M) and years (Y). The diagram represents 
gradual lengthening of cell cycle G1 phase stretching through embryogenesis to postnatal 
quiescent state and postmitotic state of terminal differentiation. Modified with 
permission: Landes Bioscience Journals© and Lange and Calegari 2010, Cell Cycle. 2010 
May 15;9(10):1893-900. doi.org/10.4161/cc.9.10.11598. 
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D-type Cyclins in neural fate 
D-type Cyclin function is essential in regulation of the early, mitogen dependent 
portion of G1 phase that is speculated to constitute a critical period during which cell fate 
decisions are made (Takahashi, Nowakowski et al. 1995; Sherr 2000; Calegari and 
Huttner 2003). Experiments involving electroporation of  Cyclin D1-CDK4 or Cyclin E1-
CDK2 into the lateral cortex of 13.5 day embryos (E13.5) revealed that only the Cyclin 
D1-CDK4 complex had the ability to prevent lengthening of G1 phase in the neural 
progenitors (Lange, Huttner et al. 2009). In these experiments overexpression of Cyclin 
D1 resulted in suppressed neurogenesis within the SVZ and an increased proportion of 
proliferating precursors. Interestingly, forced expression of Cyclin D1 shortens G1 phase 
during a window of embryogenesis, suggesting that downregulation of Cyclin D1 is 
essential in the natural lengthening of G1 phase but these overt phenotypes later in 
development are not apparent (Lange, Huttner et al. 2009). Alternatively, deletion of 
Cyclin D1 in progenitor cells within the embryonic ventricular zone was compensated by 
an endogenous increase of Cyclin D2 levels and its function (Glickstein, Monaghan et al. 
2009; Lange and Calegari 2010). In contrary, Cyclin D2 deficient progenitors 
demonstrated precocious neurogenesis that was not rescued by endogenous accumulation 
of Cyclin D1 (Glickstein, Monaghan et al. 2009; Lange and Calegari 2010). These data 
imply cell-type dependent and redundant functions of D-type Cyclins in controlling the 
duration of G1 phase. 
While all three D-type Cyclins are expressed during embryonic to early juvenile 
stages of CNS development, the neural stem cell populations within the adult brain were 
demonstrated to critically depend on the expression of Cyclin D2 (Kowalczyk, 
Filipkowski et al. 2004). The olfactory bulb region that constitutes one of the restricted 
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neurogenic zones within the adult brain requires a continual accumulation of progenitor 
cells as a source of neurons. The Cyclin D2
-/-
 mouse model manifested a significant 
decrease in the number of proliferating progenitor cells within the adult brain including 
the olfactory bulb (Kowalczyk, Filipkowski et al. 2004; Imayoshi, Sakamoto et al. 2009). 
This indicates that Cyclin D2 deficiency at adult stages of development results in 
suppressed cell cycle progression and reduced pools of proneurogenic cells.  
E-type Cyclins in neural fate 
Manipulation of Cyclin E1-CDK2 expression in mouse embryonic cell lines 
demonstrated that decreased CDK2 activity in murine stem cells contributes to the gene 
expression and morphology modifications that are characteristic of differentiation 
(Koledova, Kafkova et al. 2010). Furthermore, the inhibition of CDK2 activity alone was 
sufficient to increase the frequency of cells residing in G1-phase and resulted in a 
subsequent switch to neurogenesis. The neurogenic shift was demonstrated to occur due 
to the prolonged G1 phase, suggesting that the Cyclin E1-CDK2-induced - cell cycle 
length may play a causal role in differentiation at embryonic stages of nervous system 
development (Koledova, Kafkova et al. 2010). Importantly, CDK2 activity in ESCs 
appears to be higher than that of CDK4 or CDK6, implying a crucial role for CDK2 in the 
dynamics of ESC G1 phase (Neganova et al. 2009). Consequently, the delivery of Cyclin 
E1 to the precursor cells lining the embryonic ventricular zone resulted in a shorter G1 
phase and increased frequency of proliferative divisions (Pilaz, Patti et al. 2009). Cyclin 
E1 electroporation into cells of the germinal zone exhibited a significant increase in 
germinal zone thickness due to the expansion of the total precursor pool (Pilaz, Patti et al. 
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2009). These data demonstrate the importance of Cyclin E1 in controlling progenitor 
populations in the developing brain in vivo. 
Although electroporation of Cyclin D1 produced analogous results to Cyclin E1 at 
embryonic stages, the overexpression of Cyclin E1 showed less effect on the reduction in 
the proportion of neurons produced in the postnatal brain. Consequently, Cyclin E1-
CDK2 activity, but not the activity of Cyclin D1-CDK4, was demonstrated to rapidly 
decrease between postnatal day 15 and 30 of the development (Ghiani and Gallo 2001). 
These data point to some distinct differences in the expression, and potential functional 
importance, of Cyclin E1 and Cyclin D1 in the adult brain (Ghiani and Gallo 2001).  
Both cyclins were found to be upregulated in proliferative neural populations versus 
those arrested or terminally differentiated (Ghiani and Gallo 2001). In contrast to this,  
decreasing levels of Cyclin E1-CDK2, but not Cyclin D1-CDK4/6, mediate reversible 
cell cycle withdrawal (Ghiani and Gallo 2001).  These data demonstrate differences in 
cell cycle regulation in cases of permanent vs. transient cell cycle arrest. Upon application 
of mitogenic stimuli to quiescent progenitor cells, Cyclin E1-CDK2 is readily activated, 
confirming an important role in the cell cycle re-entry (Ghiani and Gallo 2001). As shown 
by Geng et al., the inability to re-enter the cell cycle is among the most severe phenotypes 
of the double Cyclin E1/E2 knockout mouse model (Geng, Yu et al. 2003). The authors 
revealed that ablation of both E-type Cyclins caused impaired assembly of the origin of 
replication complex in quiescent cells, however, the origin loading and firing occurred 
without error in continuously proliferating double knockout cells. These results 
emphasize the role of the E-type Cyclins as a limiting factor in G0 - G1 progression 
(Geng, Yu et al. 2003). The data suggest that the timing of Cyclin E1/ E2 expression may 
be critical in the fate of quiescent cell populations.  
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In summary, the Gap 1 phase cyclin components play an essential role in 
developmental processes and neuronal phenotype determination. These cyclins modulate 
the length of G1 phase, the timing of cell cycle arrest and the ability of quiescent cells to 
re-enter the cell cycle. Several studies on the key G1 phase regulators collectively 
indicate an exact correlation between G1 phase lengthening and differentiation (Lange 
and Calegari 2010) (Table 1). Consequently, G1 phase shortening reduces sensitivity to 
differentiation stimuli and may have other effects as well, such as reducing the time 
required for epigenetic remodelling of chromatin that may be required for differentiation 
to occur (Egli, Birkhoff et al. 2008). Despite well defined participation of certain G1 
cyclins in timing and duration of G1 phase at diverse stages of development, how neural 
cells initiate exit from G0 stage and what are the required endogenous regulators of 
differentiation in diverse stem and progenitor cell pools remains to be determined.  
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Table 1. Collected data on G1 phase components manipulation during development and 
in the adult mouse and correlation between lengthening of G1 phase and differentiation. 
Red arrows indicate downregulation and green- upregulation in the columns 2-4 
cyclin/cdk activity, G1 length, differentiation and proliferation respectively. Effects not 
observed/detected are marked as N.D. Manipulations are indicated as parmacological 
(Ph), knockdown (RNAi), knockout (KO), overexpression (OE) and knockin (KI) types 
of manipulations are indicated. Modified with permission: Landes Bioscience Journals© 
and Lange and Calegari 2010, Cell Cycle. 2010 May 15;9(10):1893-900. 
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Cell cycle regulation over mode of division during neural development 
The self-renewing NSCs of the neuroepithelium are polarized along the apical-basal 
axis, exhibit high proliferative potential and form the most apical cell layer lining the 
ventricle referred to as the ventricular zone (Huttner and Brand 1997; Wodarz and 
Huttner 2003). In an early embryo prior to neurogenesis (E9- E11), the NSCs use 
symmetric division to self-renew and increase their pool of daughter cells with identical 
proliferative fate (McConnell 1995; Rakic 1995). From the onset of neurogenesis, 
asymmetric division becomes the predominant way to establish the pool of progressively 
more committed radial glial cells and basal progenitors capable of generating all of the 
brain tissues (Gotz and Huttner 2005). Although, radial glia represent several NSC 
characteristics including apical-basal polarity and expression of the neurofilament protein 
Nestin, they express astroglial markers such as glial fibrilary acidic protein (GFAP) or 
Vimentin and are more fate restricted in their potential (Kriegstein and Gotz 2003; Gotz 
2003; Williams and Price 1995; (Fishell and Kriegstein 2003). Basal progenitors form the 
SVZ, a cell layer basal to the ventricular zone, and divide symmetrically to increase the 
number of neurons generated from ventricular zone precursors by providing an additional 
round of cell division in the SVZ, reviewed in (Gotz and Huttner 2005). Overall, from 
studies at the embryonic and postnatal level of CNS development the main principle 
arises that along the progression of developmental stages NSCs switch from using 
proliferative symmetric division to asymmetric division to form populations of progenitor 
cells capable of differentiating down various cell lineages. Asymmetric division of NSCs 
is characterized by the distribution of specific apical and basal cell structures that have 
been shown to function as cell fate determinants between the two daughter cells reviewed 
in (Gotz and Huttner 2005; Tsunekawa, Britto et al. 2012). Several characterized proteins, 
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including Numb, CD133 and Par complex proteins, are known to localize to the apical 
surface of dividing progenitors and serve as fate determinants (Wodarz and Huttner 
2003). Moreover, as the cells divide asymmetrically along the course of development, the 
rate of their cell cycle progression decreases due to the gradual stretching of G1 phase 
(Takahashi, Nowakowski et al. 1995). The cell cycle machinery that regulates the length 
of G1 is speculated to affect the function of fate determinants (Caviness, Takahashi et al. 
1995), suggesting the hypothesis that regulatory components of the G1-S transition may 
participate regulating the mode of division of stem cell populations.  
D-type Cyclins in mode of division 
Recently, a novel mechanism regarding Cyclin D2 distribution has been proposed 
by Tsunekawa et al. that involves active localization and at-the-site translation of Cyclin 
D2 mRNA to the basal progenitors during division (Tsunekawa, Britto et al. 2012). As a 
consequence, the basally positioned daughter cell acquires the self-renewing fate of an 
apical progenitor. The distribution of Cyclin D2 to the basal border is suggested to 
shorten G1 phase and consequently protect the progenitor from acquiring differentiation 
stimuli.  
Cyclin D2 is found in the progenitor cells of the SVZ and its immunoreactivity 
appears to be higher than that of Cyclin D1 at the site (Glickstein, Alexander et al. 2007). 
This suggests a role for Cyclin D2, but not Cyclin D1, in regulating the mode of division 
and self-renewal of progenitor cells within the niche.  
Although it is not known whether distribution of Cyclin D1 in dividing progenitors 
affects their behaviour, the studies using a knockout mouse model established that Cyclin 
D1 performs a unique role in maintaining the proper number of self-renewing progenitor 
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cells required for full maturation of the retina (Sicinski, Donaher et al. 1995). Cyclin D1, 
but not Cyclin D2 or D3, deficiency leads to neurological abnormalities and hypocellular 
retinas resulting in small eyes in mouse and zebrafish models (Fantl, Stamp et al. 1995; 
Sicinski, Donaher et al. 1995; Rapaport, Wong et al. 2004; Duffy, McAleer et al. 2005; 
Das, Choi et al. 2009). The phenotypic manifestations were not found to be efficiently 
reversed by Cyclin D2 knock-in, suggesting that the roles of D-type Cyclins in regulating 
the mode of division and self-renewal are not fully redundant and are dependent on the 
system tested (Sicinski, Donaher et al. 1995).  Furthermore, the observed retinal 
hypoplasia in Cyclin D1 deficient mice is attributed to the changes in cell cycle transit 
time and the high rate of retinal progenitors engaging in differentiation. Interestingly, the 
premature cell cycle exit followed by disturbed balance between the numbers of early 
retinal self-renewing progenitors and the birth of committed neuronal precursors can be 
corrected with overexpression of Cyclin E1 or depletion of p27 protein (Das, Choi et al. 
2009). 
Overall these data suggest that Cyclin D2 acts as a cell fate determinant during cell 
division and selectively regulates self-renewal of the SVZ progenitor cells. Conversely, 
Cyclin D1, but not Cyclin D2, affects cellular fate in retinal progenitors by regulating the 
duration of G1 phase. How Cyclin D1 is affecting cell fate, or if it can act as a direct fate 
determinant analogous to Cyclin D2, remains under investigation. 
E-type Cyclins in mode of division 
The most detailed information on the role of Cyclin E1/ E2 in the mode of division 
and their subsequent function in the mechanisms governing neural cell fate control comes 
from studies in Drosophila. The NSCs of the thoracic segment in the CNS of the 
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Drosophila embryo, referred to as neuroblasts, are characterized by expression of Cyclin 
E1 that localizes unequally during an initial self-renewing asymmetric division (Berger, 
Pallavi et al. 2005). In the daughter neuroblast, Cyclin E1 acts upstream of prospero 
(pros) and glial cell missing (gcm) proteins that lead to the generation of a neuron while 
the other daughter generates glia (Ragone, Bernardoni et al. 2001; Berger, Pallavi et al. 
2005; Kannan, Berger et al. 2010). The neuroblasts in the abdominal segment however, 
use a specific mechanism involving Abdominal-A protein mediated downregulation of 
Cyclin E1 levels to restrict the multipotent character of the neuroblasts. The decrease in 
Cyclin E1 results in symmetric division and generation of two glial cells (Kannan, Berger 
et al. 2010). 
In contrast to the asymmetrically self-renewing neuroblasts in the developing CNS 
of Drosophila, their progeny, ganglion mother cells (GMCs), undergo asymmetric 
terminal divisions (Thomas, Bastiani et al. 1984; Wai, Truong et al. 1999). According to 
Bhat et al. an uneven distribution of the Cyclin E1 protein confers self-renewing, 
asymmetric division potential to GMCs (Bhat and Apsel 2004). High levels of Cyclin E1, 
accumulating in one of the two descending progenitors, cause enhanced progression from 
G1 to S phase and a blockage in cell cycle exit in one daughter cell while the other 
commits to differentiation (Bhat and Apsel 2004). Although the question of whether 
Cyclin E1 distribution is a passive or an active process still remains to be answered, 
Cyclin E1 emerges as a key and direct component of fate decisions based on the mode of 
division control.  
To date the mechanisms observed in Drosophila have not been reported in 
vertebrates. Nonetheless, the available studies suggest that Cyclin E1/ E2 participates in 
fate determination through regulation of division symmetry in the mammalian neural 
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system. An ex vivo study that investigated the cell cycle mechanisms behind the 
development of the primate cortex (corticogenesis) established that Cyclin E1 plays an 
essential role in cell fate decisions and self-renewal among a population of supragranular 
progenitors of the outer subventricular zone (OSVZ) (Lukaszewicz, Savatier et al. 2005). 
These results demonstrated that the levels of Cyclin E1 were upregulated in the region 
characterized by a high frequency of cell cycle re-entry, reduced G1 phase and an 
elevated proliferation rate (Lukaszewicz, Savatier et al. 2005). Furthermore, despite the 
developmental characteristics that are specific to primates, rodent corticogenesis 
demonstrates similar crucial features including patterning of the germinal zone and 
common expression of specific genes within the SVZ (Kennedy and Dehay 1993; Sestan, 
Rakic et al. 2001; Nieto, Monuki et al. 2004; Lukaszewicz, Savatier et al. 2005). 
Data by Noctor et al. revealed that the SVZ of the mouse brain is characterized by 
predominant symmetric divisions in opposition to the ventricular zone where the majority 
of progenitor cells divide asymmetrically (Noctor, Martinez-Cerdeno et al. 2004). 
Interestingly, in this work the symmetric pattern of division in the SVZ includes both, a 
small population of cells that divide symmetrically to self-renew and a prevalent number 
of populations that undergo symmetric neurogenic divisions. Consistently, the regulation 
of Cyclin E1 in the primate OSVZ orchestrated the ongoing extensive neurogenesis 
within that region (Lukaszewicz, Savatier et al. 2005). These data suggest that Cyclin E1-
mediated effects can regulate the mode of division in the SVZ and are important for 
sustained neurogenesis during development. To date there is insufficient evidence 
implying the role of Cyclin E1 as a direct fate determinant in the symmetry of division in 
the developing mammalian CNS. A careful redistribution analysis of Cyclin E1 to the 
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mitotic pairs of the progeny within the SVZ, followed by a study of the cell cycle 
mechanisms underlying fate determination are required for further conclusions.  
As discussed previously, both D-type and E-type Cyclins regulate the duration of 
G1 phase and affect the window of time available for specific developmental cues acting 
at the indicated stage. Importantly, an analogous model has been proposed that involves 
changes in the timing of cell cycle transit and intrinsic fate determinant segregation 
(Calegari and Huttner 2003; Gotz and Huttner 2005; Dehay and Kennedy 2007) (Fig.4). 
The overexpression of cyclins is unequivocal for delaying the generation of post-mitotic 
cell populations. Cyclin upregulation will keep the competent precursor in the cell cycle, 
endorsing its self-renewal. Hence, the reduced expression of cyclins is expected to cause 
cell cycle exit and differentiation. According to the proposed model, the changes in cyclin 
expression can regulate the window of time sufficient for the intrinsic fate determinants to 
act effectively, thus affecting the symmetry of division. Hence it can be hypothesized that 
even in the face of uneven fate determinant segregation the overexpression of G1 phase 
cyclins may result in symmetric division due to insufficient time for the determinant to 
execute its effects (Calegari and Huttner 2003; Gotz and Huttner 2005; Dehay and 
Kennedy 2007). This hypothesis would indicate that G1 phase duration is closely 
associated with mode of division control, providing a mechanism by which cyclin 
dependent regulation of G1 phase lengthening can regulate neurogenesis. 
In conclusion, the neurogenic switch in NSCs resulting in gradually more restricted 
progenitors along development is associated with stretching of their cell cycle 
predominantly due to cyclin regulated lengthening of G1 phase (Takahashi, Nowakowski 
et al. 1995). We hypothesize that this supports a mechanistic model whereby cyclin-CDK 
complexes  can affect fate determinant function and control the symmetry of division.   
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Figure 4. The link between cell cycle length and mode of division. Following mitosis the 
daughter cells A and B inherit uneven amount of a cell fate determinant (light and dark 
blue bar respectively). The fate determinant can induce neurogenesis depending on the 
G1 phase time sufficient for it to act. The G1 phase machinery can regulate the G1 phase 
duration so in the shortest time (1) none of the cells becomes a neuron. If the G1 phase 
gets longer (2) cell A becomes a neuron due sufficient time for the amount of the 
determinant to act. Further prolonged G1 phase allows both cells to differentiate as its 
duration is sufficient even for low amount of the fate determinant to exert its effect. 
Modified with permission: Nature Publishing Group© (license# 3126700971609) and 
Gotz and Huttner 2005, Nature Reviews. Molecular Cell Biology, 2005 Oct;6(10):777-88.  
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Cell cycle inhibitors in neural development 
The cell cycle can be negatively regulated by Ink4 and Cip/Kip groups of CDK 
inhibitors. Both families play an essential role in the development of the nervous system, 
reviewed in (Beukelaers, Vandenbosch et al. 2012). At the embryonic stages of 
development the expression of cell cycle inhibitors remains low to allow for high levels 
of proliferative expansion, reviewed in (Cheng 2004). The overexpression of p21
Cip1
 or 
p27
Kip1
 in embryonic stem cells results in the lengthening of G1 phase. This p21
Cip1
/ 
p27
Kip1
 driven mechanism is speculated to control the proper schedule of differentiation 
events along development (Li, Ballabeni et al. 2012). During postnatal development CDK 
inhibitors  regulate entry into quiescence in early G1 phase (Blomen and Boonstra 2007) 
and their expression in the postmitotic neurons suggest that cell cycle inhibitors sustain 
mature neuronal phenotype (Herrup and Yang 2007).     
 p21
Cip1
 
During adult neurogenesis p21
Cip1
 plays an antiproliferative role in the neurogenic 
regions of the brain, maintaining cellular quiescence (Qiu, Takagi et al. 2004). The 
lifelong supply of neural progenitor cells and continual neurogenesis rely on p21
Cip1
 
expression as p21
Cip1
 loss correlates with observed exhaustion of the neural stem cell pool 
(Kippin, Martens et al. 2005) in vivo. Importantly, p21
Cip1
 deficient neural progenitor 
cells demonstrate an increased proliferation rate in neurosphere formation assays in vitro 
(Kippin, Martens et al. 2005). Alternatively, some groups reported no proliferation 
defects in p21
Cip1
- deficient animals at early stages of postnatal development (Qiu, Takagi 
et al. 2004; Kippin, Martens et al. 2005). This observation was attributed to the fact that 
p21
Cip1
 specific expression in found to accumulate at late stages of development in the 
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most stem-like population of neural progenitor cells that reside within the neurogenic 
niche of the SVZ (type B cells) (Kippin, Martens et al. 2005).  Recently, a p21
Cip1
-
mediated molecular mechanism behind neural stem cell maintenance was proposed that 
involves direct regulation of the pluripotency inducing factor, Sox2 (Marques-Torrejon, 
Porlan et al. 2013). The study revealed that p21
Cip1
 is capable of blocking Sox2 enhancer 
by a direct interaction thus reducing Sox2 expression in neural progenitors. Upregulation 
of Sox2 in p21
Cip1
- deficient neural progenitors resulted in increased entry into 
senescence due to accumulation of DNA damage and activation of p53 and p19
ARF
 
tumour suppressor genes (Marques-Torrejon, Porlan et al. 2013).   
 p27
Kip1
 
p27
Kip1
 overexpression in the populations of oligodendrocyte precursors at 
embryonic stages of development result in lower rates of proliferation (Lukaszewicz, 
Savatier et al. 2005). Consistently, in the adult SVZ p27
Kip1
 deficient progenitor cells 
demonstrate an increase in proliferative potential. Indeed, p27
Kip1
 is considered to act as 
an inhibitor of proliferation during neural development. p27
Kip1
 was demonstrated to 
repress Sox2 during differentiation in a mechanism similar to the one presented for 
p21
Cip1
 (Li, Ballabeni et al. 2012). In contrast to the type B cell specific expression of 
p21
Cip1
, p27
Kip1
 deletion was demonstrated to selectively expand the transit amplifying 
precursor (type C cells) population followed by a decreased number of neuroblasts (type 
A cells) (Doetsch, Verdugo et al. 2002). Interestingly, since C-type cells give rise to A-
type neuroblasts, it is speculated that the loss of p27
Kip1
 results in a prolonged 
proliferative state of the amplifying precursors at the expense of the more committed 
neuroblast progenitors  (Doetsch, Verdugo et al. 2002).  
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Studies on the role of p27
Kip1
 in neural commitment and differentiation established 
that p27
Kip1
 is a crucial component of the internal timer required for neural progenitors to 
differentiate at specific times during development (Durand, Gao et al. 1997). Experiments 
on oligodendrocyte populations  revealed that p27
Kip1
 protein accumulates gradually in 
cells over time as they continue to proliferate (Durand, Gao et al. 1997).  In addition, it 
has been demonstrated that p27
Kip1
 deficiency confers increased mitogen sensitivity to 
progenitor cells. Upon mitogen withdrawal, p27
Kip1
- deficient cells demonstrate a delay in 
cellular arrest suggesting that p27
Kip1
 regulates the mitogen response in neural cells 
during development (Durand, Fero et al. 1998). Overall, p27
Kip1
 appears to play a crucial 
role in the orchestrated network of events regulating neural development. 
p16
Ink4a 
Aging of the CNS results in a significant decrease of the proliferative pool at 
neurogenic sites, most likely due to age progressive senescence (Campisi 2005; Lombard, 
Chua et al. 2005; Molofsky, Slutsky et al. 2006). The levels of p16
Ink4a
 cell cycle inhibitor 
are reported to increase with age in the SVZ and olfactory bulb, two main sites of 
proliferation and neurogenesis within the adult brain, respectively (Molofsky, Slutsky et 
al. 2006). Loss of p16
Ink4a
 prolongs self-renewal of multipotent progenitors in aging 
animals (Molofsky, Slutsky et al. 2006). Interestingly, p16
Ink4a
 deficiency-induced 
proliferation and neurogenesis were the most profound on the type B progenitors than the 
other lineage committed cells (Molofsky, Slutsky et al. 2006). These data  suggest the 
hypothesis that cell cycle changes along lineage commitment render more restricted 
progenitors less dependent on the p16
Ink4a
 inhibitor (Molofsky, Slutsky et al. 2006). 
Moreover, the deletion of p16
Ink4a
 did not prolong proliferation in the dentate gyrus, 
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pointing to regional specific differences in cell cycle regulation of the adult neurogenic 
progenitors (Molofsky, Slutsky et al. 2006). Hence, p16
Ink4a
 regulates senescence 
mechanisms that play a critical role in the aging brain.  
 
 Brain tumours 
A brain tumour is a mass of abnormal cells growing within the brain structures, or 
in the periphery of the brain (Louis, Ohgaki et al. 2007).  Due to the organ's vitality brain 
tumour formation is devastating in nature. Tumours of the CNS are the leading cause of 
death among children and the third leading cause of death in young adults between 20 and 
39 years of age. It is estimated that 27 Canadians are diagnosed with a brain tumour every 
day (http://www.braintumour.ca/2494/brain-tumour-facts).  
Brain tumour subtypes and complexity 
Over 120 types of brain tumours are included into classification prepared by the 
World Health Organization (WHO) that distinguishes between histopathological entities, 
variants of entities and histological patterns of differentiation (Louis, Ohgaki et al. 2007). 
Every separate type or entity represents a distinct morphology, biological behavior, 
location and age distribution. Variants of a specific entity are defined by a certain, 
confirmed histological identity with a specific pathological significance. 
Glioma is considered a brain tumour of a glial origin that encompasses all grades of 
WHO astrocytic tumours, oligodendrogliomas, ependymomas and mixed gliomas (Louis, 
Ohgaki et al. 2007). Histological grading included in the WHO brain tumour 
classification defines the malignancy scale and plays a role in the choice of therapy and 
proper chemotherapy protocol in the clinical setting. Across all tumour entities the WHO 
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established four grades of malignancy (Louis, Ohgaki et al. 2007). Grade I is 
characterized by low proliferative potential where the lesion can be cured following 
surgical resection. Grade II neoplasms (diffuse astrocytomas) are defined as a low 
proliferative lesion but can infiltrate and often recur with a propensity to progress to a 
higher grade of malignancy. The WHO grade III tumours (anaplastic astrocytomas) 
present with malignancy characteristics such as high mitotic index and nuclei atypia. The 
choice of therapy regimen in patients with grade III tumours usually includes adjuvant 
radiation and chemotherapy. Finally, grade IV glioma or glioblastoma multiforme (GBM) 
represents the most aggressive form of brain tumour due to its highly infiltrative nature, 
pre- and postoperative spread to surrounding tissues and very poor survival (Table 2). 
GBM demonstrate extreme heterogeneity when assessed by gross pathology (necrosis 
prone lesions or hemorrhage), microscopic assessment (microvascular proliferation, 
pleomorphic nuclei) and genetic diversity. At a molecular level glioma is characterized by 
a multitude of genetic amplifications, deletions and mutations; these characteristics 
contribute to the chemo- and radio- resistance of this disease.  
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Table 2. WHO Grading of Tumours of the Central Nervous System. Modified with 
permission: Springer© (license# 3150870813401) and Louis, D. N., H. Ohgaki, et al. 
2007.  Acta Neuropathol. 2007 Aug;114(2):97-109 . 
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Molecular multiplicity of brain cancer 
Genomic profiling leading to molecular classification of tumours is emerging as an 
indispensible tool in modern medicine. By sequencing 22,661 genes Parsons et al. 
established that on average over 45 different mutations characterize a single GBM tumour 
(Parsons, Jones et al. 2008). Work performed by The Cancer Genome Atlas (TCGA) 
Research Network (TGCA 2008), involving 91 GBM samples, established that 223 genes 
were affected by 453 non-silent somatic mutations (Verhaak, Hoadley et al. 2010). The 
high throughput and comprehensive analysis of next-generation sequencing technologies 
provides extensive data useful for molecular classification of GBM. The detailed analysis 
of 601 genes revealed a mutational spectrum within p53, Rb and tyrosine kinase pathways 
establishing the noted aberrations as the requirement in GBM pathogenesis (TGCA 
2008). Based on the core gene expression, as well as copy number data, four GBM 
subtypes emerged that contribute to better understanding of molecular networks behind 
GBM pathology and potentially advance therapeutic strategies in a clinical setting. The 
specifics of these subtypes are outlined below:  
Classical subtype 
The Classical subtype is characterized by amplification of chromosome 7 and loss 
of chromosome 10. Epidermal growth factor receptor (EGFR) amplification was also 
observed in 97% of samples tested and was followed by a four-fold increase in EGFR 
expression. Point or variant III (vIII) mutations of EGFR accounted for 54% of the pool 
analysed (Verhaak, Hoadley et al. 2010). Interestingly, focal homozygous deletion of the 
9p21.3 locus encoding for both p16
Ink4a
 and p14
ARF 
occurs frequently in this subtype and 
is correlated with EGFR amplification in almost 95% of samples tested. Furthermore, 
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mutations in the 9p21.3 locus exclusively affected the integrity of the Rb pathway. 
Notably, several marker proteins involved in stemness were upregulated in the Classical 
subtype including Notch and Sonic hedgehog signaling pathways. Although mutations to 
p53 are the most common aberration among human brain tumours, the Classical subclass 
demonstrates lack of mutations in the gene. Moreover, the Classical subtype is strongly 
associated with the gene expression characteristic of mature astrocytes (Verhaak, Hoadley 
et al. 2010).  
Mesenchymal subtype 
Deletion of neurofibromatosis 1 (NF1) was observed to be the most significant and 
frequent mutation in the mesenchymal subclass of glioma, accounting for 53% of the 
samples tested. Interestingly, the NF1 deletion frequently co-occurred with phosphatase 
and tensin homolog (PTEN) mutations indicating that the Akt pathway plays a crucial 
role in this subset. PTEN holds phosphatase activity and acts primarily through PI3K 
pathway inhibition but a role in cell cycle regulation has been reported as well (Koul 
2008). The high activity of the super family of tumour necrosis factor and Nuclear Factor 
kappa-light-chain-enhancer of activated B cells (NFB) pathway was demonstrated to 
occur in the mesenchymal subclass (Verhaak, Hoadley et al. 2010). This suggests that an 
elevated fraction of necrosis and presence of inflammatory infiltrates. In addition, 
characteristic expression of mesenchymal markers were noted and samples tested within 
the subclass expressed the signature of astroglial cultured cells, as well as elevated levels 
of microglial markers. Interestingly, the majority of immortalized cell lines analyzed 
represented the genetic signature of the mesenchymal subset of GBM (Verhaak, Hoadley 
et al. 2010). 
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Proneural subtype 
Focal 4q12 amplification of the platelet-derived growth factor receptor 
(PDGFRA) locus was found in all GBM samples tested, the proneural subset of glioma 
was characterized by a significant upregulation in the frequency of this aberration and 
subsequent overexpression of PDGFRA (Verhaak, Hoadley et al. 2010). In addition, 
several point mutations in the so called lg-domain of PDGFRA are found, these mutations 
can potentially disrupt the binding of the PDGF ligand to the receptor (Verhaak, Hoadley 
et al. 2010). Another major feature of the proneural subtype is multiple point mutations in 
the isocitrate dehydrogenase 1 gene (IDH1) (Verhaak, Hoadley et al. 2010). The overall 
analysis showed that p53 mutations and loss of heterozygosity (LOH) are more frequent 
in the proneural samples than in any other subtype of glioma. Interestingly, the proneural 
samples expressed oligodendrocytic but not astroglial markers and were characterized by 
upregulation of oligodendrocyte development related genes (Verhaak, Hoadley et al. 
2010). Oligodendrocyte developmental genes have a pronounced downregulation of 
p21
Cip1
 levels and an increase in markers indicative of proliferative potential in neural 
stem cells and glioma. Patients falling under the proneural subtype tend to be at an overall 
younger age distribution (Verhaak, Hoadley et al. 2010). Proneural-type tumours 
represented three out of four secondary GBMs tested (Verhaak, Hoadley et al. 2010). The 
secondary GBMs were originally derived from lower grade neoplasia or IDH1 mutations. 
Importantly, unlike any other subtype, intensifying chemotherapy did not decrease 
mortality in patients with proneural tumours (Verhaak, Hoadley et al. 2010). 
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 Neural subtype 
Neural subtypes are characterized by the expression of neuronal markers, including 
genes involved in neurite and axon outgrowth, synaptogenesis and synaptic transmission 
(Verhaak, Hoadley et al. 2010). The neural subclass samples expressed several genes 
reflecting differentiated neuronal phenotype but were positive for astrocytic and 
oligodendrocytic markers as well. Importantly, the gene expression signatures are very 
close to the ones obtained from normal brain tissue despite the fact that the samples 
analysed demonstrate typical GBM tumour morphology, multiple mutations as well as 
copy number alterations (Verhaak, Hoadley et al. 2010).  
In conclusion, the genetic multiplicity of the proposed GBM subtypes indicates the 
importance and need for the development of therapeutically diverse strategies to achieve 
clinical success. Targeting the populations of cells responsible for GBM initiation, 
progression and resistance to therapy requires their prior identification. The work 
performed by the TCGA research network demonstrated a strong correlation between the 
established GBM classes and normal neural lineages suggesting that a common neural 
stem cell that undergoes aberrations at different levels of its commitment may constitute 
the source of glioma. Importantly, self-renewing neural cells found within the brain 
demonstrate expression of distinct markers including either EGFR or PDGFRA (Jackson, 
Garcia-Verdugo et al. 2006) indicating potential diversity among the populations, 
possibly correlating to their level of lineage commitment. 
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The role of G1 phase in neural tumourigenesis 
 Compromised control of progression from G1 to S phase and reactivation from the 
quiescent state leading to inappropriate proliferation characterises virtually all malignant 
cells. As anticipated, disrupting the network of G1 phase regulation constitutes an 
important mechanistic basis behind neoplasia. Among extensive literature demonstrating 
distinct aberrant pathways behind cancer, several lines of evidence support the 
uncontrollable role of cyclins, CDKs and cell cycle inhibitors in multiple cancers 
including glioma.  
D-type Cyclins and gliomagenesis 
Deregulation of the D-type Cyclins in glioma 
Glioma cells gain proliferative benefit by evading the strict control of the G1-S cell 
cycle checkpoint. The Cyclin D-CDK4/ Rb axis is a primary mechanism controlling the 
checkpoint (Serrano, Hannon et al. 1993). Chakravarti et al. demonstrated that Rb control 
over E2F1 is lost or deregulated in 91% of the glial tumours tested (Chakravarti, Delaney 
et al. 2001). This occurs due to deactivating or deletion mutations in the Rb gene 
(Chakravarti, Delaney et al. 2001). Furthermore, amplification of the CDK4 and D-type 
Cyclin loci are also reported (2008; Koyama-Nasu, Nasu-Nishimura et al. 2012). G1 
activators, Cyclin D1, Cyclin E1 and CDK4 have been reported to be upregulated in 
~22% of human glioma (Chakravarti, Delaney et al. 2001). Furthermore, Cyclin D1 is 
elevated in progressively higher grades of glioma (Cavalla, Dutto et al. 1998; Hecker, 
Grammer et al. 2002). Several studies have reported that the overexpression of Cyclin D1 
is associated with proliferative, antiapoptotic and proinvasive phenotypes correlating with 
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poor patient prognosis (Buschges, Weber et al. 1999; Sallinen, Sallinen et al. 1999; 
Wang, Wang et al. 2012).  
An elegant study by Read et al. which utilized an organotypic and cell type specific 
glioma model in Drosophila, revealed that constitutive co-activation of EGFR and 
phosphatidylinositide 3-kinase (PI3K) - pathways contributes to the malignant 
transformation of normal glial cells and results in tumour-like masses (Read, Cavenee et 
al. 2009). In this study, overexpression of both pathways led to the suppression of cell 
cycle exit selectively in glia but not in neurons or neuronal precursor cells. Unconstrained 
cell cycle progression and entry resulted in unchecked proliferation and formation of 
transplantable, neoplastic growths that mimic human glioma. Importantly, the study 
established pivotal EGFR and PI3K downstream pathways that cooperate in glioma 
initiation and progression. Among these, the cell cycle regulatory axis emerged as a 
crucial component in the combinatorial network behind the glial neoplastic 
transformation. Specifically, the Cyclin D1-CDK4 complex was shown to play a critical 
role in c-Myc driven EGFR/ PI3K tumourigenesis which was mediated by Rb inactivation 
and inhibition of cell cycle exit (Read, Cavenee et al. 2009).  
EGFR overexpression, amplification and frequent mutation, resulting in the 
truncated EGFRvIII form, are often observed in human glioma (Nishikawa, Ji et al. 1994; 
Huang, Nagane et al. 1997; Halatsch, Schmidt et al. 2006). Notably, EGFR inhibition was 
shown previously to correlate with reduced Cyclin D1 levels and concomitant cell cycle 
arrest in malignant glioblastoma (Ramis, Thomas-Moya et al. 2012). Furthermore, the 
regulation of Cyclin D1-mediated proliferation as a direct output of EGFR activity in 
glioma cells was demonstrated to function under the control of Notch1, which plays an 
important role in glioblastoma pathogenesis (Fan, Mikolaenko et al. 2004; Purow, Haque 
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et al. 2005; Fan, Khaki et al. 2010). Interestingly, Cyclin D1 was demonstrated previously 
to be a direct transcriptional target of activated Notch1 signalling (Ronchini and 
Capobianco 2001; Stahl, Ge et al. 2006), which is essential for Notch1-mediated 
transformation events (Stahl, Ge et al. 2006). In summary, Cyclin D1 expression and its 
cell cycle control in glioma cells can be regulated by mitogen activated transduction 
pathways or Notch, however their exact cooperation requires further investigation.  
Interestingly a novel mechanism of Cyclin D1 regulation in glioma cells was 
described by Hui et al. that involved a micro RNA molecule that is significantly 
downregulated in both brain tumour cell lines and tissues obtained from glioma patients 
(Hui, Yuntao et al. 2013). miR195 overexpression was reported to decrease the G0 and 
G1 cell  fraction, reduce anchorage independent growth and upregulate 
hyperphosphorylated Rb. The observed changes in glioblastoma cell characteristics were 
attributed to a decline in the protein levels of both Cyclin D1 and Cyclin E1. miR195 was 
revealed to downregulate the expression of both Cyclin D1 and E1 at the 
posttranscriptional level through targeting their 3' untranslated regions (3'UTRs) (Hui, 
Yuntao et al. 2013). Thus loss of miR195 in human glioma contributes to upregulation of 
Cyclin D1/ E1-mediated proliferation. 
Cyclin D1 and glioma invasion 
The aggressive character of glial tumours is associated with cellular invasion due to 
extracellular matrix (ECM) degradation and changes in cellular motility reviewed in 
(Hood and Cheresh 2002). Digestion of the ECM is performed by a family of enzymes 
known as matrix metalloproteinases (MMPs). The production of MMPs in higher but not 
in lower grades of glioma suggests their potential role in tumour progression (Sawaya, 
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Yamamoto et al. 1996; Arato-Ohshima and Sawa 1999). The function of Cyclin D1 in 
promoting glioma to more aggressive stages may depend on the ability of the D-type 
Cyclins to modulate the tumour microenvironment. Cyclin D1 overexpression is 
accompanied by an increased invasive phenotype that correlates with elevated levels and 
activity of MMPs. A Cyclin D1-mediated increase in MMP activity is speculated to 
involve extracellular-signal-regulated kinases (ERKs) (Gum, Wang et al. 1997). Cyclin 
D1 was reported previously to cause an elevation of ERK expression, whereas ERK 
dependent signalling is known to induce MMPs levels (Gum, Wang et al. 1997).  
Cyclin D1 is suggested to play a role in cellular motility as its overexpression leads 
to a significant increase in the levels of Rac-1, one of the major regulators of cytoskeleton 
organization (Arato-Ohshima and Sawa 1999). The Cyclin D1-mediated upregulation of 
Rac-1 is followed by membrane ruffling, which is a typical characteristic of invasive cells 
(Arato-Ohshima and Sawa 1999). Moreover, Cyclin D1 was demonstrated to play an 
essential role in focal adhesion kinase (FAK) -mediated proliferation. FAK is a tyrosine 
kinase that plays a role in adhesion and mobility and its overexpression was previously 
shown to increase metastatic activity in breast cancer cells (Chan, Cortesio et al. 2009). 
FAK protein levels and activity are frequently elevated in anaplastic astrocytoma and 
GBM (Zagzag, Friedlander et al. 2000; Hecker, Grammer et al. 2002). Interestingly, the 
observed increase in cell cycle progression rate in FAK overexpressing glioma cells was 
suppressed upon downregulation of Cyclin D1 but not Cyclin E1 (Ding, Grammer et al. 
2005). These data suggest a unique role for Cyclin D1 in FAK- driven invasion of glioma 
cells. Notably, Cyclin D1-CDK4 activity appears to be obligatory for glioma formation 
and progression in the platelet derived growth factor (PDGF)-induced tumour mouse 
model. Although Cyclin D1 knockout mice still develop brain tumours, the progression to 
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higher grades of malignancy is perturbed (Ciznadija, Liu et al. 2011). Interestingly, 
Cyclin D1 deficient mice fail to fully recruit and activate the tumour associated microglia 
that were previously implicated in promotion of gliomagenesis to higher stages. Thus, 
Cyclin D1 and CDK4 are required for the proper function of tumour activated microglia 
or for other populations of stromal cells that support their activation (Ciznadija, Liu et al. 
2011). This suggests an essential role for Cyclin D1 in mediating the microenvironment 
effects in glioma progression.  
In summary Cyclin D1 overexpression in glioma plays a role in cellular adhesion, 
degradation of the ECM and cellular motility through regulating key proteins involved in 
the invasive character of the GBM. The mechanistic details of this regulation remain to be 
determined.  
Cyclin D and Brain Tumour Initiating Cells (BTICs) 
A population of multipotent BTICs is speculated to reside within the brain tumour 
mass. BTICs express NSC markers, including CD133 and Musashi-1 (Toda, Iizuka et al. 
2001; Hemmati, Nakano et al. 2003; Bao, Wu et al. 2006). Functionally BTICs self-renew 
and form tumours upon xenotransplantation to immunocompromised mice (Singh, 
Hawkins et al. 2004; Wang, Wang et al. 2008; Koyama-Nasu, Nasu-Nishimura et al. 
2012). Moreover, BTICs contribute to glioma progression and to glioma resistance to 
chemo- and radiotherapy of the tumour (Barnes, Porter et al. 2003; Sakariassen, 
Immervoll et al. 2007; Beier, Schulz et al. 2011). Importantly, existence of stem-like 
cancer initiating cells has been reported in a broad variety of other tumours (Huntly and 
Gilliland 2005; Hassan, Wang et al. 2013; Zomer, Ellenbroek et al. 2013); however, the  
38 
 
characteristics of the cell cycle components that control the tumourigenicity of BTICs 
remain under investigation.  
Recently, Cyclin D2 was demonstrated to play a crucial role in cell cycle 
progression and tumourigenic potential in BTICs (Koyama-Nasu, Nasu-Nishimura et al. 
2012). In the proneural subtype of glioma, Cyclin D2 levels were upregulated in 
undifferentiated self-renewing BTICs whereas differentiated cells of the same type 
demonstrated almost no Cyclin D2 expression (Koyama-Nasu, Nasu-Nishimura et al. 
2012). Additionally, both Cyclin D2-CDK4 and -CDK6 complexes were responsible for 
Rb phosphorylation in undifferentiated cells. In contrast, Cyclin D2 downregulation in 
self-renewing populations of glioma initiating cells led to a significant increase in the 
fraction of G1-arrested cells and decreased phosphorylation of Rb. Notably, Cyclin D2 
knockdown effects were not mimicked by downregulation of Cyclins D1 or D3  
(Koyama-Nasu, Nasu-Nishimura et al. 2012).  
Cyclin D2 is not expressed in cells obtained from patients with the mesenchymal 
subtype of glioma and its expression is found to be significantly upregulated in higher 
grades of glioma in comparison to lower ones (Koyama-Nasu, Nasu-Nishimura et al. 
2012).  These data suggest a role for BTICs in the more aggressive subtypes of glioma. 
Indeed, self-renewing glioma cells transplanted into immunocompromised mice produce 
significantly more severe tumours than that seen with differentiated cells, and severity 
correlates with Cyclin D2 expression (Koyama-Nasu, Nasu-Nishimura et al. 2012). 
Xenografts of BTICs with knocked down Cyclin D2 result in increased survival of 
recipient mice in comparison to control cells (Koyama-Nasu, Nasu-Nishimura et al. 
2012). Overall, Cyclin D2, but not Cyclin D1 or D3, is the most abundantly expressed D-
type Cyclin in human glioma initiating cells contributing to their increased cell cycle 
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progression and tumourigenicity (Koyama-Nasu, Nasu-Nishimura et al. 2012). Owing to 
the fact that adult NSCs primarily express Cyclin D2, one can speculate that the presence 
of Cyclin D2 in BTICs could have conferred the tumourigenic potential to normal NSCs 
(Kowalczyk, Filipkowski et al. 2004; Walzlein, Synowitz et al. 2008; Koyama-Nasu, 
Nasu-Nishimura et al. 2012).  
Surprisingly, it has been demonstrated that in opposition to Cyclin D2, Cyclin D1 
levels are found to be higher in glioma cells that undergo differentiation, and 
consequently, the knockdown of Cyclin D1 in differentiated cells causes an increase in 
the number of tumour cells residing in G1 phase (Koyama-Nasu, Nasu-Nishimura et al. 
2012). Interestingly, Cyclin D1, but not Cyclin D2 or E1, was previously suggested to 
regulate cell cycle progression in the CD133+ glioma cell populations as its levels were 
downregulated in c-Myc knockdown cells followed by a decline in self-renewal as well as 
decreased tumour formation capacity (Pacey, Stead et al. 2006; Wang, Wang et al. 2008). 
Since the expression of Cyclin D1 but not Cyclin D2 was reported in the mesenchymal 
group of glioma cells (Koyama-Nasu, Nasu-Nishimura et al. 2012), the observed 
discrepancy in the reported role of Cyclin D1 and D2 in glioma stem cells can be 
attributed to the different subtypes of glioma used for the studies. Moreover, the 
differences suggest that the role of Cyclin D1 might be restricted to a specific, CD133+ 
population of glioma initiating cells and so far Cyclin D2 function has been only 
addressed in a heterogeneous glioma populations. 
In support of this, Cyclin D1 driven activity of CDK4 is known to play an essential 
role in the radiation resistance of the CD133+ glioma cells. The CD133 enriched 
population exhibits a significant decrease in radiosensitivity due to the upregulated Akt/ 
Cyclin D1 pathway. Akt suppresses glycogen synthase kinase-3 beta (GSK3mediated 
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degradation of Cyclin D1 and thus promotes its function (Shimura, Noma et al.). 
Importantly, besides its role in promoting G1 phase progression, Cyclin D1 plays a 
critical role in DNA damage repair as shown previously by Jirawatnotai et al., indicating 
its high importance in BTIC targeting therapies. Depletion of Cyclin D1 was 
demonstrated to reduce homologous recombination repair in radioresistant cells (Kao, 
Jiang et al. 2007; Shimura, Kakuda et al. 2011). To execute this particular function Cyclin 
D1 cooperates with Rad51, a recombinase responsible for the homologues repair 
processes (Kao, Jiang et al. 2007; Jirawatnotai, Hu et al. 2011).  
To summarize, both Cyclin D1 and D2 emerge as key players promoting 
proliferation and self-renewal in BTICs. Furthermore, the specific expression of D-type 
Cyclins in different subsets of glioma and the role of Cyclin D1 in radio-resistance 
suggest their potential advantage not only as prognostic markers but also in improving the 
efficacy of radiotherapy.  
Cyclin E1 and gliomagenesis 
Cyclin E1 and genetic instability in glioma 
Accumulation of Cyclin E1 in cancer cells occurs due to an amplification of the 
gene (Akama, Yasui et al. 1995; Kitahara, Yasui et al. 1995; Courjal, Louason et al. 1996; 
Marone, Scambia et al. 1998) as well as posttranscriptional modifications responsible for 
increased protein levels (Porter, Malone et al. 1997). In addition there are known splice 
variants of Cyclin E1 that do not appear in conditions of normal cell cycle function 
(Sewing, Ronicke et al. 1994; Mumberg, Wick et al. 1997). It has been established that 
Cyclin E1-mediated tumourigenesis is attributed to genetic instability (Loeb, Kostner et 
al. 2005). Cyclin E1 overexpression alone or with a disabled p53 dependent checkpoint 
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causes aneuploidy in human cancer and primary cells  (Spruck, Won et al. 1999; Minella, 
Swanger et al. 2002; Hwang and Clurman 2005). This aneuploidy is speculated to arise 
from defects in S-phase progression caused by faulty MCM loading, resulting in a stalled 
replication fork and subsequent breakage of the DNA  (Hwang and Clurman 2005). This 
results in overridden checkpoint and defects in chromosome condensation and pairing. 
Moreover, although centrosome function defects are not observed upon Cyclin E1 
depletion, centrosome amplification and aneuploidy were reported when Cyclin E1 was 
overexpressed following loss of p53 (Kawamura, Izumi et al. 2004; Hwang and Clurman 
2005). Multiple studies suggest that Cyclin E1 takes part in, or contributes to a neoplastic 
event, rather than initiating tumorigenesis (Geisen and Moroy 2002; Martins and Berns 
2002); (Haas, Johannes et al. 1997). Importantly, double Cyclin E1 and E2 knockout mice 
demonstrate resistance to oncogenic transformation with overexpression of Ras, c-Myc 
and a dominant negative mutant of p53 in different combinations (Geng, Yu et al. 2003). 
Consistently, several lines of evidence show that excess of Cyclin E1 in human brain 
cancer contributes to more aggressive presentation and poor patient survival (Tamiya, 
Mizumatsu et al. 2001). 
 Impaired degradation of Cyclin E1 in glioma 
Cyclin E1 degradation is known to play a crucial role in glioblastoma (Hagedorn, 
Delugin et al. 2007) as the forced expression of its non-degradable mutant contributes to 
an increase in chromosomal aberration events (Hwang and Clurman 2005). The 
ubiquitination and subsequent proteasomal degradation of Cyclin E1 in human glioma 
cells is frequently impaired due to the reduced levels or loss of function mutations in the 
Parkinson protein 2 (PARK 2) E3 ubiquitin ligase (Veeriah, Morris et al. 2010; Veeriah, 
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Taylor et al. 2010; Vlachostergios, Voutsadakis et al. 2012; Yeo, Ng et al. 2012). Cancer 
specific mutations analyzed by Veeriah et al. showed an attenuated interaction between 
PARK 2 and Cyclin E1 in glioblastoma cells (Veeriah, Morris et al. 2010). In addition, 
PARK 2 knockdown results in stabilization and accumulation of Cyclin E1 followed by 
an increased fraction of cells in S and G2/M phases, multipolar spindles and abnormal 
mitoses associated with genetic anomalies (Veeriah, Morris et al. 2010).  
Interestingly, a tumour suppressor FBXW7/ hCDC4 (Akhoondi, Sun et al. 2007), 
known to be responsible for Cyclin E1 targeted proteolysis, was shown to be significantly 
reduced in human astroglial tumours (Hagedorn, Delugin et al. 2007). FBXW7/ hCDC4 
genetic inactivation, followed by loss of function, was demonstrated previously to 
attenuate cell cycle control of Cyclin E1 and result in genetic alternations prior to 
malignant transformation (Ekholm-Reed, Spruck et al. 2004; Rajagopalan, Jallepalli et al. 
2004). According to Hedegorn et al., hCDC4 levels are significantly reduced in grade IV 
gliomas in comparison to lower grades (Hagedorn, Delugin et al. 2007). The decrease in 
FBXW7/ hCDC4 expression levels correlates with accumulation of Cyclin E1 levels and 
corresponds with defective chromosome segregation at mitosis (Hagedorn, Delugin et al. 
2007). In summary, mutations or defects in protein degradation that lead to an increase in 
Cyclin E1 levels play a significant role in human gliomagenesis. 
Cyclin E1 and p27 in neural tumourigenesis 
The role of Cyclin E1 in the initiation and progression of CNS malignancies is 
known to cooperate with the attenuated role of the p27
Kip1
 cell cycle inhibitor (Tamiya, 
Mizumatsu et al. 2001). Consequently, it has been established that patients with low 
Cyclin E1 and high p27
Kip1
 levels have the best survival prognosis, whereas the worst 
43 
 
survival is observed in patients with high Cyclin E1 and low p27
Kip1
 levels (Tamiya, 
Mizumatsu et al. 2001). These data suggest that the ratio of Cyclin E1: p27
Kip1
 could 
serve as a potential prognostic marker for at least subsets of glioma.  
Moreover, pituitary brain tumours are known to rely on defects in p27 function 
(Roussel-Gervais, Bilodeau et al. 2010). Conditional expression of Cyclin E1 into the 
corticotroph cells of the pituitary gland causes cell cycle re-entry of quiescent cells and 
subsequent hyperplasia (Roussel-Gervais, Bilodeau et al. 2010). Although the cells 
exhibit defects in centrosome structure and number, the occurrence of hyperplasia and 
pituitary brain tumours is low and suggests a limited effect of Cyclin E1 function. 
Interestingly, forced expression of Cyclin E1 in p27
Kip1-/-
 cells results in a higher 
frequency and larger size of pituitary brain tumours (Roussel-Gervais, Bilodeau et al. 
2010). 
PTEN loss of function has been widely described in glioma (Brat, Castellano-
Sanchez et al. 2002; Hill, Hunter et al. 2003; Mischel and Cloughesy 2003). Its 
overexpression in different glioblastoma cell lines causes G0/G1 cell cycle arrest due to 
suppressed activity of CDK2, but not CDK4, and accumulation of hypophosphorylated 
Rb (Cheney, Neuteboom et al. 1999). Interestingly, PTEN upregulation has no effect on 
Cyclin E1 expression levels but significantly increases the amount of p27
Kip1
 protein 
bound to Cyclin E1-CDK2 immunocomplexes (Cheney, Neuteboom et al. 1999). PTEN 
was demonstrated to selectively stimulate p27
Kip1
 transcription by the induction of 
forkhead transcription factors (Medema, Kops et al. 2000; Nakamura, Ramaswamy et al. 
2000). PTEN can also reduce the ubiquitin-mediated degradation of p27
Kip1
 
(Mamillapalli, Gavrilova et al. 2001). Each of these examples ensure there are sufficient 
levels of p27
Kip1
 to suppress Cyclin E1-CDK2 activity and keep cell cycle progression in 
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check. Hence, it can be speculated that this mechanism is frequently lost in glioblastoma 
due to PTEN mutations allowing cells to proliferate out of control.  
Skp2 is a substrate targeting subunit of the Skp2, Cullin, F-box containing E3 
ubiquitin ligase complex (SCF
Skp2
) that participates in p27
Kip1
 proteolytic degradation 
(Carrano, Eytan et al. 1999; Tsvetkov, Yeh et al. 1999) and is often overexpressed in 
cancer (Gstaiger, Jordan et al. 2001). Skp2 was shown to be significantly upregulated in 
PTEN
-/-
 embryonic cells whereas PTEN overexpression in glioma cells causes a decline 
in Skp2 levels and PTEN-mediated p27
Kip1
 upregulation, resulting in Cyclin E1-CDK2 
suppression (Mamillapalli, Gavrilova et al. 2001). Cyclin E1-CDK2 has the ability to 
phosphorylate p27
Kip1
 on Thr-187 residue to target it for degradation (Sheaff, Groudine et 
al. 1997; Vlach, Hennecke et al. 1997).  Interestingly, although Cyclin E1 overexpression 
restores CDK2 activity it does not downregulate p27
Kip1
 levels, suggesting that Cyclin E1 
expression in the absence of Skp2 is not sufficient to rescue a PTEN-induced cell cycle 
arrest in glioma cells; however, coexpression of  Cyclin E1 and Skp2 results in a greater 
effect on cell cycle progression than Skp2 alone (Mamillapalli, Gavrilova et al. 2001). 
In summary, Cyclin E1-induced cell cycle progression is not sufficient to drive 
gliomagenesis alone but Cyclin E1-CDK2 does participate in the multistep gliomagenesis 
process. This multistep process depends on many changes, including downregulation of 
cell cycle inhibitors. 
Cyclin E1 and BTIC 
The Cyclin E1-mediated hyperproliferative potential and ability to recover the cell 
cycle from a quiescent state can be useful in activation and driving of populations of 
human glioblastoma initiating cells. Several studies suggesting that Cyclin E1 expression 
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contributes to gliomagenesis address their questions in heterogeneous populations of 
glioma cells and little is known about the role of Cyclin E1 in the self-renewing BTICs. 
Inhibitor of differentiation 4 (Id4) plays role in fate determination of NSCs and was 
demonstrated to drive transformation and induce a dedifferentiated and self-renewing 
phenotype in Ink4/Arf
-/-
 glia (Jeon, Jin et al. 2008). Cell cycle analysis of the transformed 
astrocytes revealed significant upregulation of Cyclin E1 and hyperphosphorylation of 
Rb. Consequently, Cyclin E1 knockdown resulted in a significant decrease in 
proliferation. Tumour formation from Cyclin E1 overexpressing Ink4/Arf
-/-
 xenografts 
was not as pronounced as the tumour growth from Id4 Ink4/Arf
-/- 
astrocytes. Moreover, 
Cyclin E1 knockdown significantly reduced the size of the Id4 Ink4/Arf
-/-
 tumours and 
tumour cell proliferation, confirming that Id4-induced gliomagenesis depends on Cyclin 
E1-mediated proliferation (Jeon, Jin et al. 2008). Notably, self-renewal analysis, 
including stem cell marker expression and neurosphere formation capacity, showed that 
neither Cyclin E1 overexpression nor Cyclin E1 downregulation had any effect on the 
functional parameters of the stem cell population (Jeon, Jin et al. 2008). Cyclin E1 levels 
were also demonstrated to increase in human glioma upon Id4 overexpression, the above 
data suggests that the role of Cyclin E1 is important at the level of proliferation in the 
self-renewing populations of glioma cells; however its function is dispensable for clonal 
growth in this particular system studied. Consequently, whether BTIC self-renewal is 
coupled to cell cycle machinery through Cyclin E1 remains elusive. 
Cyclin E1 was demonstrated previously to act as a limiting factor in G0 arrest 
(Geng, Yu et al. 2003). Additionally, Groszer et al. suggested that the regulation of self-
renewal is tightly associated with G0/G1 cell cycle entry control in PTEN
-/-
 neural stem 
cells (Groszer, Erickson et al. 2006).  PTEN mutations that are extremely common in 
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human glioblastoma (Brat, Castellano-Sanchez et al. 2002; Hill, Hunter et al. 2003; 
Mischel and Cloughesy 2003) are found to result in enhanced cell cycle progression due 
to unchecked activity of CDK2 driven by Cyclin E1 (Groszer, Erickson et al. 2001). 
Interestingly, the loss of PTEN function in NSCs correlates with increased proliferative 
potential due to shortened cell cycle time (Groszer, Erickson et al. 2001). Furthermore, 
PTEN deficiency was demonstrated to confer sustained self-renewal and multilineage 
differentiation potential in long-term cultures of NSCs suggesting a potential mechanism 
involving PTEN and G1 regulation in glioma stem cells. PTEN
-/-
-induced self-renewal 
was demonstrated to rely on enhanced quiescent state arrest and cell cycle re-entry which 
is accompanied by increased levels of Cyclin E1 and Cyclin D1. 
Given the importance of Cyclin E1-CDK2 suppression in PTEN-mediated 
pathways, the crucial question remains if the molecular mechanism underlying self-
renewal and proliferation of PTEN
-/-
 NSCs shares similarity with PTEN-loss dependent 
tumourigenic behaviour of glioblastoma cells. Since Cyclin E1-CDK2 activity control is 
lost in PTEN-deficient glioma cells, one can speculate that the observed shortened G1 
phase contributes to a decreased growth factor dependence, one established hallmark of 
cancer (Hanahan and Weinberg 2000). 
To summarize, the available literature suggests that Cyclin E1 functions in the 
crosstalk between multiple tumour suppressors and oncogenes and constitutes an 
important link between cell cycle and gliomagenesis. Cyclin E1 overexpression alone is 
not sufficient to drive transformation in the neural systems studied, however its role 
contributes to uncontrolled S-phase entry, excessive proliferation and genetic instability. 
The role of the main G1 phase cyclin components discussed in this section reflects 
close collaboration between cell cycle machinery and frequently disrupted pathways in 
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human glioblastoma. Mutations in EGFR and PTEN, corrupted Rb pathway and 
perturbations in proper degradation of crucial proteins drive tumourigenesis in neural 
systems. The genetic instability and deregulation of signal transduction pathways 
conferred by Cyclin E1 and D-type Cyclins respectively are known hallmarks of cancer. 
All of the aberrant events presented in this section use the G1 cyclin network components 
to execute their function. Furthermore, the mechanisms underlying changes in the brain 
tumour microenvironment as well as extensively studied self-renewing populations of 
BTICs can be addressed in a cell cycle dependent manner as several of them require G1 
cyclin function.    
Spy1 family of cell cycle regulators 
Speedy/RINGO family and human Spy1 
Spy1 or Speedy/RINGO (Rapid Inducer of G2/M progression in Oocytes) protein 
was initially identified in a genetic screen of a Xenopus laevis ovarian cDNA library 
(Lenormand, Dellinger et al. 1999), in the fission yeast cell line. The cell line used was 
deficient for cell cycle checkpoint gene rad1 allowing for isolation of cell cycle 
regulatory genes that override the G2/M checkpoint and confer resistance to radiation-
induced DNA damage (Lenormand, Dellinger et al. 1999). The isolated X-Spy1 clone 
was able to partially rescue UV sensitivity and provided resistance to ionizing radiation, 
suggesting that the newly found X-Spy1 regulates the G2/M checkpoint in Xenopus 
oocytes (Lenormand, Dellinger et al. 1999). Furthermore, X-Spy1 mRNA levels were 
expressed during oogenesis and at early embryogenesis, and microinjection of X-Spy1 
mRNA into stage VI oocytes resulted in activation of mitogen-activated protein kinase 
(MAPK) and CDK1. This occurred at a much faster rate than progesterone-mediated 
48 
 
oocyte maturation with subsequent germinal vesicle breakdown (GVBD). These data 
indicated that X-Spy1 contributes to oocyte release from a G2 arrest. Despite having no 
sequence homology to any known proteins, including cell cycle regulators, X-Spy1 was 
found to associate with CDK2 and cause its precocious activity in Spy1 stimulated oocyte 
maturation (Lenormand, Dellinger et al. 1999).  
To date, no X-Spy1 homologues have been found in yeast, worms, flies or plants 
(Cheng, Xiong et al. 2005; Dinarina, Perez et al. 2005). There are six mammalian X-Spy1 
homologues that constitute the Speedy/RINGO family of proteins (Porter, Dellinger et al. 
2002). Interestingly, RINGO/Speedy proteins share a conserved ~100 residue core of a 
predicted -helical structure referred to as Speedy/RINGO box that is crucial for the 
interaction with a CDK (Cheng, Xiong et al. 2005) (Fig. 5A). Besides the 79- amino acid 
stretch within the RINGO box that confers 51-67% similarity to all RINGO mammalian 
proteins, the family members exhibit significant sequence diversity within the flanking 
termini (Dinarina, Perez et al. 2005). This diversity may reflect differences within the 
family in the specificity of association with different CDKs and potentially in substrate 
specificity. Importantly, mammalian RINGO family members were shown to bind to 
CDK1 and CDK2 but failed to activate CDK4 and CDK6 (Cheng, Xiong et al. 2005; 
Dinarina, Perez et al. 2005) (Fig. 5B). 
The first human Spy1 identified, Spy1A (often referred to as Spy1), was isolated 
from a human testis cDNA library and shares 40% overall homology with X-Spy1 
(Porter, Dellinger et al. 2002). Spy1A has two splice variants, Spy1A1 and Spy1A2, that 
are both found in mouse and human (Porter, Dellinger et al. 2002; Cheng, Xiong et al. 
2005). The Spy1A gene, SPDYA, is ubiquitously expressed in most mammalian tissues 
49 
 
with high levels found in the testis and elevated levels found in hormonally sensitive 
tissues and some fetal tissues including the fetal brain and cerebellum (Porter, Dellinger 
et al. 2002; Cheng, Xiong et al. 2005). SPDYA expression was also found to be cell cycle 
dependent and occurred specifically at the G1/S transition. Furthermore, consistent with 
X-Spy1, Spy1A was shown to bind CDK1 and CDK2 and stimulate its activity (Al 
Sorkhy, Ferraiuolo et al. 2012).  
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Figure 5. Schematic representation of Speedy/RINGO structure and Speedy/RINGO 
isoforms. (A) A simplified schematic of Speedy/RINGO protein domains. (B) Table 
demonstrating Speedy/RINGO family members. 
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Spy- mediated cell cycle regulation and CDK2 substrate specificity 
Several lines of evidence demonstrate that mammalian Spy1 proteins are essential 
for mitotic cell cycle progression. Spy1A, herein referred to as Spy1, overexpression 
results in an overall increased proliferation characterized by more rapid divisions (Porter, 
Dellinger et al. 2002, (Golipour, Myers et al. 2008). Furthermore, the upregulation of 
Spy1 causes a significant reduction in the frequency of cells residing in G1 phase (Porter, 
Dellinger et al. 2002). Consistently, the decline in endogenous levels of Spy1 results in 
decreased mitotic index and a higher percentage of cells in late G1/early S phase. The 
Spy1-mediated increase in cellular replication is attributed to its ability to induce CDK2 
activity. Moreover, CDK2 inhibitor treatment attenuates Spy1 stimulated proliferation 
(Porter, Dellinger et al. 2002), suggesting that Spy1-induced cell cycle progression 
depends on CDK2 activity. Although mutation analysis of CDK2 shows that the residues 
responsible for binding to Spy1 are comparable with the ones interacting with canonical 
cyclins, proteins from the Speedy/RINGO family exhibit surprising differences in CDK 
activation (Dinarina, Perez et al. 2005). The stimulation of CDK activity by Spy1 does 
not require the CAK-mediated T-loop Thr-161 and Thr-160 phosphorylation on CDK1 
and CDK2 respectively (Cheng, Xiong et al. 2005; Dinarina, Perez et al. 2005. 
Importantly, Spy1-CDK complexes are less sensitive to the inhibitory phosphorylation on 
Thr-14/Tyr-15 on human CDK1 and CDK2-mediated by Wee1 and Myt1 kinases and are 
less susceptible to p21
Cip1
 cell cycle inhibitor action (Karaiskou, Perez et al. 2001).  
In addition, the mechanism behind Spy1-mediated cell cycle progression was 
demonstrated to occur, at least in part, through Spy1 binding directly to the cell cycle 
inhibitor p27
Kip1
 (Porter, Kong-Beltran et al. 2003; McAndrew, Gastwirt et al. 2007). The 
Spy1-CDK2 interaction was enhanced when p27
Kip1
 was overexpressed, supporting the 
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hypothesis that these proteins can exist in a trimeric complex (Porter, Kong-Beltran et al. 
2003; McAndrew, Gastwirt et al. 2007). Interestingly, Spy1 overexpression overrides the 
ability of p27
Kip1
 to inhibit CDK2 kinase activity (Porter, Kong-Beltran et al. 2003; 
McAndrew, Gastwirt et al. 2007).  Spy1 thereby overrides a p27
Kip1
-induced cell cycle 
arrest, activating CDK2 and stimulating proliferation. Importantly, the Spy1-mediated 
proliferative pathway was shown to be p27
Kip1
 dependent, as Spy1 was unable to 
stimulate proliferation in p27
Kip1-/- 
fibroblasts (Porter, Kong-Beltran et al. 2003). The 
G1/S phase transition is facilitated by p27
Kip1
 SCF
Skp2
 dependent proteolysis that is 
initiated by the phosphorylation of p27
Kip1 
on Thr-187 (Pagano, Tam et al. 1995). This 
modification occurs by Cyclin E-CDK2 (Sheaff, Groudine et al. 1997; Vlach, Hennecke 
et al. 1997). How p27
Kip1 
is phosphorylated by the kinase it inhibits was previously not 
known. McAndrew et. al. demonstrated that Spy1-CDK2 prevents p27
Kip1
 from 
interacting with CDK2, allowing for CDK activation and subsequent phosphorylation and 
degradation of p27
Kip1 
(McAndrew, Gastwirt et al. 2007). The reported mechanism 
explains one mechanism by which Spy1-CDK2 can regulate S phase transition. 
In addition to profound differences in the regulation of CDK activity between 
known cyclins and Speedy/RINGO proteins, the substrate specificity conferred by both 
was demonstrated to be quite diverse (Cheng, Gerry et al. 2005). It has been established 
that the canonical Cyclin A-CDK2 complex has a defined ((S/T)PX(K/R)) consensus 
target site and demonstrates strong affinity for the Lys at the +3 position of the substrate 
(Cheng, Gerry et al. 2005). In contrast, Spy1 bound to CDK2 displays broad substrate 
specificity with a preference to phosphorylate noncanonical substrates (Cheng, Gerry et 
al. 2005). Furthermore phosphorylation of the CDK within the T-loop was not required 
for Spy1 activation of the CDK (Cheng, Gerry et al. 2005). It is speculated that in analogy 
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to cyclins, Speedy/RINGO proteins may have their own specific substrate interacting 
motifs that would further explain the observed divergence in substrate specificity.  
Spy1, DNA damage response and apoptosis 
The regulation of CDK activity by Speedy/RINGO proteins represents a novel and 
unconventional model of cell cycle control. The importance of CDK stimulation 
independent of T-loop modification and altered substrate specificity imply an activating 
mechanism that can be utilized when CDKs are held in an inactive state due to p21
Cip1
 or 
Wee-like kinases inhibition. The circumstances that show a need for such activation may 
include DNA damage repair or inhibition of apoptosis required in normal development; 
however if set out of control, can lead to cell cycle deregulation and potential 
oncogenesis.  
Checkpoint activation is characterized by tight regulation of CDK2 activity. In the 
face of DNA damage, published and unpublished data support that Spy1 levels must be 
tightly regulated to allow for inhibition of CDK2 activity (Barnes, Porter et al. 2003).  
When Spy1 levels are elevated Spy1-CDK2-mediated phosphorylation of Cdc25, and 
insensitivity of the complex to p21
Cip1
, bypasses the S and G2/M checkpoints promoting 
DNA synthesis and division of damaged cells (Barnes, Porter et al. 2003; Gastwirt, 
McAndrew et al. 2007). In addition, Spy1 was reported to regulate the intrinsic DNA 
damage response and confer resistance to apoptosis in a p53 and p21
Cip1
 dependent 
manner (Gastwirt, Slavin et al. 2006). These data suggest that Spy1-mediated pro-survival 
effects may rely on p53 pathway inhibition. Overall, Spy1-CDK2- mediated resistance to 
genotoxic agents and radiation confers survival and subversion of apoptosis to damaged 
cells (Barnes, Porter et al. 2003). Heightened resistance to chemotherapy and radiation-
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induced programmed cell death are established hallmarks of cancer stem cells. Hence, 
targeting Spy1 overexpression in self-renewing populations of cells within a tumour can 
potentially contribute to novel strategies in cancer therapy. 
The role of Spy1in normal development and tumourigenesis 
The initial report on the role of Spy1 in the development of the mammary gland 
demonstrated that Spy1 levels are tightly regulated during development in this system 
(Golipour, Myers et al. 2008). The upregulation of Spy1 was shown to be characteristic of 
the proliferative stages in the gland, followed by the reduction of Spy1 levels during 
terminal differentiation. When Spy1 was overexpressed however, premature development 
and an increase in ductal morphogenesis was observed. Moreover, Spy1 was 
demonstrated to be regulated downstream of the c-Myc and MAPK pathways frequently 
activated in many breast cancers. Overexpression of Spy1 in mouse models resulted in 
rapid and invasive tumourigenesis (Golipour, Myers et al. 2008). Notably, Spy1 was 
found among the most upregulated genes in metastatic ductal breast carcinoma (Zucchi, 
Mento et al. 2004) and recent data shows that Spy1 levels are indicated in the majority of 
the most common breast cancer types (Al Sorkhy, Ferraiuolo et al. 2012).  
Although the role of Spy1 in the development of the nervous system is still under 
investigation, the studies addressing the behavior of Spy1 in neural regeneration shed 
some light on its potential functions in the nervous system. Under physiological 
conditions Spy1 is found to be expressed in both neurons and astrocytes of the lumbar 
spinal cord region (Huang, Liu et al. 2009). The sciatic nerve injury model revealed that 
Spy1 levels were readily upregulated after the nerve crush mainly in Schwann cells, 
astrocytes and microglia and its levels correlated with enhanced proliferation. In Schwann 
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cells, Spy1 localized mainly to axons and was expressed in an opposite manner to the 
growth associated protein 43 (GAP43), neuronal marker (Cao, Yang et al. 2013). 
Moreover, a corresponding increase of CDK2 activity and decline of p27
Kip1
 levels was 
reported, suggesting that Spy1-mediated cell cycle effects play a role in the glial response 
to injury (Huang, Liu et al. 2009).  Collectively these data support that Spy1 may induce 
the regenerative processes within the nervous system. Zhang et al demonstrated that Spy1 
was selectively expressed in the glial but not in the neuronal cells, and its overexpression 
correlated with the highest stages of glioma (Zhang, Shen et al. 2012). The 
downregulation of Spy1 in glioma cell lines resulted in decreased proliferation, 
downregulated CDK2 activity and upregulation of p27
Kip1
 levels. Spy1 expression 
correlated negatively with patient prognosis indicating that Spy1 may serve as a valuable 
prognostic marker for patients with glioma.  
Recently, Spy1 was also indicated as a prognostic marker in human Non Hodgkin's 
Lymphoma (NHL) as levels correlated with poor patient prognosis (Hang, Fei et al. 
2012). Upregulated levels of Spy1 in human NHL specimens were demonstrated to 
correspond with increased Thr-187 phosphorylation on p27
Kip1
 and enhanced 
proliferation. The knockdown of Spy1 in leukemia cells resulted in decreased 
phosphorylation of p27
Kip1
 and cell cycle arrest (Hang, Fei et al. 2012). These data 
support that Spy1-mediated proliferation in human NHL depends on its ability to induce 
p27
Kip1
 Thr-187 phosphorylation followed by its degradation.  
Spy1 overexpression was also suggested to play a role in the pathogenesis of 
hepatocellular carcinoma (Ke, Ji et al. 2009). The increase in histological grade was 
characterized by upregulated levels of Spy1 and Ki67 proliferation marker expression 
(Ke, Ji et al. 2009). The overexpression of Spy1 in a wide variety of human cancers 
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suggests the importance of Spy1-mediated cell cycle effects in malignant transformation. 
Despite the significant cancer type diversity observed, common features included positive 
correlation between Spy1 levels, the stage of malignancy and poor patient prognosis. 
These data collectively suggest a role for Spy1 as a prognostic marker, and potential 
therapeutic target, in a vast number of human cancers.  
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HYPOTHESIS AND OBJECTIVES 
This work aims to determine the role of the novel cell cycle regulator Spy1in neural 
proliferation and commitment. We will address the potential implications of Spy1-
mediated effects in tumours of neural origin.  
This study will test the hypothesis that: Spy1 is a key player in neural cell fate, 
playing a role in the self-renewal and differentiation of neural stem and progenitor 
populations. Furthermore we hypothesize that Spy1-mediated molecular mechanisms 
drive tumour initiating cell decisions and regulate potential neural malignancies.  
To address this hypothesis we have the following objectives: 
 To elucidate the role of Spy1 in proliferation and self-renewal of neural 
stem cells and tumour initiating cells in human glioma 
 To determine the expression and localization of Spy1 during development 
of the central nervous system and in adult neurogenesis  
 To elucidate the role of Spy1 in the differentiation of human neuroblastoma 
progenitor populations 
The data obtained during the course of this study will contribute to advancing  our 
understanding of cell cycle mechanisms behind fate determination in neural systems. This 
work may reveal novel diagnostic and therapeutic avenues for brain cancer therapy.  
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CHAPTER 2 
THE CYCLIN-LIKE PROTEIN SPY1 REGULATES GROWTH AND DIVISION 
CHARACTERISTICS OF THE CD133+ POPULATION IN HUMAN GLIOMA 
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INTRODUCTION 
Primary brain tumours can be driven by a population of brain tumour-derived cells 
with stem-like characteristics, or brain tumour initiating cells (BTICs) (Hemmati, Nakano 
et al. 2003; Singh, Hawkins et al. 2004). Whether these cells arise through 
dedifferentiation of lineage specified progenitors or through malignant transformation of 
endogenous neural stem cells (NSCs) is a subject of much debate. Regardless of the 
origin, understanding how BTICs regulate growth and development is of utmost 
importance for future treatment strategies (Dean, Fojo et al. 2005). Analogous to the 
hematopoietic system, neural markers are emerging which correlate primitive neural cells 
with BTICs (Hemmati, Nakano et al. 2003). One such example is the pentaspan 
transmembrane glycoprotein CD133 (Prominin1). CD133 is found in undifferentiated 
NSCs as well as in invasive glioma populations harboring stem-like properties (Yan, Lu 
et al. 2011 ). Ultimately the growth of BTICs correlates with high levels of positive cell 
cycle regulators and reduced levels of cell cycle inhibitors (Hidaka, Hama et al. 2009). 
Despite this the essentiality of core cell cycle machinery has yet to be fully elucidated. 
Spy1 (Spdya; Speedy; Spy1A; RINGO) is a cyclin-like protein highly conserved 
in all vertebrates and some invertebrates, that is implicated in several cancers including 
glioblastoma (Porter, Dellinger et al. 2002; Cheng, Xiong et al. 2005; Golipour, Myers et 
al. 2008; Al Sorkhy, Ferraiuolo et al. 2012; Zhang, Shen et al. 2012). Spy1 can directly 
bind and activate the cyclin dependent kinases (CDK) independent of phosphorylation 
within the T-loop of the CDK, and with decreased dependency on dephosphorylation by 
the Cdc25 phosphatases (Porter, Dellinger et al. 2002; Cheng, Xiong et al. 2005). This 
unique manner of activating CDKs implies a mechanism by which Spy1 can bypass 
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classically defined cell cycle checkpoints. Indeed Spy1 is required for cell cycle re-entry 
in maturing vertebrate oocytes (Lenormand, Dellinger et al. 1999; Arumugam, MacNicol 
et al. 2012). The Spy1 gene, SPDYA, was initially isolated as a gene that conferred 
resistance to UV damage in a rad1 deficient strain of S. pombe (Lenormand, Dellinger et 
al. 1999). Since this time Spy1 protein has been shown to override a number of cell cycle 
checkpoints, and is capable of directly binding and promoting degradation of the CDK 
inhibitor p27
Kip1
 (p27) (Porter, Kong-Beltran et al. 2003; McAndrew, Gastwirt et al. 
2007). The implication of this in the molecular processes regulating development and 
aging is also interesting. In mammary progenitor cells Spy1 levels are tightly regulated 
through normal development and accumulated protein levels abrogate differentiation and 
promote precocious development (Golipour, Myers et al. 2008). In the acute sciatic injury 
model Spy1 levels are dramatically upregulated in populations of proliferating astrocytes 
and microglia of the lumbar spinal cord, consequently implicating Spy1 in the 
regenerative processes of this system (Huang, Liu et al. 2009). Interestingly, upregulation 
of Spy1 is accompanied by an increase in CDK2 activity and downregulation of p27 in 
this system. The Spy1 effectors CDK2 and p27 are known mediators of normal 
neurogenesis (Dobashi, Shoji et al. 2000; Jablonska, Aguirre et al. 2007; Li, Tang et al. 
2009). Stimulating neuronal differentiation in cell culture leads to the consequent 
downregulation of levels and activity of CDK2, as well as an increase in the protein levels 
of p27 (Kranenburg, Scharnhorst et al. 1995; Dobashi, Shoji et al. 2000). CDK2 knockout 
mice have marked defects in the proliferative capabilities and self-renewal of adult neural 
progenitors in the subventricular zone (SVZ) (Jablonska, Aguirre et al. 2007). Indeed, 
enhanced CDK2 activity and downregulation of p27 are observed in many cases of brain 
cancer (Narita, Nagane et al. 2002; Fiano, Ghimenti et al. 2003; Hemmati, Nakano et al. 
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2003). CDK inhibitors have shown efficacy in human glioma in vitro (Jane, Premkumar 
et al. 2006); however, many biological questions remain to be elucidated before this 
approach can be reliably used in vivo. One important question is whether the cyclin 
partner of the CDK2 confers specificity in the decisions of NSCs or BTICs.  
Recently, Zhang et al. demonstrated that Spy1 protein levels are elevated in 
malignant human glioma and protein levels correlate with poor prognosis (Zhang, Shen et 
al. 2012). Our work confirms this result and further quantifies Spy1 levels in increasing 
stage of glioma. We demonstrate that amplification of the SPDYA gene loci is an 
indicator of poor prognosis for glioma patients. Herein we show for the first time that 
endogenous levels of SPDYA decrease as NSCs differentiate. We also show that elevated 
levels of SPDYA expand the population of cells expressing BTIC markers and promote a 
BTIC phenotype. Furthermore, knockdown of SPDYA decreases stemness parameters and 
symmetric division of the CD133+ population. These effects are not seen with 
knockdown of classic G1/S cyclin, CCNE1, indicating that the observed changes are 
unique to Spy1. These data demonstrate that the Spy1/RINGO family of CDK regulators 
plays an important role in neural fate decisions. Abrogation of these decisions may 
promote the initiation and/or progression of human glioma. 
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EXPERIMENTAL PROCEDURES 
Animals  
Balb/c mice (Jackson Labs) were maintained and cared for following Canadian Council 
for Animal Care guidelines, under the University of Windsor AUPP# 10-08.  
Cell Lines  
Rat pheochromocytoma PC12 cells and human GBM U-87 MG cells were obtained from 
ATCC. U251 cell line was a kind gift from Dr. James Rutka (The Hospital for Sick 
Children Research Institute, University of Toronto, Canada). The SJ-GBM2 cell line was 
obtained from The Children's Oncology Group repository (Arcadia, CA, USA). PC12 
cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Sigma, USA, St. 
Luis, MO) containing 10% heat inactivated horse serum, 5% FBS, 1% L-glutamine and 
1% penicillin/streptomycin. PC12 DMEM differentiation media contained 5% horse 
serum and 1% FBS. U-87 MG and U251 cells were cultured in Eagle's Minimum 
Essential Medium (EMEM; Sigma) and DMEM ,respectively, supplemented with 10% 
FBS and 1% penicillin/streptomycin. SJGBM2 cells were cultured in Iscove's Modified 
Dulbecco Medium (IMDM) supplemented with 20% of FBS, 5g Insulin, 5g 
Transferrin and 5ng Sodium Selenite. All cells were maintained at 37C in 5% CO2. Cell 
proliferation and viability were measured using trypan blue exclusion assay. Cell numbers 
were quantified using TC100 Automated Cell Counter (BioRad). 
Plasmids  
Vectors pJT0013 and pEIZ were generously donated from Drs. D. Donoghue and B. 
Welm respectively. Spy1 (SPDYA) was inserted into the EcoRI and XbaI sites of pEIZ to 
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create pEIZ-Spy1. Spy1-pLXSN (described previously (Porter, Kong-Beltran et al. 2003)) 
was modified to remove the polyA tail and renamed pBAM04. pLKO-scrambled control 
(#8453) and lentiviral constructs: pLB (#11619), pMD.G (#12259), pMDLg/pRE 
(#12251) and pRSV-Rev (#12253) were all obtained from Addgene. pLKO-SPDYA  was 
cloned to express the short hairpin previously described in place of the scrambled 
sequence (Porter, Dellinger et al. 2002). pLB vector was cloned to express either shRNA 
specific to target murine SPDYA or scrambled control.   
Lentivirus Production and Infection 
VSV-G pseudotyped lentivirus was produced by transient transfection of HEK293 LentiX 
cells with transfer vector plasmid (pEIZ, pLKO or pLB) and the multi-deleted packaging 
plasmids (pMDG, pMDL2, pRSV) using Polyethylenimine (PEI) (408719, Sigma) 
reagent with 1:3 DNA to PEI ratio and incubation for 5 hours at 37°C, 5% CO2. The virus 
was collected on the next day and concentrated for 3 hours at 4ºC using and 
ultracentrifuge. The titer for pEIZ and pLB was determined by transducing 293T cells and 
analysis of eGFP protein expression by flowcytometry at 72 hours post transduction. The 
titer for pLKO lentivirus was assessed by puromycin selection followed by crystal violet 
staining and quantification of resistant colonies. The titered virus was filter sterilized and 
stored at -80°C. Cells were seeded into 96 well plate in serum and antibiotic free media 
containing 4-8 g/ml of Polybrene. PEIZ- vector or pEIZ-SPDYA viral particles at MOI-
2, pLKO- vector or pLKO-shSPDYA viral particles at MOI-3 and pLB- vector or pLB-
shSPDYA at MOI-3 were incubated on cells overnight at 37°C, 5% CO2. The media 
containing virus were changed and cells were left to recover. After 72 hours the 
expression of pEIZ or pLB constructs was confirmed by the expression of eGFP 
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fluorescent protein. All the experiments utilizing pLKO vectors were performed under 
1g/ml Puromycin selection.  
Protein Isolation from Brain Tumour Tissues  
Flash frozen brain samples were thawed quickly and cut into 0.03-0.13 g pieces. Tissue 
pieces were weighed and 250 l of NP40 Extraction Buffer (50 mMTris-Hcl pH 7.5, 1% 
NP40, 1 mM EGTA pH 8.0, 0.2% SDS, 150 mM NaCl, 0.25% sodium deoxycholate, 
1.5% antifoam A) with protease inhibitors (leupeptin 2 g/mL, aprotinin 5 g/mL, 
sodium fluoride 50 mM, pepstatin A 1 g/mL and PMSF 100 g/mL) was used per 0.1 g 
of tissue. Tissues and extraction buffer were homogenized on ice (3x10 sec.). Samples 
were then centrifuged at 13,000 rpm for 15 min at 4C. Supernatant was collected and 
stored at –20C until use.  
qRT-PCR 
Total RNA was extracted using the RNAeasy Plus Mini Kit (Qiagen) and reverse 
transcribed using 200U Superscript II (Invitrogen), 0.5 g OligodT’s and 0.5 g random 
nanomers (Sigma) according to the manufacturer instructions. Primers were designed 
using Primer Express software (Applied Biosystems). Real time PCR was carried out 
using SYBR green detection (Applied Biosystems) with 200-400 nM of each primer 
(Table 1; Suppl. Mat.) and was performed and analyzed using ViiA
TM
 7 Real-Time PCR 
system (Life Technologies) or ABI Prism 7300 thermocycler and software. Data 
represented log10 relative quantification (RQ) relative to control.  
Tissue Microarray (TMA) 
Paraffin embedded TMA slides consisting of 204 tissue cores in total were purchased 
from U.S. Biomax (cat no. GL241, GL803, GL1001).  Slides were deparaffinized in 
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xylene and decreasing percentages of ethanol according to the manufacturer’s protocol. 
Antigen retrieval was performed at 95
o
C in citrate buffer (0.01M sodium citrate buffer, 
pH 6.0). Slides were washed in 1 times PBS and subjected to immunofluorescence using 
Spy1 antibody (Novus, NB 100-2521) followed by Alexa- 488 conjugated secondary 
antibody (Sigma). Nuclei were counterstained with TOTO-3 T-3600 (Molecular Probes). 
The fluorescent signal was detected and quantified by ScanArray Express (Perkin Elmer 
Inc.) The Spy1 signal intensity was normalized to nuclear stain signal. 
Primary Cell Harvest & Neurosphere Assays 
Tissues were micro-dissected and primary cells were dissociated from the region 
surrounding the SVZ of P1-P4 mouse brains as described previously (Jacqueline, Kasia et 
al. 2006). Cells were seeded at less than 5x10
4 
cells per well in 6-well Ultra Low Cluster 
Plates (ULCP) (Corning, 3471) and cultured in serum free Dulbecco’s Modified Eagle’s 
Medium (DMEM)/ Ham’s Nutrient Mixture F-12 media (Sigma) containing N2 
supplement hEGF (20ng/ml; Gibco) and bFGF (10ng/ml; Sigma), 2mM L-glutamine at 
37°C in 5% CO2. Formed spheres were subcultured every 5-10 days. Differentiation was 
conducted on primary spheres in media supplemented with 2% FBS as described 
previously (Kerosuo, Piltti et al. 2008). Primary, secondary and tertiary neurospheres 
were dissociated and 10000 cells were seeded in 100l of media in 96 well anti-adhesive 
plates. 20l of 5mg/ml MTT solution in PBS were added to each well and incubated for 4 
hours. 100l of extraction buffer was added for 2 hours to dissolve the formazan crystals 
and the absorbance at 590nm was assessed using Victor plate reader (Perkin Elmer). 
Clonal assays ware conducted in neurosphere media in 96 well ULCP plates, cells were 
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plated by serial dilution and wells containing 1-10 cells/well were included in 
experiments and analysis. 
Magnetic Bead Sorting 
Cells were incubated for 48 hours in stem cell media. Pellets were resuspended in PBS 
buffer pH 7.4 containing 0.1% BSA, (B1). 25l of magnetic beads (Dynabeads M-450 
Epoxy, Invitrogen) labeled with CD133 antibody according to Invitrogen protocol 
(Abcam, 27699) were used for 2.5x 10
6
 cells/1ml B1. Suspension was incubated 20 
minutes at 4°C with gentle rotation followed by 2 minute positive isolation using 
EasySepmagnet (Stem Cell Technologies, #18000). Bead- bound cells were washed 4 
times using 1ml of B1. 
Cell Pair Assay and Immunofluorescence 
Single cells were isolated with 0.05% Trypsin- EDTA and plated in a drop of media onto 
MaxGel
TM
 ECM (Sigma, E0282) coated cover-slips. Cell division was monitored over 20 
hours and then fixed in 3.7% paraformaldehyde (PFA) for 20 minutes at room 
temperature. Cells were washed, permeabilized and incubated with Numb antibody (Cell 
signaling, C29G11, 1:200). Alexa-488 conjugated secondary antibody (Invitrogen, 1:1000 
dilution) was applied for 1/2 hour. Nuclei were stained with TOTO-3 T-3600 (Molecular 
Probes). CD133 antibody (Abcam, 27699) staining was performed directly in media 
without fixation and was followed by the immunofluorescence protocol. Five random 
fields of view were scored for Numb protein distribution in mitotic cell pairs, per 
treatment, per replicate. Analysis was performed using Leica CTR 6500 microscope 
(Leica Microsystems, Heidelberg, Germany) and AF software. 
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Statistical Analysis 
Student t-test was used and a p-value of 0.05 was considered significant. All data are 
reported as means ± s.d. qRT-PCR statistics were performed as describe previously 
(Yuan, Reed et al. 2006). Briefly, Ct value of the housekeeping gene (GAPDH) was 
subtracted from the corresponding Ct value of a target gene producing dCt value further 
subjected to the Student t-test analysis. Statistical analyses and normality testing were 
performed using Statistica software.  
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RESULTS 
Spy1 Protein Levels are Elevated in Multiple Types of Glioma and Correlate with 
Increasing Tumour Grade  
Analysis of the protein levels of Spy1 in oligoastrocytoma (OAC; Fig. 1A), 
oligodendroglioma (ODG; Fig. 1B) and invasive glioblastoma multiforme (GBM; stage 
IV astrocytoma; Fig. 1C) tissue was conducted using tissues obtained from the Ontario 
Brain Tumour Tissue Bank. Each sample set analyzed consisted of tissue derived from 
the tumour center (I), peritumour (II-IV) and normal tissue (V). Average levels of Spy1 
protein from tumour centre out to normal tissue were calculated over 3 sets of samples 
per patient (Fig. S1). Spy1 protein levels were significantly elevated in the tumour tissue 
over normal in 3 of 4 ODG and OAC sample sets and 1 of 4 GBM sample sets (Fig. S1). 
Notably, tumour samples from patients 976 and 977 (GBM; Fig. 1C) and 865 (OAC; Fig. 
1A) were highly necrotic in patient records; Spy1 levels were not elevated in these 
samples. In all 32 sample sets combined, Spy1 protein levels were significantly elevated 
in 63% of tumour centre samples and 62% of peritumour samples in comparison to the 
pair matched control tissues. 
To further correlate the levels of Spy1 protein with the grade of brain tumour we 
utilized tissue microarrays (TMAs) consisting of 188 different patient cores, including 
cores taken from non-cancerous (normal) brain samples. Representative H&E stained 
core images are presented in Fig.S2. IHC performed on TMAs revealed extensive Spy1 
staining in tumour tissues over pair matched adjacent ‘normal’ brain tissues taken from 
the same patients (Fig. 1D, S3, S4). Spy1 protein levels were progressively elevated with 
increasing grade of astrocytoma, demonstrating statistical significance over benign tissue 
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as well as both pair match normal adjacent tissue and non-cancerous normal tissues 
(combined as ‘normal’) (Fig. 1E). While sample numbers were limited, we found that 
Spy1 levels correlated with increasing grade of OAC (Fig.S4A) and ODG (Fig.S4B). 
Overall, protein levels of Spy1 were significantly elevated, at least 2 fold, in 69% of the 
glioma tumour samples tested (Fig. 1A-E&S4A-B). Work performed by The Cancer 
Genome Atlas (TCGA) research network demonstrated a strong correlation between the 
established GBM classes and normal neural lineages (Verhaak, Hoadley et al. 2010). 
Notably, we found that in comparison to primary neural cells cultured in monolayer, 
SPDYA levels are significantly upregulated in neurospheres derived from clonal 
expansion of those cells and correlate with the expression of stemness markers such as 
Nestin and Vimentin (Fig. S4D). 
 
 
 
 
 
 
 
 
 
87 
 
 
 
 
88 
 
Figure 1. Spy1 Protein is Overexpressed in High-Grade Glioma. 
(A-C) Spy1 protein expression in human brain tumour tissues microdissected from OAC 
(A), ODG (B) and GBM (C) patients. Biopsies taken from the tumour center (I), 
peritumour (near tumour infiltrate - scant tumour cells; II-IV) or normal brain tissue (V). 
Patient identifier number is at the bottom of each graph panel. One representative blot of 
3 is depicted. Values presented as the mean of Integrated Density Values (IDV) 
Spy1/Actin. Average values over multiple blots quantified in Fig.S1.  
(D-E) TMAs containing normal brain and brain tumour tissue samples obtained from 188 
different patients for Spy1 expression. The Spy1 signal intensity normalized to nuclear 
stain (TOTO-3) signal. Data are shown as mean ±s.d; *p < 0.05, **p < 0.01. 
(D) IHC of Spy1 positive cells in astrocytoma tissues of different grade (black bars) in 
comparison to normal adjacent brain tissue (white bars) over 2 separate arrays. Grade I-II 
astrocytoma (n=3), grade III astrocytoma (n=3) and normal controls (n=6). Data 
represented as mean ±s.d. **p<0.01. 
(E) Spy1 protein levels analyzed in different grades of astrocytoma (I-III) (n=112), GBM 
(n=24) and benign brain tumours (n=8). See Fig.S2-S4. Data represented as mean ±s.d. 
*p<0.05, **p<0.01. 
(F-G) Patient survival data from Rembrandt NCI database correlated with CDK2 
expression levels over all glioma samples (F) or SPDYA amplification/deletion from all 
glioma data (G). See Fig.S4C. 
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Figure S1. Spy1 protein levels are significantly elevated in patient brain tumour cores 
and peritumour compared to normal matched tissue. Spy1 protein expression in human 
brain tumour tissues microdissected from OAC (A), ODG (B) and GBM (C) patients. 
Biopsies taken from the tumour center (I), peritumour (near tumour infiltrate to scant 
tumour cells; II-IV) or normal brain tissue (V). Patient identifying number is located at 
the top of each panel.  Data is presented as the mean of Integrated Density Values (IDV) 
Spy1/Actin. Average values over 3 representative blots for each patient are depicted. 
Errors ±s.d. *p < 0.05, **p < 0.01. 
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Figure S2. H&E stained sections from Human Normal and Brain Tumour TMA Cores. 
TMA core images at diverse magnifications were obtained from fully scanned TMA 
slides and are available at US. Biomax, Inc. website; http://www.biomax.us/index.php.(a) 
Normal brain tissue,(b) Astrocytoma grade I core, (c) Grade II of astrocytoma core, (d-f) 
three different cores representing grade III astrocytoma and (g) GBM cores.  Columns 
represent 5x, 10x and 20x magnification as indicated. Scale bars: i & ii = 100m, iii = 
25m. 
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Figure S3. Immunofluorescent Detection of Spy1 Positive Cells in Human Normal and 
Brain Tumour TMA Cores. 
Immunofluorescent image of TMA cores with Spy1 positive cells (green). Nuclei stained 
with TOTO-3(magenta). Rows represent:(a) Normal brain tissue, (b) Astrocytoma grade 
I, (c) Grade II astrocytoma, (d-f) Grade III astrocytoma, and (g) GBM. All cores in (i) are 
magnified in ii, or further magnified in iii. Scale bars= 25m. 
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Figure S4. Spy1 is upregulated in malignant grades of OAC and ODG and its 
amplification correlates with reduced patient survival in ODG. 
(A) Spy1 levels in lower grade (I-II) (n=3) vs. high grade (III) (n=6) of OAC.  
(B) Spy1 levels in lower grade (I-II) (n=3) vs. high grade (III) (n=6) of ODG.  
(C) Patient survival data from the Rembrandt NCI database correlated withSpy1 gene 
amplification/deletion from all ODG data. (D) Primary cell cultured as a monolayer (ML) 
or in neurosphere formation assay (NS) analysed by qRT-PCR for SPDYA, Nestin and 
Vimentin levels. Representative data shown as mean ±s.d. n=3. **p<0.01. 
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Amplification of the SPDYA Loci Correlates with Poor Patient Prognosis  
To determine if alterations at the genetic loci of Spy1 (SPDYA) could be 
implicated in patient prognosis, survival data from the Rembrandt NCI database was used 
to evaluate the effects of Spy1, and the Spy1 effector CDK2, on overall patient survival 
(NCI 2005). CDK2 was found to be overexpressed in 236 out of 343 cases of all glioma 
and overexpression very significantly correlated with reduced patient survival, p=0.00002 
(Fig. 1F). Importantly, there were no cases of downregulation of CDK2 in all 343 cases. 
Similarly in the dataset of Li et al. consisting of 257 patients (Li, Walling et al. 2009), 
there were 198 cases with upregulated CDK2, no cases of significant downregulation and 
upregulation very significantly correlated with decreased survival, p=0.0000007 (data not 
shown). SPDYA was found to be amplified in 31 of 56 cases of ODG and amplification 
statistically correlated with reduced patient survival, p=0.01 (Fig.S4C). SPDYA was 
amplified in 3 of 5 cases of mixed glioma and amplification correlated with reduced 
patient survival, p=0.06 (data not shown). For total glioma cases, SPDYA was amplified 
in 143 out of 222 cases of all glioma and amplification significantly correlated with 
reduced patient survival, p=0.005 (Fig. 1G). Notably, the Rembrandt database does not 
specify whether loci amplification is due to events such as focal amplification or whole 
arm gain. Nonetheless, from this data, amplification of SPDYA and overexpression of the 
Spy1 effector, CDK2, significantly correlate with reduced survival in glioma patients.  
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Knockdown of Spy1 Reduces Proliferation and Stemness Properties in Human 
Glioma 
To address the importance of Spy1 protein in brain tumourigenesis in vitro we 
utilized the human U-87MG (U87), SJ-GBM2 and U251 glioma cell lines. The 
heterogeneous U87 and U251 cells contain a well characterized population of CD133+ 
cells established to be highly tumourigenic, possess stem-like properties and to be highly 
resistant to both radio- and chemo- therapy (Jeon, Jin et al. 2008; Verhaak, Hoadley et al. 
2010). The SJ-GBM2 cells are established from pediatric glioma and constitute a model 
successfully used in evaluation of diverse chemotherapy strategies in childhood solid 
tumours (Middlemas, Stewart et al. 2000). Cells were infected with lentivirus carrying 2 
different shRNA constructs against SPDYA (shSPDYA) or a scrambled control (pLKO) 
and subsequently selected. Both of the SPDYA-shRNA constructs effectively reduced 
their targeted genes at least 3 fold (Fig. 2A inset). Proliferation kinetics show that SPDYA 
knockdown significantly reduces cell growth in all cell types tested (Fig. 2A). This result 
was confirmed by BrdU incorporation in the U87 line, where the shSPDYA cells showed 
over a 60% reduction in DNA synthesis compared to control cells (Fig. 2B). Interestingly, 
shSPDYA cells exhibited extensive chromatin condensation, characteristic of apoptotic 
nuclei (Fig. 2B; white arrows, left panel). Spy1 inhibits apoptosis (Gastwirt, Slavin et al. 
2006), further studies are needed to determine whether SPDYA knockdown is indeed 
capable of triggering apoptotic events in these cells. 
Marker analysis determined that Spy1 knockdown significantly reduced 
expression of the proliferation marker Ki67 and enhanced expression of p27 (Fig. 2C; 
black bars). Interestingly, SPDYA knockdown also correlated with increased levels of the 
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growth-associated protein 43 (GAP43), a marker of mature neurons, and decreased levels 
of markers known to identify both normal stem-like cells and BTICs, CD133 and glial 
fibrillary acidic protein (GFAP). These data prompted the hypothesis that Spy1 levels 
may be important for both proliferation and directing the fate of at least subsets of cells 
within the heterogeneous tumour.  
Spy1 binds and activates CDK2 in a unique manner, and Spy1-bound CDK2 has 
altered substrate specificity when compared to Cyclin E/A-bound CDK2 (Cheng, Gerry et 
al. 2005).  Hence, to determine if the effects of Spy1 are due to a general reduction of 
CDK2 activity, or if Spy1 has unique roles in proliferation and stemness in human 
glioma, we compared SPDYA knockdown effects to the knockdown of the Cyclin E1 
gene, CCNE1. Here we targeted CCNE1 using two different shRNA constructs (Fig. 2C 
inset). Only SPDYA knockdown significantly altered expression of the proliferation 
marker Ki67 (Fig. 2C). A reduction in Ki67 with SPDYA knockdown was consistent with 
an increase in the cell cycle inhibitor p27 and the neuronal marker GAP43. Both SPDYA 
and CCNE1 knockdown did however reduce expression of both stemness markers GFAP 
and CD133, albeit the effect of Spy1 knockdown had a more robust effect. These data 
demonstrate that while depletion of either SPDYA or CCNE1 demonstrate effects on cell 
fate markers GFAP and CD133, SPDYA knockdown had a more pronounced effect and 
also demonstrated effects on proliferation (Ki67 and p27) and neuronal differentiation 
(GAP43).  
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Figure 2. Spy1 Levels are Essential for Proliferation and Stem-Like Properties of Human 
Glioma Cells. 
(A: inset) qRT-PCR of U87 cells infected with scrambled control (pLKO) or two 
different shRNA against SPDYA (sh#1 and sh#2). Data shown as mean ±s.d. n=3. *p < 
0.05, **p < 0.01. 
(A) Growth curves measured by trypan blue exclusion for U87 (left), SJ-GBM2 (middle) 
and U251 (right). Data represent mean cell number ±s.d. n=3; *p<0.05, **p<0.01, 
***p<0.001. 
(B) Imaging (left panel) and quantification (right panel) of U87 cells positive for BrdU 
staining. Data shown as mean ±s.d. At least 5 fields of view per infection. n=3; *p<0.05. 
Scale bar, 10m.   
(C) qRT-PCR of U87 cells infected with scrambled control (pLKO) or two different 
shRNA against SPDYA (black bars) or CCNE1 (hollow bars). Genes indicated on X-axis. 
Data shown as mean ±s.d. n=3; *p < 0.05. 
(C; inset) qRT-PCR of CCNE1 levels following infection of two different shRNA 
constructs (sh#1 and sh#2). Data shown as mean ±s.d. n=3. **p < 0.01, ***p < 0.001. 
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Spy1 Regulates Stemness Properties of the CD133+ Glioma Population  
To determine the potential role of Spy1 in the BTIC populations with neurosphere 
formation capacity, U87 cells were cultured and passaged in monolayer or as spheres to 
promote self-renewal in vitro (Lee, Kotliarova et al. 2006). SPDYA expression levels 
were upregulated when cells were cultured as spheres (Fig. 3A). This increase correlated 
with upregulation of the stemness markers Nestin and CD133 and downregulation of p27 
and the oligodendrocyte marker NG2 (Fig. 3A). CD133- cells are capable of initiating 
tumours in vivo, however sorting for a CD133+ population in human glioma has been 
shown to enrich sphere formation, initiate glioma in a mouse xenograft model and to 
correlate with decreased prognosis for glioma patients (Bao, Wu et al. 2006; Zeppernick, 
Ahmadi et al. 2008). SPDYA expression is significantly higher in the CD133+ population, 
and this correlates positively with expression of the stem/progenitor markers Nestin and 
Vimentin (Fig. 3B&C). This population also expressed higher amounts of the proliferation 
marker Ki67 along with the oncogenes c-Myc and MYCN and reduced expression of p27 
(Fig. 3C). Additionally, the CD133+ population was characterized by lower expression of 
oligodendrocyte markers OLIG2 and NG2 which, along with the upregulated levels of 
GFAP, suggests an astrocyte progenitor lineage and supports NSC nature of these cells. 
Downregulation of BMI1 suggested that the sorted population represents a higher stem-
like hierarchy, as BMI1 was recently shown to mark progenitor populations at the 
intermediate stages of differentiation within human glioma (Venugopal, Li et al. 2012). 
We then measured the effects of depleting Spy1 on stemness characteristics of the 
CD133+ population in multiple cell lines. In U87 cells sorted for CD133 (Fig. 1D, top 
panel), knockdown of SPDYA (Fig. 1D, lower right panel) resulted in a marked reduction 
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of CD133 levels that occurred along with a decline in BTIC/proliferation markers GFAP, 
Ki67, c-Myc and upregulation of p27 levels (Fig. 3D; bottom left panel). These results 
were similar in other glioma cell lines known to contain a CD133+ population (Fig. S5A 
& S5B). Notably, the c-Myc, Ki67 and p27 effects were not significant in the U251 cells 
(Fig. S5B). Although both shRNA constructs consistently reduced CCNE1 expression 
levels at least 14 fold in the sorted population (Fig. S5C), there were no significant effects 
on the expression of the BTIC marker CD133 (Fig. 3E). Furthermore, when comparing 
the effects of SPDYA knockdown to that of CCNE1, depletion of Spy1 significantly 
reduced stemness markers Nestin and GFAP and upregulated progenitor markers BMI1 
and GAP43 markers over that of CCNE1 knockdown (Fig. 3F). This data supports 
marked differences in the requirement for specific CDK partners in select BTIC 
populations.   
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Figure 3. Spy1 Expression Plays a Critical Role in the Stemness Properties of the 
CD133+ BTIC Population.  
(A) qRT-PCR of U87 cells cultured as monolayer (ML) or in a neurosphere formation 
assay (NS) at passage 5. Data shown as mean ±s.d. n=3. *p < 0.05, **p < 0.01. 
(B) U87 cells sorted and CD133+ and CD133- populations analyzed by qRT-PCR for 
CD133 (upper panel) and SPDYA (lower panel) levels. Data shown as mean ±s.d. n=3.*p 
< 0.05. 
(C) CD133+ and CD133- populations analyzed by qRT-PCR for several genes. The 
CD133+ population is compared to the CD133- population. Data shown represent mean 
±s.d. n=3. *p<0.05 and p- values presented. 
(D) U87 cells sorted for CD133 (confirmed by qRT, top right graph). The CD133+ 
population was infected with either shRNA scrambled control (pLKO) or one of two 
shSPDYA constructs (shSPDYA
#1
 (hollow bars) or shSPDYA
#2
 (solid bars)). Knockdown 
confirmed by qRT-PCR (lower right graph). Effects on gene expression reported as 
relative expression of shSPDYA over pLKO-scrambled control (Lower left graph). Data 
shown represent mean ±s.d. n=3. *p<0.05, **p<0.01and p- values presented.  See 
Fig.S5A & B. 
(E) qRT-PCR for CD133 in cells infected with shSPDYA or shCCNE1 as comparison to 
control (pLKO). Representative data shown as mean ±s.d. n=3. **p<0.01. See Fig.S5C. 
(F) qRT-PCR of different markers (X-axis) in a CD133+ population treated with two 
shSPDYA constructs (shSPDYA
#1
 (solid bars) or shSPDYA
#2
 (hollow bars)). Data shown 
as relative to levels with knockdown for shCCNE1. Representative data shown as mean 
±s.d. n=3. **p<0.01, ***p<0.001 
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Figure S5. Spy1 Expression Plays a Critical Role in the Stemness Properties of the 
CD133+ BTIC Population in diverse glioma cell lines. 
 (A) qRT-PCR analysis of CD133+ SJ-GBM2cells infected with a scrambled control 
vector (pLKO) and two different constructs (sh#1, sh#2) against SPDYA  (shSPDYA). 
Representative data shown as mean ±s.d. n=3. *p<0.05,**p<0.01. 
(B) qRT-PCR analysis of CD133+ U251 cells infected with a scrambled control vector 
(pLKO) and two different constructs (sh#1, sh#2) against SPDYA (shSPDYA). 
Representative data shown as mean ±s.d. n=2. 
(C) qRT-PCR analysis of SPDYA and CCNE1 levels in CD133+ U87 cells. 
Representative data shown as mean ±s.d. n=3. *p<0.05,**p<0.01. 
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Downregulation of Spy1 is Critical for Specific Differentiation Decisions 
Given that SPDYA knockdown reduced stem/progenitor markers and increased 
neuronal differentiation markers, we questioned whether Spy1 was endogenously 
regulated during differentiation. Primary neural cells obtained from the neurogenic 
regions of early post-natal mouse brains grown as neurospheres (Fig. 4A) or monolayer 
(Fig. 4B) were subjected to differentiation using 2% FBS. In both cases Spy1 expression 
decreased with differentiation morphology and correlated with a decrease in stemness 
markers GFAP and Nestin (Fig. 4A& B) and an increase in the neuronal differentiation 
marker GAP43 (Fig. 4B). To determine whether Spy1 levels are similarly reduced along a 
neuronal differentiation lineage in human neural progenitor cells, PC12 
pheochromocytoma cells were induced to differentiate over several days using nerve 
growth factor (NGF). Cells were scored as differentiated when the neurite length 
exceeded twice the size of the cell body (Fig. 4C; upper panel). Spy1 protein levels are 
undetectable by day 6 when 80-90% of control cells are differentiated (Fig. 4C; lower left 
panel). Notably, Spy1 expression was inversely correlated with that of p27, where p27 
levels reached maximal levels by day 4-5 post-differentiation. QRT-PCR of SPDYA 
demonstrates that expression followed a similar trend, being significantly decreased by 
day 4 of differentiation (Fig. 4C; lower right panel). These changes occur with a decrease 
in CDK2 kinase activity (Fig. 4D). 
To determine whether decreasing levels of Spy1 protein are essential for 
differentiation to occur, SPDYA, or an empty vector control, were overexpressed in both 
the PC12 cell line (Fig. 5A) and primary neural cells (Fig. 5B). PC12 stable cell lines 
were induced to differentiate and observed over an 8 day time course (Fig. 5A). By day 8, 
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95% of the control cells underwent differentiation, while only 50% of the Spy1 
overexpressing counterparts were differentiated. Similarly, in primary neurospheres, 60% 
of control spheres successfully differentiated by 72 hours, while only ~20% of Spy1 
overexpressing neurospheres were visibly differentiating (Fig. 5B). Spy1 overexpressing 
cells, induced to differentiate, had reduced expression of the neuronal differentiation 
marker GAP43 and enhanced expression of the progenitor marker GFAP (Fig. 5B; right 
panel). While levels of Nestin were increased, they were not significant (Fig. 5B; right 
upper panel). Effects on mature astrocytes require further investigation pending the 
expansion of available markers. Depletion of SPDYA in primary neural cells using 
shRNA demonstrated a significant increase in functional differentiation; these effects 
were rescued using a human SPDYA overexpression plasmid resistant to knockdown with 
SPDYA shRNA (Fig. S6A). These results support that elevated levels of Spy1 favor 
expansion of stem/progenitor cells possessing glial characteristics and prevent functional 
differentiation toward a neuronal lineage. 
To further determine whether Spy1 levels are critical for normal stem/progenitor 
characteristics; primary neural cells manipulated for SPDYA or control were assessed for 
self-renewal capacity and neurosphere formation. Spy1 overexpressing cells significantly 
increased the overall number, clonality and viability of neurospheres as compared to 
controls (Fig. 5C-E). An opposite effect was observed with SPDYA knockdown (Fig. 
S6B). Cells overexpressing Spy1 had notable elevation in stemness markers such as 
Nestin, Vimentin and CD133 (Fig. 5F). These data demonstrate that the cyclin-like protein 
Spy1 is an important regulator in the expansion and growth of NSCs. Although this data 
does not reveal a cell of origin for glioma, we provide an additional mechanistic link 
regulating the common growth characteristics between NSC and BTIC populations.  
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Figure 4. Spy1 Protein Levels are Tightly Regulated During Neural Progenitor Fate 
Decisions.  
(A) Differentiation of mouse primary neural cells grown as neurospheres. Morphology 
assessed by phase contrast microscopy (upper panel). Scale bar, 25m. SPDYA, Nestin 
and GFAP levels analyzed at indicated time points by qRT-PCR (lower 
panels).Representative data shown as mean ±s.d. n=3. **p<0.01. 
(B) Differentiation of mouse primary neural cells recorded by phase contrast microscopy 
(upper panels; Scale bar, 10m). qRT-PCR of SPDYA, GAP43 and Nestin tested along 
the differentiation time course (lower panel). Non-treated cells were used as a control. 
Results presented as mean ±s.d. n=4; *p < 0.05.  
(C) NGF-induced differentiation of PC12 cells recorded by phase contrast microscopy 
(upper panel). Spy1 expression analyzed by SDS-PAGE (lower left panel). -Tubulin 
used as a loading control. Scale bar, 10m. qRT-PCR of SPDYA levels at each time point 
of differentiation (lower right panel). Non-treated cells were used as a control. Results 
presented as mean ±s.d.n=3; *p < 0.05.  
(D) CDK2 activity measured by histone 1 (H1) kinase assay and quantified as Density 
Light Units (DLU) /mm
2
 along PC12 differentiation time course (top panel). Lower panel 
indicates kinase activity detected by phosphorimaging. One representative experiment of 
two. 
 
 
 
112 
 
 
113 
 
Figure 5. Spy1 Overexpression Abrogates Neuronal Differentiation and Promotes 
Neurosphere Clonal Growth. 
(A) Differentiation of PC12 cells stably infected with flag-tagged SPDYA (PC12- 
SPDYA) versus empty vector (PC12-WT). Morphology by light microscopy (upper 
panel). Scale bar, 25m. Differentiation scored by axon length. Ratio of differentiated 
cells to total cell number presented. Control (hollow), SPDYA overexpressing (black 
bars). Values are mean ± s.d. n=3; *p < 0.05, ***p < 0.001. 
(B) Primary neurospheres infected with pEIZ-SPDYA versus control (pEIZ) over the 
indicated time points. Morphology was monitored by light microscopy (upper left panel). 
Scale bar, 25m. Differentiation was scored by neurite length and presented as the ratio 
of differentiated spheres to total spheres (lower left panel). Control (hollow), SPDYA 
overexpressing (black bars). Values are mean ± s.d. n=3; *p < 0.05.qRT-PCR of markers 
in control (pEIZ) and Spy1 overexpressing (pEIZ-SPDYA) primary cells (right panel top 
to bottom). Representative data are shown as mean ±s.d; n=3; *p < 0.05. See Fig.S6A&B. 
(C) Clonal assay performed on primary neural cells overexpressing Spy1 (pEIZ-SPDYA) 
vs. control (pEIZ). Total neurosphere numbers indicated as mean ±s.d. n=3; **p < 0.01. 
(D) Neurospheres scored according to diameter after they were maintained in culture for 
14-20 days. mean ±s.d. n=2. 
(E) Longevity of pEIZ or pEIZ-SPDYA primary, secondary and tertiary neurospheres 
(NS) in culture assessed by MTT assay. Neurospheres were passaged as single cells every 
6-9 days. Absorbance at 590nm corrected for background absorbance. Representative 
data shown as mean ±s.d. n=3; *p < 0.05. 
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(F) qRT-PCR of stemness markers in pEIZ or pEIZ-SPDYA primary cells cultured as 
neurospheres (NS). Data shown is mean ±s.d. n=3; **p < 0.01.  
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Figure S6. The SPDYA knockdown accelerates differentiation and decreases neurosphere 
forming capacity in primary neural cell populations. 
(A) The target specificity of the shRNA construct used was confirmed in rescue assays 
utilizing shRNA against mouse SPDYA (pLB-shSPDYA) and human Spy1 overexpressing 
vector (pEIZ-SPDYA). Primary neural cells treated with control vectors (pLB-scrambled 
or pEIZ), control vector and SPDYA shRNA (pEIZ/ pLB-shSpy1), control vector and 
SPDYA overexpressing plasmid (pLB/ pEIZ-SPDYA) and the rescue treatment (RE) 
consisting of pLB-shSPDYA and pEIZ-SPDYA, subjected to differentiation time course. 
Differentiated cells were scored according to neurite length, and the ratio of differentiated 
cells to total cell number represented as percentage was scored at the indicated time 
points. Data shown is mean ±s.d. n=3; *p<0.05, **p<0.01. 
(B) Clonal assay performed on Balb/c primary neural cells infected with shRNA against 
SPDYA (pLB-SPDYA) vs. scrambled control (pLB). Representative data are shown as 
mean ±s.d. n=3; **p < 0.01. 
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Symmetric Division of CD133+ U87 Glioma Cells Relies Uniquely on Spy1 
To assess Spy1 effects on the self-renewal characteristics of BTICs in human 
glioma, cell lines with manipulated levels of either SPDYA or CCNE1 (Fig. S5C) were 
cultured at low densities (<10 cells/well) in media supporting self-renewal. Sphere 
diameter were scored (Fig. 6A&B). SPDYA knockdown caused significant reduction in 
both the number and diameter of resulting spheres; characteristics previously correlated 
with tumourigenic capacity and percent of CD133+/Nestin+ cells in glioma (Wang, Wang 
et al. 2008; Yoon, Kim et al. 2012). Sphere formation over an excess of 10 passages in 
CD133+ U87 cells revealed that SPDYA knockdown caused a 5 fold decrease in number 
and longevity of spheres compared to control (Fig. S7A; left panel and S7B). The 
reciprocal effect was also noted in cells over-expressing Spy1 (pEIZ- SPDYA; Fig. S7A; 
right panel). EGF and FGF are essential growth factors that support stem cell self-renewal 
(Morshead, Reynolds et al. 1994; Li, Wang et al. 2009). Sorted cells were cultured in 
media without EGF and FGF for 48 hours. Interestingly, Spy1 overexpression resulted in 
significantly increased levels of CD133 in the absence of EGF/FGF (Fig. S7C), 
suggesting that cell cycle regulation by Spy1 may lie downstream of associated growth 
factor signaling. 
How BTICs use symmetric vs. asymmetric division to regulate expansion and 
support tumour growth are very important points that are not fully understood. Utilizing 
computer modeling Boman et al. have established that increasing symmetric division is 
the only mechanism to adequately explain the expansion of the cancer stem cell 
population (Boman, Wicha et al. 2007). Drosophila and mammalian systems have shown 
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that symmetry of division is influenced by the segregation of the protein Numb 
(Knoblich, Sauer et al. 1994; Lu, Rothenberg et al. 1998). Numb is able to promote neural 
differentiation, at least in part, through antagonizing Notch and Hedgehog pathways; thus 
localization of Numb serves as an indicator of cellular fate determination (Di Marcotullio, 
Ferretti et al. 2006; Couturier, Vodovar et al. 2012). While the functional role is 
unknown, asymmetric distribution of CD133 also co-localizes with Numb in 
differentiating glioma stem cells (Wang, Wang et al. 2008). Utilizing the cell pair assay to 
monitor protein expression in single cells through division we found that Spy1 
knockdown resulted in marked asymmetric distribution of both Numb and CD133 protein 
(Fig. 6C (left panel)&S7D&E). Analysis over multiple infections of multiple glioma cell 
lines with 2 separate knockdown constructs for CCNE1 and SPDYA showed significant 
asymmetric localization of Numb protein in the SPDYA -knockdown cells, but not in the 
CCNE1 knockdown (Fig. 6C; right panel). Western blot analysis of Numb protein 
expression levels in CD133+ cells upon SPDYA or CCNE1 knockdown show that SPDYA 
downregulation, but not downregulation of CCNE1, causes a significant and repeatable 
accumulation of Numb protein levels (Fig. 6D). Interestingly, even within heterogeneous 
populations of human glioma SPDYA levels were found to inversely correlate with Numb 
and p21 levels (Fig. S7F). These data support the hypothesis that levels of the atypical 
cyclin-like protein Spy1 promote NSC self-renewal and expansion of stem/progenitor 
populations by regulating the balance of symmetric vs. asymmetric division. 
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Figure 6. Spy1 is Critical for Symmetric Division and Self-Renewal of CD133+ Cells. 
(A) Clonal assay performed on pLKO-Control, shSPDYA
#1/#2
 and shCCNE1
#1/#2 
U87 
CD133+ cells.  Emerging neurospheres of over 25m scored per well. Min. of 30 wells 
per replicate (upper panel). Neurosphere size presented as a pie chart. Data shown as 
mean ±s.d. n=3; **p < 0.01. See Fig. S7A-C. 
(B) As described for (A) using the CD133+ population in the SJ-GBM2 cells. Data shown 
as mean ±s.d. n=3; **p < 0.01. Results obtained from both shRNA constructs were 
pooled. 
(C) Cell pair assay conducted using the CD133+ population of U87, SJ-GBM2 and U251 
cells treated with pLKO-scrambled control (pLKO), shSPDYA
#1/#2
 and shCCNE1
#1/#2
. 
Representative U87 cells stained for Numb (left upper panel) and CD133 (left lower 
panel). Quantification of each cell type scored for Numb distribution (right panel). Data 
shown as mean ±s.d. n=3; *p < 0.05, **p < 0.01.Scale bars: 10 m. See Fig.S7D-E. 
(D) Levels of Numb protein in U87 cells treated with shSPDYA or shCCNE1. One 
representative blot of 3 (upper panel).Values are presented as the mean of Integrated 
Density Values (IDV) Numb/Actin. Data shown as mean ±s.d. n=3; **p < 0.01. See 
Fig.S7F. 
(E) Cartoon of putative mechanism for Spy1-mediated effects on division characteristics.  
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Figure S7. Spy1 Sustains Viability of Glioma Tumourspheres in Long Term Culture and 
Supports CD133 Expression Upon Growth Factor Withdrawal. 
(A-B) Knockdown (left panel) and overexpression (right panel) of SPDYA in CD133+ 
U87 neurosphere long-term cultures. 
(A) Number of neurospheres formed. Neurospheres were passaged at least 10 times and 
total number of spheres generated per well were scored per 10
3
 cells plated initially. Data 
shown is mean ±s.d.  
(B) MTT assay in SPDYA knockdown CD133+ U87 cells. Spheres were cultured and 
passaged over a time period of 90 days prior to analysis. The obtained absorbance at 
590nm was corrected for background absorbance. Data shown is mean ±s.d. 
(C) Spy1 effects on CD133 expression upon withdrawal of growth factors. CD133+ U87 
cells were infected with pEIZ-Cnt and pEIZ-SPDYA. qRT-PCR analysis of CD133 
expression in pEIZ-SPDYA and non-infected cells upon growth factor withdrawal. pEIZ- 
SPDYA levels were corrected for pEIZ. Data shown is mean ±s.d. n=3, **p<0.01, 
***p<0.001. 
(D) Additional images of cell pair assay conducted using the CD133+ U87 cells treated 
with pLKO-Control, shSPDYA
#1/#2
 and shCCNE1
#1/#2
. Representative immunofluorescent 
micrograph analysis of U87 cells stained for Numb. Scale bar: 10m. 
(E) Low magnification images of cell pair assay using CD133+ U87 cells treated with 
shSPDYA and shCCNE1. Scale bar: 25m. 
(F) Endogenous levels of MSI1, Numb and p21 from cell lines listed above panels were 
measured by western blot (left panels). Right panels depict qRT-PCR reactions from 
cDNA prepared from each of the specified cell lines.  SPDYA levels (upper right) and p21 
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levels (lower right) are depicted for each. Data is corrected for GAPDH and then 
graphically depicted as normalized to the lowest value (U87).  Error bars reflect mean 
±s.d. n=3, **p<0.01. 
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DISCUSSION 
 The dynamics of neurogenesis rely on the balance of stem/progenitor self-renewal 
with commitment to specific lineages. Extensive literature indicates that anti-proliferative 
genes preventing the activation of G1/S CDKs act as important timers to permit 
neurogenesis (Durand, Fero et al. 1998; Hindley and Philpott 2012). Similarly, while not 
as extensively investigated, proliferative genes and signals resulting in an activation of 
the G1/S CDKs support expansion of stem/proliferative populations and retard successful 
neurogenesis (Dobashi, Kudoh et al. 1995; Lange and Calegari 2010). Which cyclin-
CDKs regulate specific neurogenic events, and how their activation is controlled remains 
to be elucidated. As multicellular organisms have evolved to possess regenerative systems 
capable of sustaining long life, so have the families of proteins regulating cell cycle 
progression. The Spy1/RINGO family of cyclin-like proteins is such an example. 
Expressed in all vertebrates and some invertebrates, these proteins have demonstrated 
roles in spinal cord regeneration and to possess stem-like qualities in the developing 
mammary gland (Golipour, Myers et al. 2008; Huang, Liu et al. 2009). In this work we 
demonstrate that one member of the Spy1/RINGO family, Spy1A1, is expressed at high 
levels in clonally derived neurospheres and levels decline during differentiation. Elevated 
levels of Spy1 prevent functional differentiation and enhance the number and longevity of 
neural stem/progenitor cells able to grow in neurosphere culture. While the link between 
NSCs and BTICs remains to be determined, BTICs are found to express several normal 
NSC markers and possess growth characteristics mimicking that of normal NSCs (Chen, 
McKay et al. 2012).  Hence, regardless of the BTIC origin, resolving the regulatory 
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properties driving normal NSCs may shed light on novel ways to target these aggressive 
populations therapeutically. 
Another defining property of NSCs and BTICs alike, is the ability to divide both 
symmetrically and asymmetrically. A shift in division characteristics to favor symmetric 
division is thought to contribute to exponential increase in the numbers of cancer stem 
cells in a variety of different types of tumours (Gonczy 2008). One mechanism regulating 
the critical switch between modes of division depends on the cellular distribution of the 
protein Numb (Song and Lu 2012). Functionally Numb inhibits the Notch pathway to 
permit asymmetric division and subsequent differentiation (Song and Lu 2012). Our study 
demonstrates that Spy1 is important for maintaining symmetric mode of division and self-
renewal, implicating a mechanistic role for this cyclin-like protein in retaining the 
hallmark properties of BTICs.  A recent study published by Arumugam et al. pointed at 
the Spy1 (RINGO)/CDK signaling pathway as a highly conserved activator of Musashi-1 
(Msi1) during cell cycle re-entry in oocyte maturation (Arumugam, MacNicol et al. 
2012). Activated mammalian Msi1 stimulates Notch signaling through the translational 
repression of Numb (Toda, Iizuka et al. 2001). Hence, Msi1 may rely on Spy1-directed 
CDKs to mediate the self-renewal of normal NSCs as well as clonal expansion, 
malignancy and proliferation of glioblastoma cells (Sakakibara, Nakamura et al. 2002; 
Muto, Imai et al. 2012) (Fig. 6E). Our data reveals that downregulation of SPDYA, but not 
CCNE1, leads to increased levels of Numb protein followed by altered expression of 
select Notch transcriptional targets. Spy1 activates both CDK1 and CDK2, and CDK1 is 
an essential regulator of the switch between symmetric/asymmetric division in 
Drosophila neuroblasts (Tio, Udolph et al. 2001); hence Spy1-CDK1 could have unique 
functions in regulating effects on neural symmetry in vertebrates. The altered regulation 
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of Numb, and consequently Notch, may also alter overall self-renewal parameters. A 
study by Noseda et al. showed that Notch can act as a transcriptional repressor of p21 
which further prevents nuclear localization of Cyclin D/CDK4 (Noseda, Chang et al. 
2004). In mammals p21 maintains quiescence of adult NSC populations (Kippin, Martens 
et al. 2005). Hence, Spy1 appears to coordinate signals directing both self-renewal as well 
as the balance of symmetric/asymmetric division. Both of these activities are not simply 
due to CDK2 activation, as the effects of manipulating Spy1 do not mirror the effects 
seen with Cyclin E1. We show that while both Spy1- and Cyclin E1- activated CDKs play 
a role in proliferation of cancer stem cells, Spy1 uniquely demonstrates an effect on the 
stemness characteristics of the CD133+ population.  
It is known that Spy1 activates CDKs in a Cyclin Activating Kinase (CAK) 
independent manner and demonstrates less stringent substrate specificity than cyclin-
bound CDKs (Cheng, Gerry et al. 2005). In addition, atypical of cyclins, Spy1 can both 
activate CDKs as well as directly bind and promote the degradation of the CDK inhibitor 
p27 (Porter, Kong-Beltran et al. 2003). Functional differentiation requires a decrease in 
the kinase activity of CDK2 as well as an accumulation in p27 protein levels (Dobashi, 
Kudoh et al. 1995; Sasaki, Tamura et al. 2000). This work therefore supports the specific 
requirement for this unique class of proteins over the established CDK2 partners Cyclins 
E and A during neural differentiation and in promoting stemness properties in neural 
cells. The importance of these unique 'cyclin-like' proteins has been overlooked in the 
cancer therapeutics arena for over a decade (Porter, Dellinger et al. 2002). Although CDK 
inhibitors are being tested clinically for a number of different types of cancer, the studies 
in brain malignancies remain preliminary (Fischer and Lane 2000; Jane, Premkumar et al. 
2006). In other types of cancer, despite the pre-clinical success of this approach, the data 
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on actual therapeutic outcome has been quite disappointing (Stone, Sutherland et al. 
2012). Therefore, this work adds to the accumulating evidence that will aid in improving 
the effectiveness of CDK inhibitors in their use as chemotherapeutic agents for specific 
subsets of cancer. 
Directing therapy to the appropriate patient population is also a pressing area of 
importance. Spy1 levels were most significantly elevated in high grade of glioma, known 
to be more anaplastic with features resembling immature astrocytes and/or 
oligodendrocytes. This correlates with the elevated levels of glial progenitor markers seen 
in our cell systems overexpressing Spy1, such as the BTIC marker CD133. A significant 
amount of data supports the use of CD133 as a stem cell surface antigen to identify a 
subpopulation of brain tumour initiating stem cells (Singh, Hawkins et al. 2004). While 
CD133- BTIC populations are able to generate heterogeneous tumours in vivo (Korur, 
Huber et al. 2009), tumours containing a CD133+ BTIC population correlate positively 
with higher grades of glioma, poorer patient prognosis, as well as multi-drug resistance 
(Dean, Fojo et al. 2005; Zeppernick, Ahmadi et al. 2008; Yan, Ma et al. 2011). Resolving 
the lineage commitment, stage of differentiation and genetic/genomic signatures of BTIC 
populations for the different forms and stages of glioma is an essential next step in 
correlating prognostic markers with effective treatments for brain cancers. Importantly, 
knockdown of SPDYA levels in a heterogeneous population of GBM cells decreased the 
proliferative index, as well as expression levels of CD133 and GFAP. Abrogation of 
normal differentiation events can contribute to the initiation of tumourigenesis and 
understanding such events has proven to constitute a valuable strategy in the treatment of 
acute promyelocytic leukemia (Nakamura, Ramaswamy et al. 2000). Hence, it is feasible 
that a similar strategy would be a valuable approach for a cancer of neural origin.  
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INTRODUCTION 
The dynamics of neurogenesis rely on different factors including the size of the 
stem/ progenitor cell population and the commitment of cells to specific lineages 
followed by neuronal growth and differentiation. Differences in the mechanisms of cell 
cycle regulation between embryonic and adult stages are responsible for the diverse 
developmental potential of neural progenitors. Active neurogenesis is associated with 
fluctuations in the cell cycle status throughout central nervous system (CNS) 
development (Ma, Qi et al. 2009). The specifics of how the cell cycle drives CNS 
developmental mechanisms, particularly with regard to stem/progenitor cell turnover and 
regulation of the neurogenic niche density, remain to be established. Embryonic stem 
cells (ESCs) use their self-renewing pluripotent potential at early stages of development; 
thereby expanding in number to establish a population of multilineage progenitors. ESCs 
demonstrate unique dynamics of the cell cycle. Their rapid division rate is attributed to an 
extremely short cell cycle due to a significant reduction in G1 phase (Takahashi, 
Nowakowski et al. 1995). Shortening of G1 in ESCs may also conserve their pluripotency 
and prevent differentiation (Orford and Scadden 2008; Singh and Dalton 2009; Lange and 
Calegari 2010). In contrast, adult stem cells need to carefully control growth to ensure 
that they are capable of expanding and differentiating throughout the life of an organism 
reviewed in (Mimeault and Batra 2006; Mimeault, Hauke et al. 2007). Adult stem cells 
predominantly accomplish this by residing in a quiescent state maintained by a network 
of cell cycle inhibitors. This ultimately reflects the stem cell commitment to preserve 
genomic integrity and prevent proliferative exhaustion.  
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Early postnatal development of the CNS is characterized by an important window 
of apoptotic events and synaptogenesis to form networks between mature neurons. These 
events are necessary for proper development and are potentially linked to events such as 
learning (Gordon 1995; Han, Wu et al. 2009). In the mature mammalian brain, 
proliferation and neurogenesis are limited to the populations of slowly proliferating adult 
stem cells. The primary neurogenic regions in the adult brain are restricted to the 
forebrain subventricular zone (SVZ) of the lateral ventricles  (Doetsch, Caille et al. 1999) 
and subgranular zone within the dentate gyrus of the hippocampus (Palmer, Ray et al. 
1995). A rare population of adult neural stem cells (NSC)s has also been found in the 
migratory circuit between the SVZ and olfactory bulb (Gritti, Bonfanti et al. 2002). A 
significant amount of research is accumulating to characterize factors regulating stem and 
progenitor cell proliferation as well as fate determination within these regions of the brain 
(Falk, Wurdak et al. 2008; Schmidt, Bicker et al. 2009). Cell cycle regulation plays a key 
role as the control system, not only during neurogenesis in the developing brain, but also 
in sustaining proliferative potential in the adult brain.  
Spy1 (Speedy, Spdya, RINGO), encoded by SPDYA gene, belongs to a family of 
unconventional cell cycle regulators that can stimulate cyclin dependent kinase 2 (CDK2) 
independent of classically defined post-translational modifications required to activate 
Cyclin-CDK complexes (Karaiskou, Perez et al. 2001; Cheng, Xiong et al. 2005). Spy1 
can also bind directly to the CDK-inhibitor p27, promoting further activation of CDK2 
and subsequent degradation of p27 (Porter, Kong-Beltran et al. 2003; McAndrew, 
Gastwirt et al. 2007) and Spy1 overexpression reduces the length of G1 phase and 
promotes cell proliferation (Porter, Dellinger et al. 2002). Importantly, Spy1-mediated 
effects have been implicated in a variety of different human cancers as well as in normal 
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development (Golipour, Myers et al. 2008; Ke, Ji et al. 2009; Zhang, Shen et al. 2012). 
Recently, Spy1 has been suggested to participate in the neuroregenerative processes of 
the spinal cord (Huang, Nagane et al. 1997; Cao, Yang et al. 2013). Several lines of 
evidence support a role for the Spy1-effectors CDK2 and p27 in regulating the balance 
between self-renewal and differentiation among adult stem cells in the postnatal brain 
(Ghiani and Gallo 2001; Doetsch, Verdugo et al. 2002; Lukaszewicz, Savatier et al. 2005; 
Jablonska, Aguirre et al. 2007; Li, Collado et al. 2012). Collectively, these published data 
suggest a role for Spy1 in neural progenitors during adult neurogenesis.  
This study investigates the spatio-temporal expression of Spy1 in the mammalian 
CNS. We demonstrate for the first time that Spy1 protein is found at sites of adult 
neurogenesis and that Spy1 expression correlates with NSC and progenitor populations of 
the SVZ. Moreover, Spy1 levels peak during late stages of murine embryogenesis and 
decline in the early postnatal brain, suggesting that Spy1 expression is tightly regulated at 
the different stages of mammalian CNS development. The outcome of this study will shed 
light on cell cycle regulation in populations of self-renewing neural progenitors. This 
advance in knowledge is indispensable for creating new strategies for regenerative 
medicine and brain cancer therapy.  
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EXPERIMENTAL PROCEDURES 
Animals 
Balb/c mice (Jackson Labs) were bred on site for the purposes of this study. Mice were 
maintained and cared for following the Canadian Council for Animal Care guidelines 
under the University of Windsor AUPP# 10-08. 
Immunohistochemistry 
Rat brain cryosections (obtained from Dr. Zhang, University of Windsor), mouse brain 
cryosections or formalin-fixed and paraffin-embedded brain tissue sections were 
incubated 15 minutes in 4% paraformaldehyde at 4C on microscope slides and then 
washed 3 times with PBS. They were permeabilized in 0.2% TritonX-100 in PBS for 1 
hour at room temperature followed by 3 washes with PBS-TritonX-100. Sections were 
blocked in normal goat serum for 1 hour at 37
o
C. Antibodies were added for 2 hours at 
37
o
C, followed by a 10 minute wash in PBS-TritonX-100 containing 1% of blocking 
Normal Goat Serum. Secondary antibodies were applied for 1 hour at 37
o
C, washed 2 
times for 10 minutes each in PBS-TritonX-100, 1 time in Hank's Balanced Salt Solution 
(HBSS) and incubated with Hoechst 33342 (Sigma) (0.35 mg/ml) for 30 minutes. 
Counterstained sections were washed with HBSS 3 times for 5 minutes. Tissues were 
mounted with Vectashield mounting medium and imaged using a IX8I Olympus confocal 
microscope, using Fluoview 1.7 software. The proper antibodies were used at the 
following concentrations: human Spy1 – 1:1000-1:10000 (Novus), GAP43 G9264 
(Sigma) 1:1000 GFAP G4546 (Sigma) 1-1000, Nestin G-20 (Santa Cruz) 1:1000. 
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Protein isolation from brain tissues  
Flash frozen brain samples were thawed quickly and cut into 0.03-0.13 g pieces. Tissue 
pieces were weighed and 250 l of NP40 Extraction Buffer (50 mM Tris-Hcl pH 7.5, 1% 
NP40, 1 mM EGTA pH 8.0, 0.2% SDS, 150 mM NaCl, 0.25% sodium deoxycholate, 
1.5% antifoam A) with protease inhibitors (leupeptin 2 g/mL, aprotinin 5 g/mL, 
sodium fluoride 50 mM, pepstatin A 1 g/mL and PMSF 100 g/mL) was used per 0.1 g 
of tissue. Tissues and extraction buffer were homogenized on ice (3 times, 10 seconds). 
Samples were then centrifuged at 13,000 rpm for 15 minutes at 4C. Supernatant was 
collected and stored at –20C until use. 
Western blotting 
Protein concentrations were assessed by Bradford assay, samples were prepared with 4x 
sample buffer (10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2% SDS, 0.01 mg/mL 
bromophenol blue, 2% -mercaptoethanol), and boiled for 5 minutes at 95-105C. 
Samples were loaded onto 10% polyacrylamide gels and run at 110 volts for 3- 4.5 hours. 
Proteins were then transferred to PVDF membranes through semi-wet transfer at 30 volts 
for 2.5 hours. Membranes were blotted in 3% milk for durations ranging from 2 hours to 
overnight. Primary antibodies were incubated overnight at 4C except for Actin mouse 
which was incubated for 2 hours at room temperature. Membranes were washed with 
Tris-Buffered Saline Tween-20 (TBST) 3 times for 5-10 minutes, followed by a 1 hour 
incubation in secondary antibody at room temperature. Membranes were washed with 
TBST 3 times for 15 minutes and were visualized using FluorChem HD2 imaging system 
(Alpha Innotech). The proper antibodies were used at the following concentrations: Actin 
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MAB150 1R (Chemicon- Millipore; 1:1000), -Tubulin TU-02 (Sigma; 1:1000), human 
Spy1 (Novus; – 1:1000-1:10000), p27Kip1 NA35 (Calbiochem; 1:100).  
qRT-PCR 
Total RNA was extracted using the RNAeasy Plus Mini Kit (Qiagen) and reverse 
transcribed using 200U Superscript II (Invitrogen), 0.5 g OligodT’s and 0.5 g random 
nanomers (Sigma) according to the manufacturer instructions. Real time PCR was carried 
out using SYBR green detection (Applied Biosystems) with 250-400 nM of each primer 
(Table 1; Suppl. Mat.) and was performed using an ABI Prism 7300 thermocycler. Data 
were analyzed using ABI 7300 software and represent log10 relative quantification (RQ) 
relative to control. Primers were designed using Primer Express software (Applied 
Biosystems). 
Statistical analyses 
Student's t-test was used to perform statistical analyses. A p-value of 0.05 was 
considered significant. All data are reported as means ± s.d. Real time PCR analyses were 
performed as described previously (Yuan, Reed et al. 2006). Briefly, the Ct value of the 
housekeeping gene (GAPDH) was subtracted from the corresponding Ct value of a target 
gene to produce a dCt value which was further subjected to the Student's t-test analysis. 
Statistical analyses and normality testing were performed using Statistica software.  
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RESULTS 
Spy1 protein levels are tightly regulated during neural progenitor lineage 
commitment 
To determine how Spy1 protein levels are regulated through neural development, 
endogenous protein levels in the murine brain were measured at embryonic days (E) 12-
18 and postnatal days 4 through to 21 weeks. At the postnatal stages Spy1 levels were 
measured in the tissues microdissected from the hippocampus and olfactory bulb that 
were pooled for the protein analysis. A dramatic accumulation of Spy1 protein was 
observed during late embryonic stages, E 14-18, and then again in late postnatal stages, 
beginning to rise at day 15 and continuing to accumulate through to approximately day 
90. Spy1 levels were reduced at time points correlating with decreased neurogenesis such 
as early postnatal stages (day 4-15) and in the aging brain (> day 90) (Fig. 1A). Cells 
were then isolated from E14 brains or from the neurogenic regions of postnatal brains 
(days 2-7) and expression levels were measured by q-RT-PCR. In correlation with the 
NSC marker Nestin and the pluripotency marker Oct-4, SPDYA expression substantially 
declined with age and during differentiation (Fig. 1B). 
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Figure 1. Spy1 is tightly regulated in neurogenic regions of the developing brain.  
(A) Balb/c mice were sacrificed at the indicated time points (D=days; W=weeks). 
Neurogenic sites (hippocampus and olfactory bulb) were microdissected and subjected to 
western blot analysis (upper panel). Samples were pooled over at least 3 mice per data 
point, bands were quantified by densitometry analysis and values are expressed as the 
Integrated Density Values (IDV) of Spy1/ -Tubulin (lower panel). Results are presented 
as mean ±s.d. n=3; *p < 0.05, **p < 0.001, ***p < 0.0001 between selected groups. 
(B) Primary cell cultures established from embryonic (E14) and postnatal (PN2-7) mouse 
brains plated in serum free media supplemented with 20ng/ml EGF and 10ng/ml bFGF or 
differentiated for 5 days upon addition of 2% FBS. Analyzed using qRT-PCR for SPDYA 
(left graph), Nestin (middle graph) and Oct-4 (right graph). Error bars represent triplicate 
of each sample; n=3. Results are presented as mean ±s.d. n=3; *p < 0.05. 
 
 
 
 
 
 
 
 
 
144 
 
Spy1 protein localizes to the neurogenic regions of the mammalian brain 
Spy1 protein levels were high in neurogenic regions of the adult brain including the 
hippocampus and olfactory bulbs (Fig. 2A). While a lower band of Spy1 was also found 
in the cerebellum, it is noted that p27 levels were significantly reduced only in the 
neurogenic regions; this provides the possibility that Spy1 is functionally active in the 
neurogenic tissues.  Quantification of Spy1 expression over multiple postnatal brains 
demonstrated that Spy1 protein levels were significantly upregulated in the olfactory 
bulbs containing neural progenitors in comparison to a non-neurogenic region (cortex) 
(Fig.2B). Interestingly, q-RT-PCR analysis of SPDYA in the olfactory bulbs at different 
developmental stages demonstrated higher levels of SPDYA mRNA at the sites of 
ongoing neurogenesis at both early and late postnatal stages when compared to the cortex 
(Fig. 2C). Spy1 was found to be localized specifically in the dentate gyrus along the 
subgranular zone, a region associated with high levels of neurogenesis (Goldman and 
Chen 2011) (Fig. 2D; left panels). Moreover, Spy1 positive cells were observed in the 
choroid plexus, subependymal zone around the lateral ventricles and SVZ (Fig. 2D; right 
panels). Immunolabeling with the NSC marker Nestin revealed its colocalization with 
Spy1 protein, supporting the progenitor nature of detected cells. Stem-like properties of 
neural progenitors can be addressed in a neurosphere formation assay where specific 
culture conditions support the self-renewing potential and clonal growth of true stem cells 
(Pastrana, Silva-Vargas et al. 2011). The microenvironment within the neurosphere 
facilitates heterogeneity where the populations capable of clonal growth that express stem 
cell markers like Nestin coexist among more committed progenitors (Suslov, Kukekov et 
al. 2002).  Culturing cells as neurospheres revealed that Spy1 is consistently expressed in 
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Nestin positive cells (Fig. 2E). Neurospheres were treated with 2% FBS and stained for 
the differentiation markers Growth-Associated Protein (GAP43) and Glial Fibrilary 
Acidic Protein (GFAP) to test their ability to functionally differentiate (Fig. 2E; right 
panels). Spy1 and Nestin levels were undetectable following differentiation (data not 
shown).  
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Figure 2. Spy1 protein localizes to the neurogenic regions of the mammalian brain. 
(A) Neurogenic sites: HC, and OB or non-neurogenic sites: CX or CB microdissected 
from Wistar albino rat brains and analyzed by SDS-PAGE (left panel). Liver was used as 
a control and -Tubulin as a loading control.  
(B) HC, OB, CB and CX were microdissected from 8 mouse brains at different 
developmental stages and analyzed by SDS-PAGE. Densitometry is presented as the 
Integrated Density Values (IDV) of Spy1-Tubulin control. Results are presented as 
mean ±s.d. n=8; *p < 0.05.  
(C) SPDYA expression levels in OB and CX of mouse brains at early (2-7 days) and late 
postnatal (81- 90 days) analyzed using qRT- PCR. Values are mean ±s.d. for triplicate 
samples from a representative experiment. 
(D) IHC on rat coronal cryosections of the DG (left column) or LVs (right column). 
Colocalization of Spy1 (green) and neural stem cell marker Nestin (red) is marked in 
yellow (merge). Hoechst 33342 was used to counterstain nuclei. Scale bar, 50 m.  
(E) Primary cells extracted from neurogenic sites of a mouse brain were passaged using 
neurosphere assays. Undifferentiated neurospheres (left column) were probed with Spy1 
(green) and Nestin (red). Coexpression visualized in yellow (merge). Differentiated 
neurospheres (right column) were subjected to phenotype analysis using neuronal 
(GAP43) and glial (GFAP) markers; cells magnified in insets. Hoechst 33342 was used as 
a nuclear control. Scale bar, 50m. Abbreviations: hippocampus (HC), olfactory bulb 
(OB), cortex (CX), cerebellum (CB), dentate gyrus (DG), lateral ventricles (LVs). 
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Spy1 is expressed in cells within the rostral migratory stream and SGZ of the 
hippocampus 
Murine brain sections were stained for Spy1 and analyzed using bright field 
microscopy. Spy1 positive cells were found along the rostral migratory stream (Fig. 3A i-
iii) and in the region of the olfactory bulb (Fig. 3A iv-vi). Cells found in the former 
presented morphology typical for migratory neural stem cells. Analysis of the dentate 
gyrus also revealed Spy1 positive cells along the subgranular zone (Fig. 3A vii-viii). 
Interestingly, the most intensive Spy1 specific labeling was found in the region of the 
subependymal zone on the lateral and anterior wall of the lateral ventricles (Fig. 3B i-v). 
The three-dimensional model for the organization within the SVZ proposed by Doetsch et 
al. addresses the specific cell morphology and topographical relationship between the 
cells (Fig. 3B vi). Using the morphology criteria proposed by this model, the cells that 
stained positively for Spy1 resemble B-type cells. Immunohistochemical analysis of 
specific markers is required to further determine the SVZ phenotype of the Spy1 positive 
cells. 
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Figure 3. Spy1 positive populations of neural cells are found in the RMS, SGZ and SVZ 
of the LVs. 
Coronal and sagittal sections from mice between 3-10 weeks of age were analyzed by 
DAB IHC for Spy1 expression. 
(A) (i-iii) RMS Spy1 immunostaining. (i) Low magnification view. (ii) Magnification 
from boxed region in (i) (Boxed in region is further magnified in iii). (iv) DG of 
hippocampus. Box is further magnified in images v and vi. (vii) OB; (viii magnified box 
from vii). Spy1 positive cells (indicated with an arrow on some panels) present 
morphology typical for migratory neural stem cells. Scale bars: (i),(iv) and (vii), 100m; 
(ii),(v) and (vi) 25m; (iii) and (viii), 10m. 
(B) (i) Spy1 specific staining found in the ASVZ and in the LSVZ of the LVs. Boxed in 
region of ASVZ is magnified in (ii) which has a further boxed in region magnified in the 
inset. The inset of (ii) is further magnified in (iii). (iv-v) View of the LSVZ. (v) A 
magnified view of the boxed in region in (iv). (vi) Contiguous electron micrographs of 
the SVZ were assembled onto a computer and in depth analysis conducted to determine 
the characteristics and positioning of the A cells (red), B cells (blue), C cells (green), 
ependymal (ciliated cells; grey). Used with permission: Doetsch F. et al. J. Neurosci. 
1997;17:5046-5061. Scale bars: (i),100m; (ii) and (iv), 25m; (iii) and (v), 10m. 
Abbreviations: rostral migratory stream (RMS), subgranular zone (SGZ), subventricular 
zone (SVZ), lateral ventricles (LVs), dentate gyrus (DG), olfactory bulb (OB), anterior 
subventricular zone (ASVZ), lateral subventricular zone (LSVZ). 
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Spy1 positive cells in the SVZ express markers of B-type cell subpopulation 
Data from Doetsch et al. originally identified the subtypes of cells residing in the 
germinal layer of SVZ and the markers to adequately define these cells continue to evolve 
(Fig. 3B vi) (Doetsch, Garcia-Verdugo et al. 1997; Kriegstein and Alvarez-Buylla 2009; 
Ihrie, Shah et al. 2011). In general, astrocyte-like cells, referred to as B-cells, stain 
positively for GFAP and Nestin and give rise to the transient amplifying C-cells that only 
stain at low levels for Nestin. C-cells in turn differentiate into migrating neuroblasts (A-
cells) staining with neural specific markers. Although multiciliated ependymal cells were 
previously reported to acquire stem-like characteristics upon injury (Mothe and Tator 
2005), it has been established that they neither divide in vivo nor form neurospheres in 
vitro (Doetsch, Caille et al. 1999; Mirzadeh, Merkle et al. 2008). Moreover, in contrary to 
the conventional model describing the ependymal cells as directly contacting the 
ventricle, the B-type cells were reported to constitute 31% of the population lining the 
LVs (Mirzadeh, Merkle et al. 2008). To further investigate the identity of the SVZ Spy1 
positive cells, immunofluorescent analysis was performed using stemness and glial 
markers (Fig. 4A). The obtained data showed that Spy1 expressing cells observed along 
the anterior wall of the LV not only contact the ventricle, but also co-stain with SSEA-
1/CD15/Lewis X (LeX) (Fig. 4A ai-ci). LeX was previously found to enrich for tumour 
initiating cells (TIC) along with the CD133 marker in 85% of established TIC cell lines 
(Son, Woolard et al. 2009). Immunolabeling with the NSC marker Nestin (Fig. 4B d-di) 
as well as with GFAP (Fig.4B; e-ei), along the lateral wall of the LVs, revealed that both 
markers colocalized with Spy1; this supports the glial and progenitor nature of the 
detected cells (Doetsch, Garcia-Verdugo et al. 1997).  
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Figure 4. Spy1 colocalizes with glial and stemness markers in the SVZ. 
(A) Immunofluorescent analysis of the localization of Spy1, SSEA-1/LeX , Nestin and 
GFAP positive cells within the ASVZ. Sections stained with Spy1 (a-i), SSEA-1/LeX (a-
ii), Hoechst 33342 (a-iii) and merge of both (a-iv). Scale bar, 100m. SVZ staining with 
Spy1 and SSEA-1/LeX is further presented in higher magnification in (b) and (c) and the 
insets are further magnified in (b-i) and (c-i), respectively. Scale bars: 25m. 
(B) Colocalization of Spy1 with Nestin (d; further magnified in d-i) and GFAP (e; further 
magnified in e-i) in the LSVZ. Scale bars: (d), 25m and (e), 100m. Abbreviations: 
subventricular zone (SVZ), anterior subventricular zone (ASVZ), lateral subventricular 
zone (LSVZ), glial acidic fibrilary protein (GFAP). 
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DISCUSSION 
E10-12 represents a period of development coincident with onset of the astroglial 
marker expression within the ventricular zone and predominant expansion of glial 
progenitors throughout most regions of the brain (Hartfuss, Galli et al. 2001; Kriegstein 
and Gotz 2003). The findings presented here demonstrate that Spy1 protein begins 
accumulating at these early stages and becomes dramatically elevated between E14-E18, 
a period of development shown previously to correlate with extensive accumulation of 
proliferating newly born precursors in the SVZ (Mathis, Schroter et al. 2010). 
Furthermore, differential gene expression analysis has demonstrated that E18 represents 
an important day in CNS development, whereby there is a robust activation of genes 
involved in cell division and proliferation (Han, Wu et al. 2009). The formation of mature 
brain architecture at the early postnatal stages is unequivocal of extensive formation of 
neuronal networks and apoptosis. Spy1 inhibits apoptotic events in response to DNA 
damage and interestingly, Spy1 levels were found to be dramatically reduced at early 
postnatal stages (Barnes, Porter et al. 2003; Gastwirt, Slavin et al. 2006). Hence, this 
inverse correlation may suggest a role for Spy1 in maintaining pro-neurogenic 
populations of cells and may further suggest that Spy1 is subsequently downregulated to 
allow for p53 driven differentiation or apoptosis. Interestingly, these results demonstrate 
that Spy1 protein levels undergo progressive upregulation with the onset of early juvenile 
stages and peak at the later adult time points. Notably, the Spy1 effector CDK2 has been 
demonstrated to be essential for adult, but not for early postnatal neurogenesis (Jablonska, 
Aguirre et al. 2007). Further exploration into the specific requirement for Spy1 over the 
established CDK2 partners, Cyclins E and A, as well as the essentiality of Spy1 for p27 
155 
 
regulation in the developing brain and during neural differentiation is warranted. 
Importantly, Spy1 expression in the hippocampus correlated with a significant decrease of 
p27 protein levels (Fig. 2A) suggesting that Spy1/CDK2-mediated p27 degradation may 
occur at this neurogenic niche. The immunohistochemistry analysis revealed Spy1 
positive cells not only in the SGZ (Fig.3A iv-vi), but also in the progenitor cells along the 
rostral migratory strain (RMS) between the SVZ and the olfactory bulbs (Fig. 3A i-iii). 
The progenitor cells with neurogenic potential are born in the SVZ and migrate out to join 
the RMS en route to the olfactory bulb where they terminally differentiate (Lois and 
Alvarez-Buylla 1994). The alkaline phosphatase tracing of the GFAP positive cells 
revealed that the activated B-type astrocytes constitute the main migratory component 
that gives rise to neurons of the olfactory bulb. Importantly, the RMS cells staining 
positively for Spy1 exhibited the migratory morphology reported before by Doetsch et al. 
(Doetsch, Caille et al. 1999). The data suggest that Spy1 may be a component of the cell 
cycle machinery driving the astrocyte progenitor cells migrating out of the SVZ. 
According to the model proposed by Doetsch et al., among the defined subsets of neural 
progenitors that reside in the neurogenic niche of the SVZ, the B-type astrocytes were 
reported to serve as adult NSCs due to their ability to form multipotent spheres in vitro 
and to regenerate the SVZ network upon ablation of both migrating neuroblasts (A-cells) 
and C-cells (Doetsch, Caille et al. 1999). B-type astrocyte populations were enriched in 
Nestin and GFAP expression (Doetsch, Garcia-Verdugo et al. 1997) and Spy1 colocalized 
with both markers (Fig. 2D-E & Fig. 4B). Moreover, Spy1 overexpression was 
demonstrated to upregulate the levels of Nestin and GFAP (Chapter 2; Fig. 5B & F) and 
to confer the self-renewing potential to primary neural cells (Chapter 2; Fig. 5). Given the 
heterogeneous nature of the NSC population (Alvarez-Buylla, Kohwi et al. 2008; Lee da, 
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Gianino et al. 2012), these results suggest that Spy1 expression may be found in the 
neural stem cells characterized as SSEA-1/LeX non-ependymal cells as well as in at least 
one B-cell population. Further analysis is required to determine the specific SVZ cell type 
containing the highest levels of Spy1 and the functional significance of this on the cellular 
composition of the SVZ. Moreover, the populations type B adult NSCs are characterized 
by BrdU label retention which is indicative of infrequent cell division and cellular 
quiescence (Doetsch, Caille et al. 1999). Utilizing BrdU labeling time course in vivo in 
coordination with Spy1 expression analysis can be helpful in resolving the particular cell 
type within the SVZ that is Spy1 positive. We speculate that controlled regulation of 
Spy1's expression within the quiescent cell population potentially confers senescence 
resistance to those cells whereas Spy1 upregulation is observed in activated glia during 
regenerative processes (Huang, Liu et al. 2009).  
Utilizing an in vitro primary neural system, it was observed that SPDYA levels 
were upregulated in embryonic progenitors and declined in the postnatal and terminally 
differentiated cells (Fig. 1B), suggesting that Spy1-mediated cell cycle control may differ 
depending on the stage of development. Importantly, in ESCs the early portion of G1 
phase is actively omitted due to the continuous and phase-independent overexpression of 
Cyclin E1. Therefore, ESCs attribute their unusual cell cycle structure to continuous 
activation of CDK2 (Savatier, Huang et al. 1994; Orford and Scadden 2008). The 
observed overexpression of SPDYA in embryonic cell culture in comparison to the lineage 
committed cells suggests that Spy1 can participate in the cell cycle machinery that is 
specific to ESCs and can contribute to the retention of continuous CDK2 activity. 
In conclusion, this study demonstrated that Spy1 is tightly regulated during the 
development of the mammalian CNS and is expressed at the sites of adult neurogenesis. 
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The stem cell and astrocyte marker localization as well as expression analysis suggests 
that Spy1 is expressed within the B-type cells of the SVZ; cells previously proved to 
constitute a pool of adult multipotent stem cells. Further study is required however to 
firmly conclude that the unconventional fashion in which Spy1 drives the cell cycle is a 
part of the molecular mechanism behind adult neurogenesis and constitutes a potential 
link to brain tumourigenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
 
REFERENCES 
Alvarez-Buylla, A., M. Kohwi, et al. (2008). "The heterogeneity of adult neural stem cells 
and the emerging complexity of their niche." Cold Spring Harb Symp Quant Biol 
73: 357-65. 
Barnes, E. A., L. A. Porter, et al. (2003). "Human Spy1 promotes survival of mammalian 
cells following DNA damage." Cancer Res 63(13): 3701-7. 
Cao, J., J. Yang, et al. (2013). "Temporal-spatial expressions of spy1 in rat sciatic nerve 
after crush." Cell Mol Neurobiol 33(2): 213-21. 
Cheng, A., W. Xiong, et al. (2005). "Identification and comparative analysis of multiple 
mammalian Speedy/Ringo proteins." Cell Cycle 4(1): 155-65. 
Doetsch, F., I. Caille, et al. (1999). "Subventricular zone astrocytes are neural stem cells 
in the adult mammalian brain." Cell 97(6): 703-16. 
Doetsch, F., J. M. Garcia-Verdugo, et al. (1997). "Cellular composition and three-
dimensional organization of the subventricular germinal zone in the adult 
mammalian brain." J Neurosci 17(13): 5046-61. 
Doetsch, F., J. M. Verdugo, et al. (2002). "Lack of the cell-cycle inhibitor p27Kip1 
results in selective increase of transit-amplifying cells for adult neurogenesis." J 
Neurosci 22(6): 2255-64. 
Falk, S., H. Wurdak, et al. (2008). "Brain area-specific effect of TGF-beta signaling on 
Wnt-dependent neural stem cell expansion." Cell Stem Cell 2(5): 472-83. 
Gastwirt, R. F., D. A. Slavin, et al. (2006). "Spy1 expression prevents normal cellular 
responses to DNA damage: Inhibition of apoptosis and checkpoint activation  " J 
Biol Chem. 
Ghiani, C. and V. Gallo (2001). "Inhibition of cyclin E-cyclin-dependent kinase 2 
complex formation and activity is associated with cell cycle arrest and withdrawal 
in oligodendrocyte progenitor cells." J Neurosci 21(4): 1274-82. 
Goldman, S. A. and Z. Chen (2011). "Perivascular instruction of cell genesis and fate in 
the adult brain." Nat Neurosci 14(11): 1382-9. 
Golipour, A., D. Myers, et al. (2008). "The Spy1/RINGO family represents a novel 
mechanism regulating mammary growth and tumourigenesis." Cancer Res 68(10): 
3591-600. 
159 
 
Gordon, N. (1995). "Apoptosis (programmed cell death) and other reasons for elimination 
of neurons and axons." Brain Dev 17(1): 73-7. 
Gritti, A., L. Bonfanti, et al. (2002). "Multipotent neural stem cells reside into the rostral 
extension and olfactory bulb of adult rodents." J Neurosci 22(2): 437-45. 
Han, X., X. Wu, et al. (2009). "Transcriptome of embryonic and neonatal mouse cortex 
by high-throughput RNA sequencing." Proc Natl Acad Sci U S A 106(31): 12741-
6. 
Hartfuss, E., R. Galli, et al. (2001). "Characterization of CNS precursor subtypes and 
radial glia." Dev Biol 229(1): 15-30. 
Huang, H. S., M. Nagane, et al. (1997). "The enhanced tumourigenic activity of a mutant 
epidermal growth factor receptor common in human cancers is mediated by 
threshold levels of constitutive tyrosine phosphorylation and unattenuated 
signaling." J Biol Chem 272(5): 2927-35. 
Ihrie, R. A., J. K. Shah, et al. (2011). "Persistent sonic hedgehog signaling in adult brain 
determines neural stem cell positional identity." Neuron 71(2): 250-62. 
Jablonska, B., A. Aguirre, et al. (2007). "Cdk2 is critical for proliferation and self-
renewal of neural progenitor cells in the adult subventricular zone." J Cell Biol 
179(6): 1231-45. 
Karaiskou, A., L. H. Perez, et al. (2001). "Differential regulation of Cdc2 and Cdk2 by 
RINGO and cyclins." J Biol Chem 276(38): 36028-34. 
Ke, Q., J. Ji, et al. (2009). "Expression and prognostic role of Spy1 as a novel cell cycle 
protein in hepatocellular carcinoma." Exp Mol Pathol 87(3): 167-72. 
Kriegstein, A. and A. Alvarez-Buylla (2009). "The glial nature of embryonic and adult 
neural stem cells." Annu Rev Neurosci 32: 149-84. 
Kriegstein, A. R. and M. Gotz (2003). "Radial glia diversity: a matter of cell fate." Glia 
43(1): 37-43. 
Lange, C. and F. Calegari (2010). "Cdks and cyclins link G1 length and differentiation of 
embryonic, neural and hematopoietic stem cells." Cell Cycle 9(10): 1893-900. 
Lee da, Y., S. M. Gianino, et al. (2012). "Innate neural stem cell heterogeneity determines 
the patterning of glioma formation in children." Cancer Cell 22(1): 131-8. 
160 
 
Li, H., M. Collado, et al. (2012). "p27(Kip1) directly represses Sox2 during embryonic 
stem cell differentiation." Cell Stem Cell 11(6): 845-52. 
Lois, C. and A. Alvarez-Buylla (1994). "Long-distance neuronal migration in the adult 
mammalian brain." Science 264(5162): 1145-8. 
Lukaszewicz, A., P. Savatier, et al. (2005). "G1 phase regulation, area-specific cell cycle 
control, and cytoarchitectonics in the primate cortex." Neuron 47(3): 353-64. 
Ma, Y., X. Qi, et al. (2009). "Identification of candidate genes for human pituitary 
development by EST analysis." BMC Genomics 10: 109. 
Mathis, C., A. Schroter, et al. (2010). "Nogo-a regulates neural precursor migration in the 
embryonic mouse cortex." Cereb Cortex 20(10): 2380-90. 
McAndrew, C. W., R. F. Gastwirt, et al. (2007). "Spy1 enhances phosphorylation and 
degradation of the cell cycle inhibitor p27." Cell Cycle 6(15): 1937-45. 
Mimeault, M. and S. K. Batra (2006). "Concise review: recent advances on the 
significance of stem cells in tissue regeneration and cancer therapies." Stem Cells 
24(11): 2319-45. 
Mimeault, M., R. Hauke, et al. (2007). "Stem cells: a revolution in therapeutics-recent 
advances in stem cell biology and their therapeutic applications in regenerative 
medicine and cancer therapies." Clin Pharmacol Ther 82(3): 252-64. 
Mirzadeh, Z., F. T. Merkle, et al. (2008). "Neural stem cells confer unique pinwheel 
architecture to the ventricular surface in neurogenic regions of the adult brain." 
Cell Stem Cell 3(3): 265-78. 
Mothe, A. J. and C. H. Tator (2005). "Proliferation, migration, and differentiation of 
endogenous ependymal region stem/progenitor cells following minimal spinal 
cord injury in the adult rat." Neuroscience 131(1): 177-87. 
Orford, K. W. and D. T. Scadden (2008). "Deconstructing stem cell self-renewal: genetic 
insights into cell-cycle regulation." Nat Rev Genet 9(2): 115-28. 
Palmer, T. D., J. Ray, et al. (1995). "FGF-2-responsive neuronal progenitors reside in 
proliferative and quiescent regions of the adult rodent brain." Mol Cell Neurosci 
6(5): 474-86. 
Pastrana, E., V. Silva-Vargas, et al. (2011). "Eyes wide open: a critical review of sphere-
formation as an assay for stem cells." Cell Stem Cell 8(5): 486-98. 
161 
 
Porter, L. A., R. W. Dellinger, et al. (2002). "Human Speedy: a novel cell cycle regulator 
that enhances proliferation through activation of Cdk2." J Cell Biol 157(3): 357-
66. 
Porter, L. A., M. Kong-Beltran, et al. (2003). "Spy1 interacts with p27Kip1 to allow G1/S 
progression." Mol Biol Cell 14(9): 3664-74. 
Savatier, P., S. Huang, et al. (1994). "Contrasting patterns of retinoblastoma protein 
expression in mouse embryonic stem cells and embryonic fibroblasts." Oncogene 
9(3): 809-18. 
Schmidt, M. H., F. Bicker, et al. (2009). "Epidermal growth factor-like domain 7 
(EGFL7) modulates Notch signalling and affects neural stem cell renewal." Nat 
Cell Biol 11(7): 873-80. 
Singh, A. M. and S. Dalton (2009). "The cell cycle and Myc intersect with mechanisms 
that regulate pluripotency and reprogramming." Cell Stem Cell 5(2): 141-9. 
Son, M. J., K. Woolard, et al. (2009). "SSEA-1 is an enrichment marker for tumour-
initiating cells in human glioblastoma." Cell Stem Cell 4(5): 440-52. 
Suslov, O. N., V. G. Kukekov, et al. (2002). "Neural stem cell heterogeneity 
demonstrated by molecular phenotyping of clonal neurospheres." Proc Natl Acad 
Sci U S A 99(22): 14506-11. 
Takahashi, T., R. S. Nowakowski, et al. (1995). "The cell cycle of the pseudostratified 
ventricular epithelium of the embryonic murine cerebral wall." J Neurosci 15(9): 
6046-57. 
Yuan, J. S., A. Reed, et al. (2006). "Statistical analysis of real-time PCR data." BMC 
Bioinformatics 7: 85. 
Zhang, L., A. Shen, et al. (2012). "Spy1 is frequently overexpressed in malignant gliomas 
and critically regulates the proliferation of glioma cells." J Mol Neurosci 47(3): 
485-94. 
 
 
 
162 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
THE ROLE OF SPY1 
IN THE DIFFERENTIATION AND SELF-RENEWAL OF NEUROBLASTOMA 
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INTRODUCTION 
Neuroblastoma is the most common pediatric extra cranial malignancy with 98% of 
patients diagnosed by the age of 10 (Brodeur, Look et al. 2001; Maris, Hogarty et al. 
2007). The disease has an unpredictable clinical course and poor prognosis, with only 
30% long-term survival (Brodeur, Look et al. 2001; Maris, Hogarty et al. 2007). Due to 
its origin in the migratory neural crest, neuroblastoma occurs in the peripheral nervous 
system arising in sympathetic ganglia and adrenal medulla (Anderson 1997; Brodeur 
2003; Dyer 2004). The neural crest is a population of stem cells that derives from the 
neural tube during embryogenesis. Therefore, the transient embryonic structure of the 
tumours is reflected in the enormous genetic and phenotypic heterogeneity of 
neuroblastoma. Although an inherited genetic predisposition was shown in a small subset 
of patients, spontaneous genetic changes are the most frequently observed.  This 
commonly includes activation of oncogenes like MYCN and H-Ras, gain or loss of 
alleles, and alternations in cell ploidy (Schwab, Alitalo et al. 1983; Kaneko, Kanda et al. 
1987; Tanaka, Slamon et al. 1988; Ireland 1989). Neuroblastoma tumours display diverse 
immature cell types such as neuroblasts and glial precursors and an array of 
heterogeneous cell types at different stages of differentiation. Accumulating in vitro and 
in vivo evidence suggests that alteration in cell cycle control may affect the stage of 
tumour differentiation and ultimately contribute to neuroblastoma pathogenesis (Mei, 
Wang et al.). Indeed those tumours with a poorly differentiated phenotype correlate 
negatively with clinical outcomes (Mei, Wang et al.; Zha, Ding et al.). In addition, self-
renewing tumour initiating cells (TICs) were reported to correlate with refractory or 
relapse state following the initial good response to therapy observed in patients 
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(Vangipuram, Wang et al. 2010). The neuroblastoma stem-like TICs were identified 
among the heterogeneous population in cultured human cell lines (Ciccarone, Spengler et 
al. 1989; Ross, Biedler et al. 2003; Ross and Spengler 2007). Interestingly, several groups 
demonstrated the three principle populations of neuroblastoma cells: the highly 
proliferative yet weakly tumourigenic N-cells, the crest derived non-neuronal S 
precursors and the I-type malignant and multipotent neural crest stem cells of TIC 
potential (Ross, Spengler et al. 1995). The latter express CD133 and c-kit stem cell 
marker proteins, are capable of self-renewal and form rapidly growing tumours (Ross and 
Spengler 2007; Takenobu, Shimozato et al. 2011 
; Cournoyer, Nyalendo et al. 2012). Importantly, the pentaspan protein CD133 was 
shown to regulate cellular proliferation and differentiation in neuroblastoma (Takenobu, 
Shimozato et al. 2011). Proliferation and differentiation are under control of the cell 
cycle, however what regulates the balance of these decisions in the populations of cells 
found in neuroblastoma remains to be determined.  
Spy1 (Spdya; Speedy; Spy1A; RINGO), encoded by SPDYA gene, is a novel cell cycle 
regulator that controls CDK2 activity and G1-S phase transition in a fashion unique from 
that established for the classical cyclin proteins. The Spy1-CDK2 complex doesn't require 
CDK activating kinase (CAK) -mediated phosphorylation on CDK2 and it is less 
sensitive to inhibitory phosphorylation by regulators such as p21
Cip1
 and p27
Kip1
 (Cheng, 
Xiong et al. 2005; Dinarina, Perez et al. 2005); (Porter, Kong-Beltran et al. 2003; 
McAndrew, Gastwirt et al. 2007). Thus, Spy1 is able to override several known cell cycle 
checkpoints, including DNA damage checkpoints (Barnes, Porter et al. 2003; Gastwirt, 
McAndrew et al. 2007). Both CDK2 and p27
Kip1
 are known to play an important role in 
neuroblastoma progression and patient prognosis (Matsuo and Thiele 1998; Matsuo, Seth 
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et al. 2001; Molenaar, Ebus et al. 2009). Notably, p27
Kip
 was demonstrated to accumulate 
in neuroblastoma cells treated with retinoids and to necessitate neuronal differentiation 
(Cuende, Moreno et al. 2008), whereas increased CDK2 activity correlated with a 
differentiation blockage (Kranenburg, Scharnhorst et al. 1995).     
 This study investigated the role of Spy1 in proliferation, self-renewal and 
differentiation of human neuroblastoma cells. We found that Spy1 overexpression in the 
N-type neuroblastoma SH-SY5Y cells resulted in significantly upregulated proliferation 
and resistance to the 13-cis-Retinoic Acid (RA)-induced differentiation. Interestingly, 
Spy1 overexpressing cells demonstrated increased self-renewal in a neurosphere 
formation assay and upregulation of markers indicative of the multipotency. The forced 
upregulation of Spy1 levels conferred increased prolonged clonality and survival to 
serially subcultured spheres. The obtained data provides insight into the potential role of a 
novel cell cycle mechanism in driving tumourigenicity of neural crest stem cells. 
Importantly, this mechanism has strong implications in regulating resistance in at least 
subsets of neuroblastoma. Elucidating the mechanism by which Spy1 regulates these 
effects is of high importance for moving these results forward for clinical benefit.  
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EXPERIMENTAL PROCEDURES 
Generation of stable cell lines 
 Utilizing BBS/CaCl2 delivery method (pH 7.05) PT67 packaging cells were transiently 
transfected with the DNA construct of choice. Following an 8 hour incubation (37C and 
3% CO2) media was changed, and cells were allowed to recover at 37C and 5% CO2. 24 
hours later cell media containing the virus was harvested, centrifuged for 5 minutes at 
2,000 g and filter sterilized using a 0.45 m filter. Using the PT67 cell system the virus 
was amplified overnight, filter sterilized and stored at -80C. SH-SY5Y cells were 
infected with P2 virus at ~70-80% confluency upon overnight incubation in 1:2 
volume/volume virus to cell media ratio containing polybrene (25 g/ml). Media was 
changed the next day and 24 hours later infected cells were selected in media containing 
600 g of G418. Individual colonies as well as mixed populations of cells were 
maintained and the incorporation of SPDYA cDNA was checked using genomic DNA and 
primers spanning the exon-exon junctions. Following adequate selection cells were 
maintained in media containing 200 g/mL of G418.  
Differentiation assays 
 SH-SY5Y cells were grown on 60 mm or 100 mm plates to 60% confluency. 13-cis- 
Retinoic Acid (2 M) was added to SH-SY5Y growth media in order to induce neurite 
outgrowth. Cover-slips and cell pellets were harvested each day, and control samples 
(kept in growth media) were harvested on day 1. Cells were pelleted by centrifugation at 
13,000 rpm for 15 minutes at 4C, supernatant was removed, and pellets were stored at –
20C until use. Cell pellets were lysed in 0.1% NP40 Lysis Buffer (0.1% NP40, 20 mM 
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Tris pH 7.5, 5 mM EDTA pH 8.0, 100 mM sodium chloride) for 1 hour, with mixing 
every 10 minutes. Samples were centrifuged again at 13,000rpm for 15 minutes at 4C to 
remove cell debris, and stored at –20C until use. Imaging was done on the AxioSkope2 
Plus microscope (Zeiss) (Dr M. Crawford lab – U of Windsor) using Northern Eclipse 
computer software.   
BrdU assay and fluorescent detection 
SH-SY5Y cells were grown on cover slips in 60 mm culture dishes. Over a differentiation 
time course BrdU (Cat# 550891; BD Sciences) was added to the differentiation media to 
achieve a final concentration of 10 M and allowed to incubate for 30 minutes prior to 
cover slips harvesting.  The cell culture density never exceeded 2x10
6 
cells/ml. The cells 
were fixed with 70% ethanol for 30 minutes at room temperature followed by incubation 
with 0.07N NaOH for 2 minutes and neutralization in PBS, pH 8,5. Primary antibody 
against Brdu (Cat# 347580, BD Sciences) was applied for 30 minutes in humidified 
chamber. The cells were then washed 3 times with PBS and incubated with secondary 
antibody conjugated to Alexa- 488 fluorophore (A11059, Invitrogen) for 30 minutes at 
room temperature. The cell nuclei was labeled with Propidium Iodide (0.04 g/ml) for 1 
minute. The cover slips were finally washed with water and mounted on microscope 
slides with Vectashield mounting medium. The imaging was done on Eclipse E800 
microscope (Nikon, Japan) 
Proliferation kinetics 
 Cells were maintained at the density 0.5 x10
4
cells/ml in 6 well plates. The medium and 
growth factors were changed daily for SH-SY5Y cell line. Proliferation kinetics was 
determined by cell counting at indicated time points using hemocytometer.  
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MTT assay 
 The primary, secondary and tertiary neurospheres generated by SH-SY5Y-SPDYA and 
SH-SY5Y-control cells were dissociated and 10
4
 cells were seeded in 100 l of media in 
96 well anti adhesive plates. 20 l of 5 mg/ml MTT solution in PBS were added to each 
well and incubated for 4 hours. 100l of extraction buffer were added for 2 hours to 
dissolve the formazan crystals and the absorbance at 590 nm was assessed using Victor 
plate reader (Perkin Elmer) 
Neurosphere formation assay 
For the purpose of the neurosphere formation assay SH-SY5Y cells were seeded at 5x10
4
 
cells per well into 6-well Ultra Low Cluster Plates (Corning Life Sciences, cat. no.3471). 
The serum free culture medium DMEM/F12 (Sigma) was supplemented with 60 M 
putrescin, 20 nM progesterone, 5 g/ml insulin, 100 g/ml transferrin, 30 nM sodium 
selenite and 6 g/ml glucose. Growth factors: human Epidermal Growth Factor (Gibco) 
and basic Fibroblast Growth Factor (Sigma) were added every 48-72 hours in final 
concentration of 20 ng/ml and 10 ng/ml in media, respectively. Differentiation of primary 
neurospheres was obtained as described previously (Kerosuo, Piltti et al. 2008). 
Neurospheres were transferred on Poly-D-Lysine coated cover-slips placed in 6 well 
plates and allowed to attach over night in a drop of culture medium. To induce 
differentiation wells were filled with culture medium supplemented with 2% FBS. After 
7-14 days the cover-slips were examined for neural differentiation and subjected to 
immunocytochemistry. To study secondary neurosphere formation SH-SY5Y cells were 
seeded into 24 or 96-well plate at 10
2
 cells per well. After 6-7 days the number and size 
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of the neurospheres formed was recorded. The neurosphere diameter was assessed 
optically with an object micrometer.   
Western blotting 
Protein samples were prepared with 4 times sample buffer (10% glycerol, 62.5 mM Tris-
HCl pH 6.8, 2% SDS, 0.01 mg/mL bromophenol blue, 2% -mercaptoethanol), and 
boiled for 5 minutes at 95-105 C. Samples were loaded onto 10% polyacrylamide gels 
and run at 110 volts for 4.5 hours. Proteins were then transferred to PVDF membranes 
through semi-wet transfer at 30 volts for 2.5 hours. Membranes were blotted in 3% milk 2 
hours to overnight. Primary antibodies were incubated overnight at 4C, except for Actin 
mouse, which was incubated 1 hour at room temperature. Antibody concentrations used 
are as follows: Actin MAB150 1R, (Chemicon- Millipore; 1:1000), -Tubulin TU-02 
(Sigma; 1:1000), CDK2 mouse D-12 (Sigma 1:1000), CDK2 rabbit M2 (Sigma; 1:500), 
human Spy1 (Novus; 1:1000-1:10000), p27
Kip1
 NA35 (Calbiochem 1:100), GAP43 
G9264 (Sigma 1:1000), GFAP G4546 (Sigma 1:1000), Nestin G-20 (Santa Cruz 1:1000). 
Membranes were washed with TBST 3 times for 5-10 minutes, followed by a 1 hour 
incubation in secondary antibody (mouse, rabbit or goat – 1:10000) at room temperature. 
Membranes were then washed with TBST 3 times for 15 minutes and were visualized 
using FluorChemHD2imaging system (Alpha Innotech).  
Immunoprecipitation and CDK2 kinase assay 
Bradford assays were performed to ensure equal protein loading, and 100-250 g of 
protein was immunoprecipitated from SH-SY5Y cell lysates. Protein was incubated with 
5 L of CDK2-mouse antibody overnight at 4C. The following day, 5 L of protein A 
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sepharose beads were added to the samples and incubated for 1 hour at 4C. Samples 
were then washed three times with NP-40 lysis buffer at 4C and aspirated to a final 
volume of 25l.  CDK2 kinase assays were performed in kinase buffer (50 mM Tris-Hcl 
pH 7.5, 10 mM MgCl2, 1 mM DTT, 20 mM EGTA) and 0.5 Ci/L [-32P]ATP- ~3,000 
Ci/mmol obtained from Perkin Elmer. 4 g of Histone H1 was added to each 25 l 
immunoprecipitated sample (described above) incubated with 25 L of 2 times kinase 
buffer. Samples were incubated at 30C for 30 minutes, followed by the addition of 25 L 
of 4 times sample buffer. Samples were boiled for 5 minutes at 95-105C and loaded onto 
10% polyacrylamide gels. SDS-PAGE and transfer were performed as described above. 
Membranes were exposed using a Cyclone PlusPhosphoimager (Perkin Elmer – U of 
Windsor), and analyzed using OptiQuant software.   
qRT-PCR 
Total RNA was extracted from cells or tissues utilizing RNAeasyPlus Mini Kit (Qiagen) 
and reverse transcribed using 200U Superscript II (Invitrogen), 0.5 g OligodT’s and 0.5 
g random nanomers (Sigma) according to the manufacturer instructions. For each 
experiment the samples were reverse transcribed at the same time and cDNA was stored 
at -20
o
C. Real time PCR with SYBR green (Applied Biosystems) fluorescent detection 
and 400 nM of each primer was performed using ABI Prism 7300 thermocycler. GAPDH 
was used as the endogenous control. Data was analyzed using ABI 7300 software and 
represented as log10 relative quantification (RQ) relative to control. 
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RESULTS 
Endogenous levels of Spy1 are downregulated during RA-induced differentiation in 
neuroblastoma 
To determine how Spy1 is expressed through differentiation in neural progenitor 
cells human neuroblastoma SH-SY5Y cells were induced to differentiate over several 
days using RA. Cells were scored as differentiated when the neurite length exceeded 
twice the size of the cell body. In SH-SY5Y cells, Spy1 protein levels were abruptly 
depleted upon addition of RA, with levels being significantly depleted between 16-48 
hours post-differentiation (Fig. 1A). This occurs concurrent with an upregulation of the 
differentiation marker GAP43 and a downregulation of the stemness marker Nestin (Fig. 
1A; lower panel). QRT-PCR analysis upon RA stimulation revealed that SPDYA 
expression levels were significantly downregulated by 48 hours after the addition of RA 
(Fig. 1B). Kinase assays showed that in vitro CDK2 kinase activity declines in parallel 
with Spy1 expression levels (Fig. 1C). 
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Figure 1. Spy1 protein levels are tightly regulated during neuroblastoma progenitor fate 
decisions.  
(A) SH-SY5Y cells differentiated in 13-cis Retinoic Acid (RA) (2M) and assayed at the 
indicated times. Differentiation was recorded by phase contrast inverted microscopy 
(upper panel) and cell lysates were analysed by SDS-PAGE (lower panel). Neuronal 
differentiation was confirmed by detection of GAP43 expression. -Tubulin was used as 
a loading control. Scale bar, 50 m.  
(B) SPDYA expression was assessed over a differentiation time course in SH-SY5Y cells 
by qRT-PCR. Non-treated cells were used as a control. Results are presented as mean 
±s.d. for triplicate samples from a representative experiment. n=4, **p < 0.01 (Student’s 
t-test). 
(C) CDK2 activity was analyzed at the indicated time points post RA treatment in SH-
SY5Y cells. Untreated cells were used as a control. Phosphorimaging analysis is 
demonstrated as Density Light Units (DLU) /mm2 (upper panel). Lower panel depicts a 
representative phosphorimage. Results are presented as mean ±s.d of a representative 
experiment. n=2, *p < 0.05 (Student’s t-test). 
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Stable overexpression of Spy1 causes delayed neural differentiation 
To determine whether decreasing levels of Spy1 protein are essential for the 
observed differentiation in neuroblastoma, Spy1 or an empty vector control were stably 
overexpressed in SH-SY5Y cells. SH-SY5Y-WT and SH-SY5Y-Spy1 cell lines were 
induced to differentiate and observed over a 72 hour time course. By 72 hours post-
differentiation over 75% of control cells successfully differentiated while no signs of 
differentiation in the Spy1 overexpressing cells are visible (Fig. 2A; right panel), 
suggesting that Spy1 induces complete resistance to RA stimulated differentiation. To 
determine whether effects could be due to the known proliferative effects of Spy1, cell 
numbers, BrdU incorporation and PCNA staining was conducted (Fig. 2B &2C). At 96 
hours post-differentiation SH-SY5Y-Spy1 cells continued to proliferate, while SH-SY5Y-
WT cells had significantly reduced proliferation indicative of terminal differentiation 
(Fig. 2B). This was also demonstrated by incorporation of BrdU (Fig. 2C; left panel) and 
PCNA (Fig. 2C; right panel). In each assay Spy1 overexpressing cells continued to 
synthesize DNA and cycle at 72 hours post-differentiation while over 50% of control 
cells enter quiescence by 48 hours post-differentiation. Interestingly, qRT-PCR of cells 
overexpressing Spy1 in the presence of differentiation stimuli revealed significantly 
higher levels of the neural stem cell (NSC) marker Nestin (Fig. 2D) and significantly 
lower expression of the neuronal differentiation marker, growth associated protein 43 
(GAP43) (Fig. 2E), than control counterparts.  
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Figure 2. Spy1 overexpression abrogates neuronal differentiation of neuroblastoma. 
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SH-SY5Y cell line was generated stably expressing flag-tagged Spy1 (SH-SY5Y-Spy1) 
and empty vector (SH-SY5Y-WT).  
(A) Cells were differentiated using 2M 13-cis-Retinoic Acid (RA). Morphology over a 
time course was documented using inverted phase contrast microscopy (left panel). 
Differentiation was scored according to axon length, and the ratio of differentiated cells to 
total cell number was calculated (right panel). Control bars (hollow), Spy1 
overexpressing (black bars). Values are mean ± s.d. n=3; *p < 0.05, **p < 0.01, ***p < 
0.001 (Student’s t-test). Scale bar, 50 m. 
(B) Cells were seeded at the density 0.5 x10
4
 cells/ml and differentiated using 2mM RA. 
Cells were harvested and subjected to the trypan blue analysis at indicated times. 
Representative data are shown as mean ± s.d. n=3, **p < 0.01, ***p < 0.001 . 
(C) SH-SY5Y cells were subjected to BrdU incorporation along the RA-induced 
differentiation time course. Immunocytochemistry was conducted at 48 hours and 72 
hours. PI was used as a nuclear counterstain (not shown). Scale bar, 100m. 
(D) PCNA negative cells and total cell number were scored in 3 different fields of view at 
48h and 72h time points. PCNA negative cells are expressed as a percentage of total cell 
number at each time point. Data are shown as mean ± s.d; n=2.  
(E & F) Expression levels of (E) Nestin and (F) GAP43 were analyzed by qRT-PCR in 
SHSY5Y-WT (WT) and SH-SY5Y-Spy1 (Spy1) along differentiation time-course. 
Representative data are shown as mean ±s.d. n=3; *p < 0.05 (E) and ***p < 0.001 (F). 
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Spy1 overexpression promotes self-renewal in neuroblastoma cells 
The pool of multipotent NSCs can be purified from heterogeneous cell population 
utilizing a neurosphere formation assay. Unlike neural progenitor cells with limited 
proliferative potential, only highly proliferative multipotent NSCs can retain the ability to 
self-renew and produce neurospheres that can be passaged in a long term culture 
(Morshead, Reynolds et al. 1994). Additionally, neurospheres derived through this assay 
retain the capacity to express GAP43 and glial fibrillary acidic protein (GFAP) upon 
differentiation conditions (Coleman, Marshall et al. 2004). SH-SY5Y neuroblastoma cells 
have been previously shown to express markers of typical neural crest stem cells 
(Biagiotti, D'Amico et al. 2006; Cui, Ma et al. 2006) and neuroblastoma cell lines, in 
general, contain populations of self renewing, multipotent tumour cells (Walton, Kattan et 
al. 2004; Mahller, Williams et al. 2009). Interestingly, we found that endogenous levels of 
Spy1 were significantly elevated in cells cultured as neurospheres when compared to 
monolayer culture, supporting the endogenous requirement for this protein in maintaining 
multipotency (Fig. 3A). We investigated the influence of Spy1 overexpression on self-
renewal in SH-SY5Y cells cultured as neurospheres. Spy1 overexpressing cells almost 
doubled the number of neurospheres as compared to controls (Fig.3B). Increases in 
neurosphere number were significant for neurospheres of a diameter smaller than 100m; 
however, there was no significant increases seen for neurospheres larger than 100m 
(Fig. 3C), notably cultures were carried out in a flat dish and not in aggregate culture 
(Kawamura, Izumi et al. 2004). Serial passaging of neurospheres demonstrated that Spy1 
overexpressing populations had enhanced longevity over control neurospheres (Fig. 3D).  
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Figure 3. Elevated levels of Spy1 protein promote neuroblastoma progenitor self 
renewal.  
(A) SH-SY5Y cells cultured as neurospheres (NS) or in monolayer (ML) were harvested 
and SPDYA expression levels determined by qRT-PCR. Data shown is mean ±s.d, ***p < 
0.001. (Student’s t-test, n=3). 
(B-D) SH-SY5Y-WT and SH-SY5Y-Spy1 cells were grown in neurosphere assays.  
(B) Morphology of cultures by light microscopy (left panels). Scale bar, 100 m. Spheres 
were passaged every 6-7 days and the neurosphere formation efficiency was quantified as 
a number of spheres relative to the total number of the cells seeded (right panel). 
Representative data are shown as mean ±s.d. of triplicates from three independent 
experiments, **p < 0.01 (Student’s t-test; n=3). 
(C) Neurospheres maintained in culture for 14 days were scored according to diameter. 
Values presented as mean ±s.d. of two independent experiments, **p < 0.01. (Student’s t-
test).  
(D) Primary, secondary and tertiary neurospheres were subjected to MTT assay. The 
obtained absorbance at 590nm was corrected for background absorbance. Data shown is 
mean ±s.d, *p < 0.05 (Student’s t-test; n=2). 
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Spy1 regulation of stemness and neural lineage commitment is controlled by 
extracellular microenvironment 
Given the environmental differences seen with Spy1 expression in neurosphere 
culture, corresponding passages of SH-SY5Y-WT or SH-SY5Y-Spy1 cells were cultured 
either in monolayer or as neurospheres and gene expression was analyzed. Interestingly, 
expression of the pluripotency marker, Oct-4 (Fig. 4A) and BMI1, stem cell marker (Fig. 
4B), was significantly elevated by Spy1 when cultured as neurospheres. However, in 
monolayer cultures, Spy1 expression significantly elevated the expression of glial 
progenitors and stem-like TIC markers (Fig. 4C-F). Specifically, Spy1 enhanced 
expression of the glial progenitor marker OLIG2 (Fig. 4C), the astrocyte-specific marker 
GFAP (Fig. 4E), the TIC marker CD133 (Fig. 4F) and Fibronectin, which has been 
shown to mediate invasiveness and cell survival in other types of neural derived tumours 
(Fig. 4D) (Lavial, Bessonnard et al.; Yuan, Siegel et al. 2007). 
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Figure 4.  Spy1 regulation of stemness and neural lineage commitment is controlled by 
extracellular microenvironment. 
SH-SY5Y control cells (WT) or overexpressing Spy1 (SPY1), cultured in monolayer 
(ML) or as neurospheres (NS). mRNA levels were analysed using qRT-PCR. 
(A-B) Expression levels of Oct-4 and BMI1.  
(C-D) OLIG2 and Fibronectin. 
(E-F) GFAP and CD133.  
Representative data are shown as mean ±s.d. of triplicates from three independent 
experiments, *p < 0.05, **p < 0.01 (Student’s t-test). 
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DISCUSSION 
Inappropriate differentiation of immature cells within the ganglionic lineage are 
thought to drive neuroblastoma (Anderson 1997; Brodeur 2003; Dyer 2004); Hoehner et 
al. 1996). Indeed the heterogeneous populations of diverse progenitor cells, seen to exist 
within the tumour, mirror neural crest plasticity (Ciccarone, Spengler et al. 1989; Ross, 
Biedler et al. 2003; Ross and Spengler 2007). Multiple studies over the years have 
attempted to elucidate the molecular basis behind the differentiation processes of 
neuroblastoma. Diverse agents, growth factors and differentiation protocols have been 
proposed (Lovat et al. 1997; Chlapek et al. 2010; Truckenmiller et al. 2001; Khan et al. 
2001); however, the information about the role of the cell cycle control in neuroblastoma 
remains insufficient. We report for the first time that a novel G1 phase regulator, Spy1, is 
implicated in differentiation and self-renewal of neuroblastoma cells.  
We utilized the SH-SY5Y cell line of an established N cell phenotype that is 
blocked at the precursor stage of neuronal development. We find that Spy1 levels are 
regulated during cell differentiation in vitro and altering expression levels of Spy1 
prevents functional RA-induced differentiation. Overexpression of Spy1 resulted in 
enhanced self-renewal and longevity of neuroblastoma cells cultured in a neurosphere 
formation assay. Spy1 levels were also significantly elevated in self-renewing 
neurospheres as compared to the populations cultured as a monolayer. Collectively, this 
suggests a potential role of the Spy1 protein as a stabilizer of proliferation among the 
populations of higher hierarchy, namely progenitors and tumour initiating cells. Spy1 has 
demonstrated roles in spinal cord regeneration and was found to possess stem-like 
qualities in the developing mammary gland, supporting a general role for Spy1 in select 
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populations of adult stem or progenitor cells (Golipour, Myers et al. 2008; Huang, Liu et 
al. 2009)). Dobashi et. al. demonstrated that a decrease in CDK2 kinase activity must 
occur in order to support functional differentiation (Dobashi, Kudoh et al. 1995) and 
others have demonstrated that p27
Kip1
 levels accumulate during neuronal cell 
differentiation (Sasaki, Tamura et al. 2000). Interestingly, suppression of CDK2 activity 
is required for reduced proliferation and survival of the primary neural crest derived 
tumour and its inhibition was demonstrated to be synthetic lethal in MYCN 
overexpressing neuroblastoma (Molenaar, Ebus et al. 2009;(Afanasyeva, Mestdagh et al. 
2011). Moreover, high expression of the Skp2 component of the SCF
Skp2
 ligase was 
included in the genetic signature of aggressive stages of neuroblastoma. Skp2 
overexpression correlated with p27
Kip1
 protein downregulation and poor patient prognosis 
(Westermann et al. 2007; Muth et al. 2010). The phosphorylated Thr-187 residue of 
p27
Kip1
 is required for its ubiquitination by SCF
Skp2
complex and its subsequent 
proteolysis (Carrano, Eytan et al. 1999; Tsvetkov, Yeh et al. 1999). Hence, Spy1-
mediated CDK2 activity may affect the outcome of patients with Skp2 overexpression.  
Interestingly, we observed a difference in gene expression when cells were grown 
in neurosphere culture versus the general population of cells grown in monolayer culture. 
In neurospheres, Spy1-induced expression of the progenitor and multipotency markers 
BMI11 and Oct-4, respectively. Both BMI1 and Oct-4 were shown to exert their 
functions in the other neural tumours by preventing cellular differentiation and 
contributing to their growth and progression (Abdouh, Facchino et al. 2009; Ma, Qi et al. 
2009)). Hence, this data supports a hypothesis that Spy1 may function in promoting the 
growth of highly undifferentiated cells in neuroblastoma. When cells were in monolayer, 
however, Spy1 promoted expression of glial progenitors such as GFAP and OLIG2. SH-
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SY5Y cells were demonstrated previously to contain a minute pool of highly clonogenic 
S cells (Biagiotti, D'Amico et al. 2006) that are also characterized by expression of glial 
markers (Ross and Spengler 2007). Thus, forced expression of Spy1 can be speculated to 
contribute to the expansion of self-renewing cell populations within the heterogeneous 
tumour. However, careful analysis is required to determine if Spy1 manipulation affects 
specific subpopulations differently and whether its role in altering potential of 
downstream progenitors is possible. While the data support a potential role for Spy1 in 
the arrested differentiation phenotype and maintaining neuroblastoma stem-like TIC 
population, further study involving cell lines of a different genetic background, primary 
tumour samples and, finally, an in vivo xenograft model is required for firm conclusions. 
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This work is the first to demonstrate a mechanistic role of a novel cell cycle 
regulator Spy1 (Spdya; Speedy; Spdy1; Spy1A; RINGO) in fate decisions in the nervous 
system and in neural cell derived malignancies. We show that Spy1 is present in the 
neurogenic sites of the adult mammalian brain characterized by populations of 
multipotent and self-renewing stem cells. Spy1 is co-expressed with Nestin and glial 
fibrilary acidic protein (GFAP) markers within the subventricular zone (SVZ). Both 
markers were reported previously to label the populations of B-type multipotent and self-
renewing stem cells (Doetsch, Caille et al. 1999). We demonstrate that the forced 
expression of Spy1 in primary neural culture affects the differentiation commitment, 
reducing neurite outgrowth and levels of neuronal markers and subsequently increasing 
self-renewing capacity. These data suggest that Spy1-mediated effects play a role in fate 
determination in neural systems.  
According to abundant literature, neural stem cells residing in the niche of the SVZ 
have been speculated to serve as a source of brain tumours and (Gilbertson and Rich 
2007; Lim, Cha et al. 2007). The subtypes of human glioma proposed by The Cancer 
Genome Atlas (TCGA) research network reflect characteristics of normal neural stem 
cells (Verhaak, Hoadley et al. 2010). The TCGA work suggested that multiple 
populations, possibly at a different commitment level, lay at the source of  brain tumour 
formation (Verhaak, Hoadley et al. 2010). Our data shows that in comparison to normal 
tissue and benign tumours Spy1 levels are significantly upregulated in the most 
aggressive forms of human glial tumours, including anaplastic astrocytoma and 
glioblastoma multiforme (GBM). Depletion of Spy1 levels in human glioblastoma cell 
lines results in significant decline of proliferation and reduction of self-renewal and 
stemness marker expression. These data support the hypothesis that Spy1 effects on cell 
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fate may regulate the self-renewing capacity of the populations of brain tumour initiating 
cells (BTICs).  
Mechanistically the tumour aggressiveness was shown to be associated with pools 
of expansive, symmetrically self-renewing cancer stem cells (Sugiarto, Persson et al. 
2011; Boman, Wicha et al. 2007). Our data demonstrate that Spy1 is involved in the mode 
of division control in CD133 enriched glioma cell lines and the downregulation of Spy1 
levels causes significant increase in a fraction of cells dividing symmetrically in 
comparison to control or Cyclin E1 knockdown cells. The decrease in Spy1 levels affects 
the even distribution of Numb in CD133+ cells. Numb is regulated by Musashi1 (Toda, 
Iizuka et al. 2001), a well established BTIC marker (Sakakibara, Nakamura et al. 2002; 
Muto, Imai et al. 2012) that can be activated by Spy1 RINGO/CDK (Arumugam, 
MacNicol et al. 2012). Hence, Spy1-mediated effects in NSCs as well as in the 
populations of BTIC may rely on Msi1 activation by Spy1-CDK2. Further investigation 
of this pathway, however, is required to support this model in human glioma. 
Spy1 has been shown to activate CDKs using an unconventional mechanism that is 
insensitive to well established inhibitory mechanisms (Cheng, Xiong et al. 2005; 
Dinarina, Perez et al. 2005). Furthermore, Spy1 can bind directly to the CDK inhibitor 
p27 and promotes degradation of this essential tumour suppressor (Porter, Kong-Beltran 
et al. 2003; McAndrew, Gastwirt et al. 2007).  It is known that Spy1 is capable of 
bypassing established checkpoints and preventing apoptosis (Barnes, Porter et al. 2003; 
Gastwirt, McAndrew et al. 2007). Whether these mechanisms participate in driving brain 
tumourigenesis is currently unknown. Our lab has developed a host of mutants that are 
unable to bind directly to CDK2 and/or p27 (Al Sorkhy, Ferraiuolo et al. 2012). It is an 
important next step to test the ability of these mutants in driving fate decisions in neural 
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cells. It is possible that mechanistically Spy1 can have different effects depending on the 
commitment of the cell type in question. For example, in stem cell populations the 
demonstrated effects of Spy1 on symmetric vs. asymmetric division may play a 
prominent role, in progenitor cells the activation of CDK2 may predominantly prevent 
differentiation from occurring and in more differentiated populations the roles of Spy1 in 
overriding checkpoint arrest and apoptosis may play a role on the predominate.   
Another important next step is to demonstrate whether Spy1 function is essential  in 
primary glioma obtained from patients. Primary tumour cells demonstrate significant 
advantage over common cell lines as they are not subjected to selective pressure of tissue 
culture. Primary cells retain the original neoplastic characteristics and closely mimic the 
phenotype and genetic/genomic signatures of the particular human brain tumour subtype 
upon ectopic xenotransplantataion in mice.  
It is also important to determine whether Spy1 expression is capable of initiating the 
development of neural tumours. For this we will use a conditional inducible mouse model 
existing in our lab to allow for cell type and developmental stage specific expression of 
Spy1 within the brain. We will initially utilize the Nestin promoter to target induction to 
self-renewing populations of stem cells. This model is essential to address the role of 
Spy1 in diverse populations of neural stem cells and progenitor cells. This model will also 
allow us to test whether Spy1 can contribute to tumourigenic events occurring at select 
developmental time points when the level of commitment within the self-renewing pools 
of progenitors varies.  
This mouse model will also be an important first step in mapping the specific neural 
stem and progenitor populations that are sensitive to Spy1-mediated effects. In vitro 
analysis of cells obtained at different developmental time points can specify whether 
193 
 
increased Spy1 protein levels cause perturbation in the mode of division. Additionally, 
microarray analysis can be utilized to determine whether Spy1-driven tumours fall under 
one specific glioma subtype. This data can also be used to generate gene expression 
signatures specific for tumours derived from Nestin+ stem cells at different 
developmental stages. It would be tremendously interesting to determine if the age of 
onset affects the subtype of the tumour.  
This study demonstrated that forced expression of Spy1 also inhibits differentiation 
in neuroblastoma cells of an established neuronal phenotype. As in human glioma, Spy1 
overexpression results in increased levels of self-renewal and upregulation of glial lineage 
markers that characterize highly clonogenic subpopulations of crest derived cells within 
neuroblastoma tumours (Corvi, Amler et al. 1994; Mahller, Williams et al. 2009). The 
amplification of the 2p24 locus including MYCN is a signature genomic aberration of 
neuroblastoma and was reported previously to confer self-renewal potential and selective 
advantage to tumour cells (Mahller, Williams et al. 2009; Reiter and Brodeur 1996; 
Brodeur 2003). Spy1 was demonstrated previously to act downstream of c-Myc, another 
oncogene from the Myc family (Golipour, Myers et al. 2008). Murine mammary cell lines 
overexpressing Spy1 and the xenotransplantation of these cells resulted in precocious 
mammary development and tumourigenesis (Golipour, Myers et al. 2008). Whether the 
observed changes in neuroblastoma cells are due solely to Spy1-mediated cell cycle 
effects or if there is a potential Myc- driven molecular pathway involved, remains to be 
determined. Besides the mechanistic background, it is of highest importance to utilize 
xenograft mouse models to address if Spy1 overexpression drives clonal expansion, 
commitment resistance and neuroblastoma tumourigenicity in vivo.  
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To summarize, the data obtained in this study supports the hypothesis that Spy1 is 
involved in regulation of cell fate decisions in neural systems and that Spy1 expression 
correlates with clonality of tumour cell lines and overall tumour aggressiveness. During 
normal development Spy1 downregulation is coincident with an established window of 
neurogenesis at early postnatal stages, while in the adult brain Spy1 positive cells are 
found in the regions characterized by sustained self-renewing potential. Consistently with 
the evolution process observed among Speedy/RINGO genes (Chauhan, Zheng et al. 
2012), their well conserved function in vertebrates versus the complete absence in yeast 
or D. melanogaster suggests that Spy1 is necessary in aiding more sophisticated 
molecular mechanisms that have been developed in the higher hierarchy organisms. One 
such example is the complex machinery involved in the cell cycle checkpoint control, 
progression through the cell cycle and cell activation out of quiescent state. In the 
circumstances of DNA damage the Spy1 protein is initially downregulated to allow for 
p53 mediated checkpoint activation (unpublished data), however Spy1 levels reestablish 
as the damage persists. In the face of the global CDK2 inhibition caused by DNA damage 
Spy1 can be potentially responsible for the active pool of CDK2 that is eventually 
required for DNA damage repair. Consequently, as the quiescent state of cell cycle is 
maintained by high levels of cell cycle inhibitors (Qiu, Takagi et al. 2004), the activation 
of progenitor or stem cells requires a mechanism that can override this restraint. CDK2 in 
complex with Spy1 is resistant to p21- mediated inhibition and Spy1/CDK2 promotes p27 
degradation. Thus in the face of mobilization signal Spy1 levels are speculated to increase 
in quiescent cells and stimulate their cell cycle progression. Interestingly, Spy1 levels 
were found to be rapidly elevated upon injury in glial cells participating in regeneration 
processes (Huang, Liu et al. 2009). Furthermore, in addition to control of cell activation, a 
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mechanism simultaneously regulating quiescent state maintenance and senescence 
suppression was described to involve Notch1 signaling (Sang, Coller et al. 2008). 
Importantly, forced expression of Spy1 blocks senescence (unpublished data). Therefore, 
we speculate that tight regulation of Spy1- Notch1 axis is responsible for senescence 
resistance observed in G0 cells whereas Spy1 upregulation is required for quiescent cell 
activation.      
Importantly, determination of the molecular mechanisms underlying Spy1-mediated 
effects in collaboration with carefully conducted in vivo studies are crucial in addressing 
the relationship between the role of Spy1 in normal neural systems and during malignant 
transformation. This may have relevance in cancer initiation and also may serve as an 
indicator of tumourigenic potential. Resolving the molecular mechanisms driving specific 
cell populations within nervous system derived tumours is indispensible in designing 
proper therapeutical anticancer strategies.         
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APENDIX A. Detailed protocols.  
I. Tissue Microarray Immunofluorescent Staining protocol 
De-paraffinization  
Before deparaffinization in xylene, tissue (microarray) section slides shall be baked in 
oven at 60°C for 30 minutes on a vertical rack to melt the extra layer of coated paraffin. 
Trial slides do not have paraffin coating so it can be deparaffinized without baking. All of 
our tissue (microarray) section slides, unless otherwise specified, were baked at 60°C for 
two hours after sectioning and are stored at 4°C. 
1. Immerse slide in xylene for 10 minutes. Repeat once in new xylene for 10 
minutes.  
2. Immerse array slide in 100% ethanol for 5 minutes.  
3. Immerse in 95% ethanol for 5 minutes.  
4. Immerse in 70% ethanol for 5 minutes.  
5. Rinse for 5 minutes in water or PBS buffer.  
 Immunostaining using fluorescent probes 
 
1. Deparaffinize and dry array slide as referred to in protocol of 
deparaffinization. 
 
2. Rinse array slide twice with PBST for 5 min each in a Coplin jar. 
 
3. Antigen retrieval (formalin-fixed, paraffin-embedded tissue sections). 
Boiling Bath. Heat the buffer (1mM EDTA, pH 8.0 or 0.01M sodium citrate buffer, pH 
6.0) to about 95°C, and then put array slides in the buffer for 10~15 minutes. Do NOT let 
the medium boil when you have array slide in. Avoid the slide drying during the 
procedure. 
 
4. Rinse array slide in PBST for 5 minutes 
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5. Apply the blocking antibody (normal goat serum- 150ul/10ml), incubate for 40 minutes 
at 
room temperature (RT), and throw off residual fluid (don't wash.). 
 
6. Apply the primary antibody 60 minutes at RT (Spy1 Novus 1:50) usually 200ul volume 
to cover all the cores. 
9. Rinse array slide twice for 5 minutes each in a Coplin jar on the orbital rotator 
. 
10. Incubate array slide with a fluorophore-conjugated secondary antibody at 
20~37°C (in a humidity chamber) for 20 minutes (Alexa488 1:1200) 
 
11. Rinse array slide twice in PBST for 5minutes each in a Coplin jar on the orbital 
rotator. 
 
12. Incubate array slide with TOTO-3 nuclear stain (0.75ul:1000) in PBST at RT 30 min. 
 
13. Rinse array slide 3 times in PBST for 5 minutes each in a Coplin jar on the orbital 
rotator. 
 
14. Dehydration and transparency of array slide. 
1. Immerse in 70% ethanol for 5 minutes. 
2. Immerse in 95% ethanol for 5 minutes.  
3. Immerse array slide in 100% ethanol for 5 minutes.  
4. Immerse slide in xylene for 10 minutes. Repeat once in new xylene for 10 minutes 
15. Mount array slides with the Vectashield mounting media and cover with a square or 
rectangulat cover slip no.1.  
 
16. The TMA slide is being placed in the slide scanner. The edges and surface of the 
cover slip have to be clean and dry in order to place the slide in the slide scanner. 
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The fluorescent signal for the secondary antibody fluorophore and nuclear stain is 
detected and quantified by ScanArray Express software (Perkin Elmer Inc.)  
 
17. The mean the fluorophore signal intensity values are normalized to the mean of the 
nuclear stain signal.  
 
II. Magnetic bead labeling 
Buffer 1: 0.1 M sodium phosphate buffer, pH 7.4–8.0 or 0.1 M sodium borate buffer, pH 
7.6–9.5. 
 
Buffer 2: Ca2+ and Mg2+ free phosphate buffered saline (PBS) supplemented with 0.1% 
bovine serum albumin (BSA) and 2 mM EDTA, pH 7.4. Note: BSA can be replaced by 
human serum albumin (HSA) or fetal calf serum (FCS). EDTA can be replaced by 
sodium citrate.  
 
This protocol describes coupling 100g of CD133 antibody (Biorbyt) to 500l (2x 108)of 
beads. 
1. The beads are resuspended in by vortexing for 30 seconds followed by rotation for 5 
minutes. 
2. 500l of beads are transferred to the magnet vial. 
3. 1ml of Buffer 1. is added and beads are resuspended. 
4. Vial is placed in a magnet for 1 minute and the liquid is pipetted out. 
5. Step 3 and 4 are repeated. 
6. Add 500l of Buffer1. for 1 minute, pipette out the liquid. 
7. Remove the vial from the magnet. 
8. Resuspend the beads in 400l and add 100l of the CD133 antibody. 
9. Incubate the mix for 15 minutes at room temperature. 
10. Add BSA to 0.01–0.1% w/v. 
11. Close the tube tightly and seal around with parafilm. 
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12. Incubate on a rotator to ensure constant movement of beads and buffer for 16-24 
hours at room temperature. 
13. Place the tube n the magnet for 1 minute, pipette the liquid out, take the tube out of 
the magnet. 
14. Add 1ml of Buffer 2 and  incubate on a rotator for 5 minutes.   
15. Repeat steps 13 and 14 twice. 
16. Suspend the labelled beads in 500l Buffer 2. 
17. Store sealed with parafilm at 4°C. 
 
III. Magnetic bead sorting 
Buffer 2: Ca2+ and Mg2+ free phosphate buffered saline (PBS) supplemented with 0.1% 
bovine serum albumin (BSA) and 2 mM EDTA, pH 7.4. Note: BSA can be replaced by 
human serum albumin (HSA) or fetal calf serum (FCS). EDTA can be replaced by 
sodium citrate.  
 
1. Prior to CD133 enrichment, cells should be cultured in SFM-N2 media for 48 hours. 
2. Cells are detached from culture dishes by gentle rinsing (CD133 is sensitive to 
Trypsin-EDTA).  
3. Transfer the cells to a conical tube, record the number of ml's the cells are suspended 
and vortex on medium for 2-3 seconds. 
4. Take 50l for cell count and spin the rest down for 5-8 minutes (depending on the 
volume) at 1000 rpm. 
5. Count the cells in meantime and multiply the number of ml's the cells were collected 
in. 
6. Discard the media and suspend the cells in Buffer 2 to obtain 2.5x 10
6
 cells/ml. 
7. Obtain the vial with labelled beads from the fridge. 
8. The beads are settle at the bottom, pipette to resuspend starting from pipetting the 
liquid supernatant to the bead pellet. 
9. Obtain 25l of beads per every 2.5x 106 cells suspended in Buffer 2. 
10. Add the beads to the cells in the buffer. 
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11. Close the tube tightly and transfer on ice to the rotator in 4 C cold room for 20 minute 
incubation. 
12. Place the vial in the magnet for 2 minutes, pipette the liquid containing large portion 
of cells out- these are your CD133- cells. Place them in a conical tube, spin down for 5 
minutes, 1000 rpm. Resuspend the pellet in SFM-N2 media and place in the ultra  low 
attachment dish or in MaxGel
TM
 coated plates.   
13. Remove the vial from the magnet, add 1 ml of Buffer 2. 
14. Place the vial in the magnet, incubate for 1 min. 
15. Repeat steps 13. and 14. three times.  
16. Suspend the beads with CD133+ cells in SFM-N2 and place in the ultra  low 
attachment dish or in MaxGel
TM
 coated plates.   
  
IV. Primary neural cell extraction 
Prior to tissue dissection the working area has to be sterilized and dissecting instruments 
have to be autoclaved.  
1. Mice are humanely euthanized in CO2 chamber or  by Pentobarbital overdose. 
2. The top of the head is shaved and swabbed with Betadine followed by 95% ethanol. 
3. Make a midline incision in the skin along the full length of the skull. 
4. Cut skin at both sides below ears to expose the skull. 
5. Using scissors cut the skull at the sides and peel it off with forceps. 
6. To cut the spinal cord, cranial nerves and blood vessels connected to the base of the 
brain, slide the forceps under the base of the brain. 
7. With the same forceps transfer the brain to 60mm dish containing media with 3% P/S 
solution. 
8. Slice the brain in the coronal fashion and under the dissecting microscope remove the 
area around the lateral ventricles. 
9. Transfer the tissue to a separate dish with media with 3% P/S solution. 
10. Using a scalpel blade no. 11 chop the tissue to 1mm
3
 cubes. 
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11. Transfer the minced tissue to a round bottom 5ml polypropylene tube with a sterile 
Pasteur pipette. 
12. Spin down for 1 minute at 250g to remove the P/S media. 
13. Remove the supernatant and add 1 ml of Trypsin- 0.05% EDTA. 
14. Place the tube in the 37°C water bath for 5-10 miutes. 
15. Remove the tube and triturate tissue- Trypsin mix gently to disrupt the tissue particles.  
16. If visible particle still remain, add 1ml of Trypsin- 0.5% EDTA and incubate in the 
37°C water bath for additional 5-10 minutes. 
16. Repeat the step 15. 
17. Centrifuge for 5 minutes at 250g. 
18. Remove the supernatant, add 2ml of media containing 10% FBS and incubate for 5 
minutes. 
19. Centrifuge for 5 minutes at 500g. 
20. Remove the supernatant and add 2ml SFM-N2. 
21. Repeat steps 19 and 20 and triturate to obtain single cell suspension. 
22. Plate cells in the ultra low attachment plates at the density of 5x 10
4
. 
 
V. Cell pair assay 
1. Circular, glass, non-coated, baked cover slips are placed in the wells of a 6-well plate. 
2. MaxGel
TM
 ECM (Sigma) is diluted in serum free media in the ratio 1:4, and kept 
chilled at all times. 
3. Add 10ul of diluted MaxGel
TM 
 per each cover slip and spread using a pipette tip. 
4. Place the plate containing now coated cover slips in the incubator 37°C, 5%CO2 for 2 
hours. 
5. After the incubation, remove the excess of MaxGel
TM
 and allow for the cover slips to 
dry for ½ hour under the laminar flow with the plate lid open. 
6. In meantime, wash the cells required for the assay and detach them from their culture 
plate using Trypsin- 0.05-0.25% EDTA.   
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7. Count the cells and seed 0.5-1 x10
3
 cells in a drop of media (SFM-N2) onto the dry, 
coated cover slips. 
8. Every cover slip is inspected carefully for single cell suspension right after seeding as 
well as in 3 hours after. 
9. The cells are incubated in a drop over night at 37°C, 5%CO2.  
10. Depending on the population doubling time the cover slips should be examined for 
mitotic pairs. 
11. Mitotic pairs on cover slips are fixed with 4% PFA for 15 minutes at room 
temperature. 
12. The cover slips can be stored till stained at 4°C in 1% PFA/PBS (if staining for 
CD133, immunocytochemistry has to be performed right away without the fixation step). 
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